2246 lines
844 KiB
Text
2246 lines
844 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK565359">
|
|
<meta name="ncbi_domain" content="niceng185er7">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK565359/?report=reader">
|
|
<meta name="ncbi_pagename" content="Evidence review for antiplatelet therapy for people with an ongoing separate indication for anticoagulation - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Evidence review for antiplatelet therapy for people with an ongoing separate indication for anticoagulation - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="author" content="National Guideline Centre (UK)">
|
|
<meta name="citation_title" content="Evidence review for antiplatelet therapy for people with an ongoing separate indication for anticoagulation">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2020/11">
|
|
<meta name="citation_author" content="National Guideline Centre (UK)">
|
|
<meta name="citation_pmid" content="33301268">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK565359/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Evidence review for antiplatelet therapy for people with an ongoing separate indication for anticoagulation">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Contributor" content="National Guideline Centre (UK)">
|
|
<meta name="DC.Date" content="2020/11">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK565359/">
|
|
<meta name="og:title" content="Evidence review for antiplatelet therapy for people with an ongoing separate indication for anticoagulation">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK565359/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng185er7-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng185er7/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK565359/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8B7A6B7D71E4910000000000070005.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK565359/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK565359/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK565359/&text=Evidence%20review%20for%20antiplatelet%20therapy%20for%20people%20with%20an%20ongoing%20separate%20indication%20for%20anticoagulation"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK565359/?report=classic">Switch to classic view</a><a href="/books/n/niceng185er7/pdf/">PDF (2.2M)</a><a href="/books/n/niceng185er7/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK565359%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8B7A6B7D71E4910000000000070005.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng185er7-lrg.png" alt="Cover of Evidence review for antiplatelet therapy for people with an ongoing separate indication for anticoagulation" /></a></div><div class="bkr_bib"><h1 id="_NBK565359_"><span itemprop="name">Evidence review for antiplatelet therapy for people with an ongoing separate indication for anticoagulation</span></h1><div class="subtitle">Acute coronary syndrome</div><p><b>Evidence review G</b></p><p><i>NICE Guideline, No. 185</i></p><p class="contrib-group"><h4>Authors</h4><span itemprop="author">National Guideline Centre (UK)</span>.</p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2020 Nov</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-3902-2</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2020.</div></div><div class="bkr_clear"></div></div><div id="niceng185er7.s1"><h2 id="_niceng185er7_s1_">1. Combination therapy</h2><div id="niceng185er7.s1.1"><h3>1.1. Review question: What is the most clinically and cost effective combination of antiplatelet and anticoagulant therapies for people who have had an ACS and a separate indication for anticoagulation?</h3></div><div id="niceng185er7.s1.2"><h3>1.2. Introduction</h3><p>The roles of anti-platelet and anticoagulant therapy in the short and long-term management of acute coronary syndromes (ACS) are relatively well established, with both having a role in the acute in-hospital treatment phase but anti-platelet therapy alone generally being recommended after discharge. However, registry data indicate that a modest proportion of patients suffering ACS will also have a co-existing medical condition (e.g. atrial fibrillation (AF), venous thrombo-embolism, or mechanical heart valve) for which long-term anti-coagulant therapy is usually indicated.</p><p>Prescribing a clinically and cost effective combination of oral anti-coagulant and anti-platelet therapy in this patient group has been the subject of debate due to potential increased risks of bleeding not only with newer anti-platelet drugs (ticagrelor and prasugrel) but also when anti-platelet and anti-coagulant therapy are co-prescribed long-term. It is also unclear how an ACS and addition of anti-platelet therapy may change the clinical and cost-effectiveness of the newer direct oral anti-coagulants (dabigatran, rivaroxaban, apixaban and edoxaban) which are increasingly prescribed in patients with AF.</p><p>NICE CG 172 recommends the combination of warfarin anti-coagulation with clopidogrel or aspirin as anti-platelet therapy for most ACS patients with an indication for anti-coagulation, and specifically recommends against combining newer anti-platelet and direct oral anti-coagulant therapies. The publication of new randomised trial data evaluating direct oral anti-coagulants in ACS and coronary stent patients means that existing guidance may need to be updated, and this current review was performed to examine that possibility.</p><p>It should be noted that this review addresses only the situations in which anti-coagulants are used for a second condition which co-exists with ACS, in contrast to NICE TA335 which recommends rivaroxaban as an option, in combination with aspirin plus clopidogrel or aspirin alone, for preventing atherothrombotic events in selected people with an ACS.</p></div><div id="niceng185er7.s1.3"><h3>1.3. PICO table</h3><p>For full details see the review protocol in <a href="#niceng185er7.appa">Appendix A</a>:.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab1"><a href="/books/NBK565359/table/niceng185er7.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab1" rid-ob="figobniceng185er7tab1"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab1/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab1/?report=previmg" alt="Table 1. PICO characteristics of review question." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab1"><a href="/books/NBK565359/table/niceng185er7.tab1/?report=objectonly" target="object" rid-ob="figobniceng185er7tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO characteristics of review question. </p></div></div></div><div id="niceng185er7.s1.4"><h3>1.4. Methods and process</h3><p>This evidence review was developed using the methods and process described in Developing NICE guidelines: the manual.<a class="bibr" href="#niceng185er7.ref70" rid="niceng185er7.ref70"><sup>70</sup></a> Methods specific to this review question are described in the review protocol in <a href="#niceng185er7.appa">Appendix A</a>:</p><p>Declarations of interest were recorded according to NICE’s 2014 conflicts of interest policy.</p></div><div id="niceng185er7.s1.5"><h3>1.5. Clinical evidence</h3><div id="niceng185er7.s1.5.1"><h4>1.5.1. Included studies</h4><p>Four studies (13 papers) were included in the review.<a class="bibr" href="#niceng185er7.ref3" rid="niceng185er7.ref3"><sup>3</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er7.ref19" rid="niceng185er7.ref19"><sup>19</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er7.ref20" rid="niceng185er7.ref20"><sup>20</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er7.ref23" rid="niceng185er7.ref23"><sup>23</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er7.ref35" rid="niceng185er7.ref35"><sup>35</sup></a><sup>–</sup><a class="bibr" href="#niceng185er7.ref37" rid="niceng185er7.ref37"><sup>37</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er7.ref43" rid="niceng185er7.ref43"><sup>43</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er7.ref49" rid="niceng185er7.ref49"><sup>49</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er7.ref50" rid="niceng185er7.ref50"><sup>50</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er7.ref60" rid="niceng185er7.ref60"><sup>60</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er7.ref62" rid="niceng185er7.ref62"><sup>62</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er7.ref75" rid="niceng185er7.ref75"><sup>75</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er7.ref88" rid="niceng185er7.ref88"><sup>88</sup></a> Evidence from these studies is summarised in the clinical evidence summary below (<a class="figpopup" href="/books/NBK565359/table/niceng185er7.tab2/?report=objectonly" target="object" rid-figpopup="figniceng185er7tab2" rid-ob="figobniceng185er7tab2">Table 2</a>).</p><p>See also the study selection flow chart in <a href="#niceng185er7.appc">Appendix C</a>:, study evidence tables in <a href="#niceng185er7.appd">Appendix D</a>:, forest plots in <a href="#niceng185er7.appe">Appendix E</a>: and GRADE tables in <a href="#niceng185er7.appf">Appendix F</a>:</p></div><div id="niceng185er7.s1.5.2"><h4>1.5.2. Excluded studies</h4><p>See the excluded studies list in <a href="#niceng185er7.appj">Appendix J</a>:</p></div><div id="niceng185er7.s1.5.3"><h4>1.5.3. Summary of clinical studies included in the evidence review</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab2"><a href="/books/NBK565359/table/niceng185er7.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab2" rid-ob="figobniceng185er7tab2"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab2/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab2/?report=previmg" alt="Table 2. Summary of studies included in the evidence review." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab2"><a href="/books/NBK565359/table/niceng185er7.tab2/?report=objectonly" target="object" rid-ob="figobniceng185er7tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Summary of studies included in the evidence review. </p></div></div><p>See <a href="#niceng185er7.appd">Appendix D</a>:for full evidence tables.</p></div><div id="niceng185er7.s1.5.4"><h4>1.5.4. Quality assessment of clinical studies included in the evidence review</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab3"><a href="/books/NBK565359/table/niceng185er7.tab3/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab3" rid-ob="figobniceng185er7tab3"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab3/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab3/?report=previmg" alt="Table 3. Clinical evidence summary: Warfarin + clopidogrel + aspirin versus warfarin + clopidogrel." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab3"><a href="/books/NBK565359/table/niceng185er7.tab3/?report=objectonly" target="object" rid-ob="figobniceng185er7tab3">Table 3</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Warfarin + clopidogrel + aspirin versus warfarin + clopidogrel. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab4"><a href="/books/NBK565359/table/niceng185er7.tab4/?report=objectonly" target="object" title="Table 4" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab4" rid-ob="figobniceng185er7tab4"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab4/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab4/?report=previmg" alt="Table 4. Clinical evidence summary: Warfarin + clopidogrel + aspirin versus dabigatran + clopidogrel." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab4"><a href="/books/NBK565359/table/niceng185er7.tab4/?report=objectonly" target="object" rid-ob="figobniceng185er7tab4">Table 4</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Warfarin + clopidogrel + aspirin versus dabigatran + clopidogrel. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab5"><a href="/books/NBK565359/table/niceng185er7.tab5/?report=objectonly" target="object" title="Table 5" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab5" rid-ob="figobniceng185er7tab5"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab5/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab5/?report=previmg" alt="Table 5. Clinical evidence summary: Rivaroxaban (2.5 mg bd) + clopidogrel + aspirin versus rivaroxaban (15 mg od) + clopidogrel." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab5"><a href="/books/NBK565359/table/niceng185er7.tab5/?report=objectonly" target="object" rid-ob="figobniceng185er7tab5">Table 5</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Rivaroxaban (2.5 mg bd) + clopidogrel + aspirin versus rivaroxaban (15 mg od) + clopidogrel. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab6"><a href="/books/NBK565359/table/niceng185er7.tab6/?report=objectonly" target="object" title="Table 6" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab6" rid-ob="figobniceng185er7tab6"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab6/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab6/?report=previmg" alt="Table 6. Clinical evidence summary: Rivaroxaban (2.5 mg bd) + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab6"><a href="/books/NBK565359/table/niceng185er7.tab6/?report=objectonly" target="object" rid-ob="figobniceng185er7tab6">Table 6</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Rivaroxaban (2.5 mg bd) + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab7"><a href="/books/NBK565359/table/niceng185er7.tab7/?report=objectonly" target="object" title="Table 7" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab7" rid-ob="figobniceng185er7tab7"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab7/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab7/?report=previmg" alt="Table 7. Clinical evidence summary: Warfarin + clopidogrel + aspirin versus Rivaroxaban (15 mg od)+ clopidogrel." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab7"><a href="/books/NBK565359/table/niceng185er7.tab7/?report=objectonly" target="object" rid-ob="figobniceng185er7tab7">Table 7</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Warfarin + clopidogrel + aspirin versus Rivaroxaban (15 mg od)+ clopidogrel. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab8"><a href="/books/NBK565359/table/niceng185er7.tab8/?report=objectonly" target="object" title="Table 8" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab8" rid-ob="figobniceng185er7tab8"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab8/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab8/?report=previmg" alt="Table 8. Clinical evidence summary: Apixaban + clopidogrel + aspirin versus apixaban + clopidogrel." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab8"><a href="/books/NBK565359/table/niceng185er7.tab8/?report=objectonly" target="object" rid-ob="figobniceng185er7tab8">Table 8</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Apixaban + clopidogrel + aspirin versus apixaban + clopidogrel. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab9"><a href="/books/NBK565359/table/niceng185er7.tab9/?report=objectonly" target="object" title="Table 9" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab9" rid-ob="figobniceng185er7tab9"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab9/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab9/?report=previmg" alt="Table 9. Clinical evidence summary: Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab9"><a href="/books/NBK565359/table/niceng185er7.tab9/?report=objectonly" target="object" rid-ob="figobniceng185er7tab9">Table 9</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab10"><a href="/books/NBK565359/table/niceng185er7.tab10/?report=objectonly" target="object" title="Table 10" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab10" rid-ob="figobniceng185er7tab10"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab10/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab10/?report=previmg" alt="Table 10. Clinical evidence summary: Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab10"><a href="/books/NBK565359/table/niceng185er7.tab10/?report=objectonly" target="object" rid-ob="figobniceng185er7tab10">Table 10</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab11"><a href="/books/NBK565359/table/niceng185er7.tab11/?report=objectonly" target="object" title="Table 11" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab11" rid-ob="figobniceng185er7tab11"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab11/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab11/?report=previmg" alt="Table 11. Clinical evidence summary: Warfarin + clopidogrel + aspirin versus apixaban + clopidogrel." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab11"><a href="/books/NBK565359/table/niceng185er7.tab11/?report=objectonly" target="object" rid-ob="figobniceng185er7tab11">Table 11</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Warfarin + clopidogrel + aspirin versus apixaban + clopidogrel. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab12"><a href="/books/NBK565359/table/niceng185er7.tab12/?report=objectonly" target="object" title="Table 12" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab12" rid-ob="figobniceng185er7tab12"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab12/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab12/?report=previmg" alt="Table 12. Clinical evidence summary: Apixaban + clopidogrel versus warfarin + clopidogrel." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab12"><a href="/books/NBK565359/table/niceng185er7.tab12/?report=objectonly" target="object" rid-ob="figobniceng185er7tab12">Table 12</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Apixaban + clopidogrel versus warfarin + clopidogrel. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab13"><a href="/books/NBK565359/table/niceng185er7.tab13/?report=objectonly" target="object" title="Table 13" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab13" rid-ob="figobniceng185er7tab13"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab13/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab13/?report=previmg" alt="Table 13. Clinical evidence summary: edoxaban + clopidogrel versus VKA + clopidogrel + aspirin." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab13"><a href="/books/NBK565359/table/niceng185er7.tab13/?report=objectonly" target="object" rid-ob="figobniceng185er7tab13">Table 13</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: edoxaban + clopidogrel versus VKA + clopidogrel + aspirin. </p></div></div><p>See <a href="#niceng185er7.appf">Appendix F</a>: for full GRADE tables.</p></div></div><div id="niceng185er7.s1.6"><h3>1.6. Economic evidence</h3><div id="niceng185er7.s1.6.1"><h4>1.6.1. Included studies</h4><p>No health economic studies were included.</p></div><div id="niceng185er7.s1.6.2"><h4>1.6.2. Excluded studies</h4><p>No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.</p><p>See also the health economic study selection flow chart in <a href="#niceng185er7.appg">Appendix G</a>:.</p></div><div id="niceng185er7.s1.6.3"><h4>1.6.3. Health economic modelling</h4><p>This area was not prioritised for new cost-effectiveness analysis.</p></div><div id="niceng185er7.s1.6.4"><h4>1.6.4. Unit costs</h4><p>Relevant unit costs are provided below to aid consideration of cost effectiveness.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7tab14"><a href="/books/NBK565359/table/niceng185er7.tab14/?report=objectonly" target="object" title="Table 14" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7tab14" rid-ob="figobniceng185er7tab14"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.tab14/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.tab14/?report=previmg" alt="Table 14. UK costs of anticoagulants and antiplatelets." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.tab14"><a href="/books/NBK565359/table/niceng185er7.tab14/?report=objectonly" target="object" rid-ob="figobniceng185er7tab14">Table 14</a></h4><p class="float-caption no_bottom_margin">UK costs of anticoagulants and antiplatelets. </p></div></div></div></div><div id="niceng185er7.s1.7"><h3>1.7. Evidence statements</h3><div id="niceng185er7.s1.7.1"><h4>1.7.1. Clinical evidence statements</h4><div id="niceng185er7.s1.7.1.1"><h5>Warfarin + clopidogrel + aspirin compared to warfarin + clopidogrel</h5><ul><li class="half_rhythm"><div>There was a clinically important benefit of the combination of warfarin + clopidogrel + aspirin compared to warfarin + clopidogrel for all-cause mortality and myocardial infarction (2038 participants in 1 study, low and moderate quality evidence respectively).</div></li><li class="half_rhythm"><div>There was a clinically important harm in TIMI major and minor bleeding when using a combination of warfarin + clopidogrel + aspirin compared to warfarin + clopidogrel (2249 participants in 1 study, moderate quality evidence).</div></li><li class="half_rhythm"><div>There was no clinically important difference between warfarin + clopidogrel + aspirin compared to warfarin + clopidogrel alone for any stent thrombosis, stroke (2038 participants in 1 study, low quality evidence), TIMI major bleeding and intracranial haemorrhage (2249 participants in 1 study, low and moderate quality evidence respectively).</div></li></ul></div><div id="niceng185er7.s1.7.1.2"><h5>Warfarin + clopidogrel + aspirin compared to dabigatran + clopidogrel</h5><ul><li class="half_rhythm"><div>There was a clinically important benefit of the combination of warfarin + clopidogrel + aspirin compared to dabigatran + clopidogrel for all-cause mortality and myocardial infarction (1962 participants in 1 study, very low and low quality evidence respectively)</div></li><li class="half_rhythm"><div>There was a clinically important harm in TIMI major bleeding, and TIMI major and minor bleeding when using warfarin + clopidogrel + aspirin compared to dabigatran + clopidogrel (1962 participants in 1 study, moderate quality evidence).</div></li><li class="half_rhythm"><div>There was no clinically important difference in stroke, definite stent thrombosis, and complications related to bleeding in terms of intracranial haemorrhage (1962 participants in 1 study, very low to low quality evidence).</div></li></ul></div><div id="niceng185er7.s1.7.1.3"><h5>Rivaroxaban (2.5 mg bd) + clopidogrel + aspirin compared to rivaroxaban (15 mg od) + clopidogrel</h5><ul><li class="half_rhythm"><div>There was a clinically important harm in all-cause mortality at 12 months (1398 participants in 1 study, very low quality evidence) when using rivaroxaban + clopidogrel +_aspirin compared to rivaroxaban + clopidogrel</div></li><li class="half_rhythm"><div>There was no clinically important difference in myocardial infarction, stroke, stent thrombosis (1398 participants in 1 study, very low quality evidence) and bleeding complications requiring medical attention, major bleeding, and minor bleeding (1402 participants in 1 study, very low quality evidence).</div></li></ul></div><div id="niceng185er7.s1.7.1.4"><h5>Rivaroxaban (2.5 mg bd) + clopidogrel + aspirin compared to warfarin + clopidogrel + aspirin</h5><ul><li class="half_rhythm"><div>There was a clinically important benefit of rivaroxaban (2.5 mg bd) + clopidogrel + aspirin compared to warfarin + clopidogrel + aspirin for bleeding complications requiring medical attention (1403 participants in 1 study, very low quality evidence).</div></li><li class="half_rhythm"><div>There was a clinically important harm in all-cause mortality when using rivaroxaban (2.5 mg bd) + clopidogrel + aspirin compared to warfarin + clopidogrel + aspirin (1399 participants in 1 study, very low quality evidence).</div></li><li class="half_rhythm"><div>There was no clinically important difference in myocardial infarction, stroke, stent thrombosis (1399 participants in 1 study, very low quality evidence) and major and minor bleeding (1403 participants in 1 study, low and very low quality evidence respectively).</div></li></ul></div><div id="niceng185er7.s1.7.1.5"><h5>Warfarin + clopidogrel + aspirin compared to Rivaroxaban (15 mg od) + clopidogrel</h5><ul><li class="half_rhythm"><div>There was a clinically important benefit of warfarin + clopidogrel + aspirin compared rivaroxaban (15 mg od) + clopidogrel for all-cause mortality (1389 participants in 1 study, very low quality evidence).</div></li><li class="half_rhythm"><div>There was a clinically important harm in bleeding requiring medical attention when using warfarin + clopidogrel + aspirin compared to rivaroxaban + clopidogrel (1393 participants in 1 study, low quality evidence).</div></li><li class="half_rhythm"><div>There was no clinically important difference in myocardial infarction, stroke, stent thrombosis, (1389 participants in 1 study, very low quality evidence), major and minor bleeding (1393 participants in 1 study, very low quality evidence).</div></li></ul></div><div id="niceng185er7.s1.7.1.6"><h5>Apixaban + clopidogrel + aspirin compared to apixaban + clopidogrel</h5><ul><li class="half_rhythm"><div>There was a clinically important benefit of apixaban + clopidogrel + aspirin compared to apixaban + clopidogrel for all-cause mortality (2306 participants in 1 study, low quality evidence).</div></li><li class="half_rhythm"><div>There was a clinically important harm in TIMI major and minor bleeding when using apixaban + clopidogrel + aspirin compared to apixaban + clopidogrel (2288 participants in 1 study, high quality evidence).</div></li><li class="half_rhythm"><div>There was no clinically important difference in myocardial infarction, stroke, stent thrombosis (2306 participants in 1 study, low to moderate quality evidence) and in TIMI major bleeding, and intracranial haemorrhage (2288 participants in 1 study, high and low quality evidence respectively).</div></li></ul></div><div id="niceng185er7.s1.7.1.7"><h5>Apixaban + clopidogrel + aspirin compared to warfarin + clopidogrel + aspirin</h5><ul><li class="half_rhythm"><div>There was a clinically important harm in all-cause mortality when using apixaban + clopidogrel + aspirin compared to warfarin + clopidogrel + aspirin (2307 participants in 1 study, low quality evidence).</div></li><li class="half_rhythm"><div>There was no clinically important difference in myocardial infarction, stroke, any stent thrombosis (2307 participants in 1 study, low quality evidence) and in TIMI major bleeding, TIMI major and minor bleeding, and intracranial haemorrhage (2268 participants in 1 study, low quality evidence).</div></li></ul></div><div id="niceng185er7.s1.7.1.8"><h5>Apixaban + clopidogrel + aspirin compared to warfarin + clopidogrel</h5><ul><li class="half_rhythm"><div>There was a clinically important benefit of apixaban + clopidogrel + aspirin compared to warfarin + clopidogrel for all-cause mortality and myocardial infarction (2307 participants in 1 study, low and moderate quality evidence respectively).</div></li><li class="half_rhythm"><div>There was no clinically important difference between apixaban + clopidogrel + aspirin and warfarin + clopidogrel for stroke, any stent thrombosis (2307 participants in 1 study, moderate quality evidence) and in TIMI major bleeding, TIMI major and minor bleeding, and intracranial haemorrhage (2271 participants in 1 study, low to moderate quality evidence).</div></li></ul></div><div id="niceng185er7.s1.7.1.9"><h5>Warfarin + clopidogrel + aspirin compared to apixaban + clopidogrel</h5><ul><li class="half_rhythm"><div>There was a clinically important harm in all-cause mortality and myocardial infarction when using warfarin + clopidogrel + aspirin compared to apixaban + clopidogrel (2307 participants in 1 study, low and moderate quality evidence respectively).</div></li><li class="half_rhythm"><div>There was no clinically important difference in stroke, any stent thrombosis (2307 participants in 1 study, low and moderate quality evidence respectively) and in TIMI major bleeding, TIMI major and minor bleeding, and intracranial haemorrhage (2269 participants in 1 study, low to moderate quality evidence).</div></li></ul></div><div id="niceng185er7.s1.7.1.10"><h5>Apixaban + clopidogrel compared to warfarin + clopidogrel</h5><ul><li class="half_rhythm"><div>There was a clinically important benefit of apixaban + clopidogrel compared to warfarin + clopidogrel for all-cause mortality (2307 participants in 1 study, low quality evidence).</div></li><li class="half_rhythm"><div>There was no clinically important difference in myocardial infarction, stroke, any stent thrombosis (2307 participants in 1 study, low to moderate quality evidence), TIMI major bleeding, TIMI major and minor bleeding, and intracranial haemorrhage (2269 participants in 1 study, low to moderate quality evidence).</div></li></ul></div><div id="niceng185er7.s1.7.1.11"><h5>Edoxaban + clopidogrel compared to VKA + clopidogrel + aspirin</h5><ul><li class="half_rhythm"><div>There was a clinically important benefit of edoxaban + clopidogrel versus VKA + clopidogrel + aspirin in major or clinically relevant non-major bleeding (1506 participants in 1 study, moderate quality evidence).</div></li><li class="half_rhythm"><div>There was a clinically important harm in all-cause mortality when using edoxaban + clopidogrel versus VKA + clopidogrel + aspirin (1506 participants in 1 study, moderate and low quality evidence respectively).</div></li><li class="half_rhythm"><div>There was no clinically important difference in stroke, myocardial infarction, stent thrombosis, and all bleeding outcomes including intracranial haemorrhage (1506 participants in 1 study, low to moderate quality evidence).</div></li></ul></div></div><div id="niceng185er7.s1.7.2"><h4>1.7.2. Health economic evidence statements</h4><ul><li class="half_rhythm"><div>No relevant economic evaluations were identified.</div></li></ul></div></div><div id="niceng185er7.s1.8"><h3>1.8. The committee’s discussion of the evidence</h3><div id="niceng185er7.s1.8.1"><h4>1.8.1. Interpreting the evidence</h4><div id="niceng185er7.s1.8.1.1"><h5>1.8.1.1. The outcomes that matter most</h5><p>The committee agreed that outcomes critical for decision making were all-cause mortality, myocardial re-infarction, stroke and complications related to bleeding, in the short term (≤30 days), intermediate term (up to 1 year) and long term (>1 year). Health related quality of life was also considered critical for decision making.</p><p>Withdrawal of study drug due to any side effect and stent thrombosis were considered important outcomes for decision making.</p></div><div id="niceng185er7.s1.8.1.2"><h5>1.8.1.2. The quality of the evidence</h5><p>Four randomised controlled trials were included in the review. One study (REDUAL) compared triple therapy with warfarin, clopidogrel and aspirin to DAPT with dabigatran and clopidogrel. The second study (PIONEER AF-PCI) compared three different treatment strategies: low dose rivaroxaban (15 mg once daily) plus clopidogrel, a very low dose rivaroxaban (2.5 mg twice daily) plus clopidogrel and aspirin, and triple therapy with warfarin, clopidogrel and aspirin. The third trial (AUGUSTUS) was a 2 × 2 factorial trial which compared apixaban with warfarin and aspirin with placebo and therefore provided several comparisons relevant to our review. This trial did not report the data for all the comparison arms that were relevant to our review and we were initially unable to obtain the raw data for this trial to be included. However, a network meta-analysis was later published by the same authors and this was used as the source of the raw data for the AUGUSTUS trial within this review. The fourth trial (ENTRUST PCI) compared edoxaban plus clopidogrel to triple therapy with a vitamin K antagonist (VKA) and aspirin. This study did not specify which VKA was used but the committee agreed that as this was a very recent study, the VKA was likely to be warfarin.</p><p>From the outset, the committee did not wish to analyse the data grouped by the different classes of drugs. The aim was to make recommendations on specific drug combinations and therefore each comparison was analysed separately.</p><p>GRADE assessments across all outcomes ranged from very low to high. This was mainly due to risk of bias and imprecision.</p><p>There was no evidence available for any of the outcomes in the short term (≤30 days), nor of health related quality of life at any time point.</p></div><div id="niceng185er7.s1.8.1.3"><h5>1.8.1.3. Benefits and harms</h5><p>The committee agreed that when using triple therapy there was a general trend towards a reduction in mortality and MI, but no firm conclusion could be drawn because of inconsistency between studies and wide confidence intervals. Moreover, these potential benefits needed to be balanced against the clinically important increase in bleeding rates when using triple therapy. This pattern of results was seen in the study that used triple therapy with an unspecified VKA compared to dual therapy with edoxaban plus clopidogrel, and in the arms of the AUGUSTUS study in which triple therapy comprising apixaban, clopidogrel and aspirin was compared to dual therapy with either apixaban or warfarin combined with clopidogrel. However, in AUGUSTUS triple therapy with warfarin combined with clopidogrel and aspirin did not reduce mortality compared to dual therapy with apixaban plus clopidogrel. In the PIONEER study the differences between triple therapy with rivaroxaban, clopidogrel and aspirin versus dual therapy without aspirin were small and in opposite directions for mortality and myocardial infarction, but again there was an increase in bleeding complications with triple therapy even though the dose of rivaroxaban was lower in this arm of the study. Overall the increase in bleeding risk with triple therapy was more consistent and larger than the benefit in reduction of mortality or MI, although the committee noted that there was no short-term data and they could not rule out a possible role for triple therapy in the first few weeks after presenting with ACS.</p><p>There are few opportunities in these data to directly compare newer anticoagulants with warfarin, but 2 arms of the AUGUSTUS study allow this. Triple therapy with apixaban, clopidogrel and aspirin led to slightly worse mortality than triple therapy with warfarin, but all other outcomes favoured apixaban; and when dual therapy with apixaban plus clopidogrel was compared to dual therapy using warfarin all clinical outcomes favoured apixaban. The differences were mostly relatively small, but more likely to be significant when considering bleeding complications which were less with apixaban. In the PIONEER study the combination of rivaroxaban, clopidogrel and aspirin was compared to triple therapy with warfarin. All-cause mortality, stroke and stent thrombosis were higher in the rivaroxaban arm, but risk of myocardial infarction and bleeding complications were lower, the latter significantly so. The dose of rivaroxaban used in this study was lower than that recommended for treating conditions such as atrial fibrillation or deep venous thrombosis, and the committee took this into account when considering the results.</p><p>There were no direct comparisons between any of the anticoagulant drugs other than those with warfarin.</p><p>Whilst reviewing the pairwise outcome data, the committee found it difficult to reach an over-arching conclusion about the most clinically effective treatment/s. The committee considered the proposal of conducting network meta-analyses (NMAs) of this evidence review to inform decision-making. Traditionally, an NMA can provide some clarity around the relative effects for treatments within a network and aid decision-making. However, this can be limited if there are few studies included in an NMA, leading to potential uncertainty in the results. This was the case with the NMAs that were conducted for the outcomes: all-cause mortality, myocardial infarction and major bleeding (see further details in <a href="#niceng185er7.appg">Appendix G</a>). There is a lot of uncertainty in the relative effects, with overlapping credible intervals.</p><p>A recently published NMA was identified and subsequently excluded from this review for the following reasons. Firstly, it did not have a threshold for the proportion of ACS in the included study populations. The committee had agreed a threshold of >60% ACS (with 50-60% being acceptable but downgraded). One of the studies included in the published NMA had been excluded from this evidence review as the population of ACS was only 28%. In addition, a recent additional study was included in our evidence review but was not included in the published NMA. Lastly, the published NMA had grouped the drugs into their respective classes but the committee wanted to look at the specific drug combinations. A sensitivity analysis was conducted which showed that there was a difference in the direction of effect for the NMAs conducted for our evidence versus the recently published NMA. It was therefore agreed that using the recently published NMA would not be appropriate for decision-making for this evidence review.</p><p>The committee noted that the majority of evidence about combining antiplatelets and anticoagulants related to clopidogrel or aspirin rather than prasugrel or ticagrelor. The committee were concerned that bleeding risk may be higher in combinations of anticoagulants and prasugrel or ticagrelor and so given the lack of evidence were cautious about using them in this population. However, the studies using newer anticoagulants with clopidogrel and/or aspirin were reassuring in that outcomes were not inferior to those with warfarin, and previous guidance in favour of using combinations with warfarin were therefore judged inappropriate.</p></div></div><div id="niceng185er7.s1.8.2"><h4>Cost effectiveness and resource use</h4><p>No economic evaluations were identified for this review. It is noted that cost effectiveness analyses have been undertaken comparing oral anticoagulants in general populations where they are indicated such as AF and VTE and comparing antiplatelets in a general ACS population (see Evidence review A) and they are all options in current NHS practice for their respective indications. Many people who come into hospital with an ACS will already be on an oral anticoagulant that has been selected as most appropriate for them based on the evidence for that indication. However, it is not clear if risks and benefits from each respective treatment are the same in people that have both indications. In particular bleeding risk is a key clinical concern.</p><p>Unit costs were presented to aid committee consideration of cost-effectiveness. There is variation in the cost of anticoagulants and antiplatelets with newer agents being more expensive than older agents. Also, different combinations of these drugs will have different costs. Although the newer anticoagulants are more expensive, the committee estimated that over 50% of people will be taking these instead of warfarin. Also, while warfarin is the cheapest anticoagulant available, there are monitoring costs associated with warfarin as people taking warfarin need to have regular blood tests. The committee did not state which anticoagulant should be offered to people as there was insufficient clinical evidence to support using a specific combination over another. However the committee discussed that the majority of people that are already taking anticoagulants when they have an MI would usually continue taking the same anticoagulant post-MI. Clopidogrel and aspirin are lower cost than prasugrel and ticagrelor.</p><p>The recommendations are mostly unchanged from the previous guideline therefore they should not lead to significant change in practice or a substantial resource impact for the NHS in England.</p></div><div id="niceng185er7.s1.8.3"><h4>1.8.2. Other factors the committee took into account</h4><p>The need for regular monitoring of warfarin dosage was noted, with the attendant inconvenience for people taking this treatment and the additional cost. The possibility that warfarin control might be less tightly regulated in routine practice than in the clinical studies was also considered. Conversely, the committee noted that warfarin effects can be reversed if necessary and whilst reversal agents have recently become available for most of the other drugs these are more expensive.</p><p>It was noted that the available studies randomised subjects to treatment arms after PCI had been performed. There is therefore no evidence to inform choice of anticoagulant/antiplatelet combinations in the acute peri-procedural treatment phase. The committee were aware that in many centres initial treatment would include triple therapy (i.e. dual anti-platelet therapy plus some form of anticoagulation, although this might be temporary administration of heparin rather than one of the anticoagulants used for continued treatment) and on balance this was felt to be appropriate since at presentation the major concern is to address the acute arterial occlusion. Triple therapy needs to be stopped at some stage because the bleeding risk shown in this Evidence Review will become the predominant problem, but the available studies do not allow a clear statement about how quickly this should happen. The committee therefore recommended that continued treatment should be with the combination of an anticoagulant plus a single anti-platelet agent (either clopidogrel or aspirin depending on individual patient circumstances). They could not specify when the third agent should be stopped but included a statement within their recommendations that prescribers should be aware of the increased bleeding risk with triple therapy.</p><p>The committee noted that there are different indications for anti-coagulation in people with ACS, and different patient risk factors (bleeding risk, thromboembolic risk and cardiovascular risk) and wishes. The evidence presented did not clearly favour any particular combination of anti-platelet and anticoagulant therapy and it was agreed that it is not possible to make specific recommendations for one treatment over another. Recommendations of a more general nature were formulated.</p></div></div></div><div id="niceng185er7.rl.r1"><h2 id="_niceng185er7_rl_r1_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="niceng185er7.ref1">Ako
|
|
J, Okumura
|
|
K, Nakao
|
|
K, Kozuma
|
|
K, Morino
|
|
Y, Okazaki
|
|
K
|
|
et al. Dual anti-thrombotic therapy with dabigatran after percutaneous coronary intervention in atrial fibrillation - Japanese and East-Asian Subgroup analysis of the RE-DUAL PCI Trial. Circulation Journal. 2019; 83(2):327–333 [<a href="https://pubmed.ncbi.nlm.nih.gov/30643079" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30643079</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="niceng185er7.ref2">Alexander
|
|
J. Safety of the factor Xa inhibitor, apixaban, in combination with antiplatelet therapy after acute coronary syndrome: Results of the APPRAISE-I dose guiding trial. Clinical Research in Cardiology. 2008; 97(12):854</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="niceng185er7.ref3">Alexander
|
|
JH. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation. 2009; 119(22):2877–2885 [<a href="https://pubmed.ncbi.nlm.nih.gov/19470889" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19470889</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="niceng185er7.ref4">Alexander
|
|
JH, Lopes
|
|
RD, James
|
|
S, Kilaru
|
|
R, He
|
|
Y, Mohan
|
|
P
|
|
et al. Apixaban with antiplatelet therapy after acute coronary syndrome. New England Journal of Medicine. 2011; 365(8):699–708 [<a href="https://pubmed.ncbi.nlm.nih.gov/21780946" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21780946</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="niceng185er7.ref5">Alexander
|
|
JH, Lopes
|
|
RD, Thomas
|
|
L, Alings
|
|
M, Atar
|
|
D, Aylward
|
|
P
|
|
et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: Insights from the ARISTOTLE trial. European Heart Journal. 2014; 35(4):224–32 [<a href="https://pubmed.ncbi.nlm.nih.gov/24144788" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24144788</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="niceng185er7.ref6">Amarenco
|
|
P, Davis
|
|
S, Jones
|
|
EF, Cohen
|
|
AA, Heiss
|
|
WD, Kaste
|
|
M
|
|
et al. Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke. 2014; 45(5):1248–57 [<a href="https://pubmed.ncbi.nlm.nih.gov/24699050" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24699050</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="niceng185er7.ref7">Anand
|
|
SS, Bosch
|
|
J, Eikelboom
|
|
JW, Connolly
|
|
SJ, Diaz
|
|
R, Widimsky
|
|
P
|
|
et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391(10117):219–229 [<a href="https://pubmed.ncbi.nlm.nih.gov/29132880" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29132880</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="niceng185er7.ref8">Anastasius
|
|
M, Lau
|
|
JK, Hyun
|
|
K, D’Souza
|
|
M, Patel
|
|
A, Rankin
|
|
J
|
|
et al. The underutilisation of dual antiplatelet therapy in acute coronary syndrome. International Journal of Cardiology. 2017; 240:30–36 [<a href="https://pubmed.ncbi.nlm.nih.gov/28476519" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28476519</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="niceng185er7.ref9">Anonymous. Acute coronary syndrome and rivaroxaban: Not so fast. Prescrire International. 2012; 21(132):260 [<a href="https://pubmed.ncbi.nlm.nih.gov/23210253" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23210253</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="niceng185er7.ref10">Banerjee
|
|
A. There may be a role for addition of rivaroxaban to aspirin in patients with stable coronary artery disease. BMJ Evidence-Based Medicine. 2019; 24(2):78–79 [<a href="https://pubmed.ncbi.nlm.nih.gov/30154084" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30154084</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="niceng185er7.ref11">Bastiany
|
|
A, Matteau
|
|
A, El-Turaby
|
|
F, Angers-Goulet
|
|
A, Mansour
|
|
S, Daneault
|
|
B
|
|
et al. Comparison of systematic ticagrelor-based dual antiplatelet therapy to selective triple antithrombotic therapy for left ventricle dysfunction following anterior STEMI. Scientific Reports. 2018; 8:10326 [<a href="/pmc/articles/PMC6037676/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6037676</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29985433" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29985433</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="niceng185er7.ref12">Bennaghmouch
|
|
N, de Veer
|
|
A, Bode
|
|
K, Mahmoodi
|
|
BK, Dewilde
|
|
WJM, Lip
|
|
GYH
|
|
et al. Efficacy and safety of the use of non-vitamin k antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation and concomitant aspirin therapy: A meta-analysis of randomized trials. Circulation. 2018; 137(11):1117–1129 [<a href="https://pubmed.ncbi.nlm.nih.gov/29101289" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29101289</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="niceng185er7.ref13">Bhagirath
|
|
VC, Eikelboom
|
|
JW, Anand
|
|
SS. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: An evaluation of COMPASS. Future Cardiology. 2018; 14(6):443–453 [<a href="https://pubmed.ncbi.nlm.nih.gov/30417662" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30417662</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="niceng185er7.ref14">Bosch
|
|
J, Eikelboom
|
|
JW, Connolly
|
|
SJ, Bruns
|
|
NC, Lanius
|
|
V, Yuan
|
|
F
|
|
et al. Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial. Canadian Journal of Cardiology. 2017; 33(8):1027–1035 [<a href="https://pubmed.ncbi.nlm.nih.gov/28754388" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28754388</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>15.</dt><dd><div class="bk_ref" id="niceng185er7.ref15">Brodin
|
|
E, Seljeflot
|
|
I, Arnesen
|
|
H, Hurlen
|
|
M, Appelbom
|
|
H, Hansen
|
|
JB. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment. Thrombosis Research. 2009; 123(4):573–9 [<a href="https://pubmed.ncbi.nlm.nih.gov/18474393" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18474393</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>16.</dt><dd><div class="bk_ref" id="niceng185er7.ref16">Brunetti
|
|
ND, Tarantino
|
|
N, De Gennaro
|
|
L, Correale
|
|
M, Santoro
|
|
F, Di Biase
|
|
M. Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: Meta-analysis. Open Heart. 2018; 5(2):e000785 [<a href="/pmc/articles/PMC6045730/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6045730</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30018775" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30018775</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>17.</dt><dd><div class="bk_ref" id="niceng185er7.ref17">Bunmark
|
|
W, Jinatongthai
|
|
P, Vathesatogkit
|
|
P, Thakkinstian
|
|
A, Reid
|
|
CM, Wongcharoen
|
|
W
|
|
et al. Antithrombotic regimens in patients with percutaneous coronary intervention whom an anticoagulant is indicated: A systematic review and network meta-analysis. Frontiers in Pharmacology. 2018; 9:1322 [<a href="/pmc/articles/PMC6252311/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6252311</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30510510" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30510510</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>18.</dt><dd><div class="bk_ref" id="niceng185er7.ref18">Cairns
|
|
JA, Wittes
|
|
J, Wyse
|
|
DG, Pogue
|
|
J, Gent
|
|
M, Hirsh
|
|
J
|
|
et al. Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. American Heart Journal. 2008; 155(1):33–41 [<a href="https://pubmed.ncbi.nlm.nih.gov/18082486" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18082486</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>19.</dt><dd><div class="bk_ref" id="niceng185er7.ref19">Cannon
|
|
CP, Bhatt
|
|
DL, Oldgren
|
|
J, Lip
|
|
GYH, Ellis
|
|
SG, Kimura
|
|
T
|
|
et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. New England Journal of Medicine. 2017; 377(16):1513–1524 [<a href="https://pubmed.ncbi.nlm.nih.gov/28844193" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28844193</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>20.</dt><dd><div class="bk_ref" id="niceng185er7.ref20">Cannon
|
|
CP, Gropper
|
|
S, Bhatt
|
|
DL, Ellis
|
|
SG, Kimura
|
|
T, Lip
|
|
GY
|
|
et al. Design and rationale of the RE-DUAL PCI Trial: A prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clinical Cardiology. 2016; 39(10):555–564 [<a href="/pmc/articles/PMC5108471/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5108471</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27565018" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27565018</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>21.</dt><dd><div class="bk_ref" id="niceng185er7.ref21">Cavallari
|
|
I, Patti
|
|
G. Meta-analysis comparing the safety and efficacy of dual versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. American Journal of Cardiology. 2018; 121(6):718–724 [<a href="https://pubmed.ncbi.nlm.nih.gov/29373105" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29373105</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>22.</dt><dd><div class="bk_ref" id="niceng185er7.ref22">Chi
|
|
G, Kerneis
|
|
M, Kalayci
|
|
A, Liu
|
|
Y, Mehran
|
|
R, Bode
|
|
C
|
|
et al. Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. American Heart Journal. 2018; 203:17–24 [<a href="https://pubmed.ncbi.nlm.nih.gov/30015064" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30015064</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>23.</dt><dd><div class="bk_ref" id="niceng185er7.ref23">Chi
|
|
G, Yee
|
|
MK, Kalayci
|
|
A, Kerneis
|
|
M, AlKhalfan
|
|
F, Mehran
|
|
R
|
|
et al. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis. 2018; 46(3):346–350 [<a href="https://pubmed.ncbi.nlm.nih.gov/29943350" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29943350</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>24.</dt><dd><div class="bk_ref" id="niceng185er7.ref24">Connolly
|
|
SJ, Eikelboom
|
|
JW, Bosch
|
|
J, Dagenais
|
|
G, Dyal
|
|
L, Lanas
|
|
F
|
|
et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: An international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391(10117):205–218 [<a href="https://pubmed.ncbi.nlm.nih.gov/29132879" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29132879</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>25.</dt><dd><div class="bk_ref" id="niceng185er7.ref25">Dewilde
|
|
W, Berg
|
|
JT. Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). American Heart Journal. 2009; 158(5):713–718 [<a href="https://pubmed.ncbi.nlm.nih.gov/19853687" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19853687</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>26.</dt><dd><div class="bk_ref" id="niceng185er7.ref26">Dewilde
|
|
WJ, Janssen
|
|
PW, Kelder
|
|
JC, Verheugt
|
|
FW, De Smet
|
|
BJ, Adriaenssens
|
|
T
|
|
et al. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: Subgroup analysis from the WOEST trial. EuroIntervention. 2015; 11(4):381–90 [<a href="https://pubmed.ncbi.nlm.nih.gov/24970794" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24970794</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>27.</dt><dd><div class="bk_ref" id="niceng185er7.ref27">Dewilde
|
|
WJ, Oirbans
|
|
T, Verheugt
|
|
FW, Kelder
|
|
JC, De Smet
|
|
BJ, Herrman
|
|
JP
|
|
et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet. 2013; 381(9872):1107–1115 [<a href="https://pubmed.ncbi.nlm.nih.gov/23415013" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23415013</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>28.</dt><dd><div class="bk_ref" id="niceng185er7.ref28">Eikelboom
|
|
JW, Connolly
|
|
SJ, Bosch
|
|
J, Dagenais
|
|
GR, Hart
|
|
RG, Shestakovska
|
|
O
|
|
et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. New England Journal of Medicine. 2017; 377(14):1319–1330 [<a href="https://pubmed.ncbi.nlm.nih.gov/28844192" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28844192</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>29.</dt><dd><div class="bk_ref" id="niceng185er7.ref29">Fortuni
|
|
F, Ferlini
|
|
M, Leonardi
|
|
S, Angelini
|
|
F, Crimi
|
|
G, Somaschini
|
|
A
|
|
et al. Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis. International Journal of Cardiology. 2018; 273:80–87 [<a href="https://pubmed.ncbi.nlm.nih.gov/30115419" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30115419</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>30.</dt><dd><div class="bk_ref" id="niceng185er7.ref30">Franchi
|
|
F, Rollini
|
|
F, Cho
|
|
JR, King
|
|
R, Phoenix
|
|
F, Bhatti
|
|
M
|
|
et al. Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel: Results from a prospective, randomised, double-blind, placebo-controlled study. Thrombosis and Haemostasis. 2016; 115(3):622–631 [<a href="https://pubmed.ncbi.nlm.nih.gov/26633836" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26633836</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>31.</dt><dd><div class="bk_ref" id="niceng185er7.ref31">Gao
|
|
F, Shen
|
|
H, Wang
|
|
ZJ, Yang
|
|
SW, Liu
|
|
XL, Zhou
|
|
YJ. Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention. Contemporary Clinical Trials. 2015; 43:129–32 [<a href="https://pubmed.ncbi.nlm.nih.gov/26003433" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26003433</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>32.</dt><dd><div class="bk_ref" id="niceng185er7.ref32">Gao
|
|
YX, Li
|
|
Y, Yu
|
|
XZ, Li
|
|
L, Li
|
|
L, Yuan
|
|
YQ
|
|
et al. Prevention of non-acute stent thrombosis after drug-eluting stent implantation. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2013; 25(5):285–289 [<a href="https://pubmed.ncbi.nlm.nih.gov/23663579" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23663579</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>33.</dt><dd><div class="bk_ref" id="niceng185er7.ref33">Gibson
|
|
CM, Levitan
|
|
B, Gibson
|
|
WJ, Yee
|
|
MK, Murphy
|
|
SA, Yuan
|
|
Z
|
|
et al. Fatal or irreversible bleeding and ischemic events with rivaroxaban in acute coronary syndrome. Journal of the American College of Cardiology. 2018; 72(2):129–136 [<a href="https://pubmed.ncbi.nlm.nih.gov/29976285" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29976285</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>34.</dt><dd><div class="bk_ref" id="niceng185er7.ref34">Gibson
|
|
CM, Mega
|
|
JL, Burton
|
|
P, Goto
|
|
S, Verheugt
|
|
F, Bode
|
|
C
|
|
et al. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. American Heart Journal. 2011; 161(5):815–821.e6 [<a href="https://pubmed.ncbi.nlm.nih.gov/21570509" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21570509</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>35.</dt><dd><div class="bk_ref" id="niceng185er7.ref35">Gibson
|
|
CM, Mehran
|
|
R, Bode
|
|
C, Halperin
|
|
J, Verheugt
|
|
F, Wildgoose
|
|
P
|
|
et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). American Heart Journal. 2015; 169(4):472–8.e5 [<a href="https://pubmed.ncbi.nlm.nih.gov/25819853" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25819853</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>36.</dt><dd><div class="bk_ref" id="niceng185er7.ref36">Gibson
|
|
CM, Mehran
|
|
R, Bode
|
|
C, Halperin
|
|
J, Verheugt
|
|
FW, Wildgoose
|
|
P
|
|
et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. New England Journal of Medicine. 2016; 375(25):2423–2434 [<a href="https://pubmed.ncbi.nlm.nih.gov/27959713" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27959713</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>37.</dt><dd><div class="bk_ref" id="niceng185er7.ref37">Gibson
|
|
CM, Pinto
|
|
DS, Chi
|
|
G, Arbetter
|
|
D, Yee
|
|
M, Mehran
|
|
R
|
|
et al. Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy. Circulation. 2017; 135(4):323–333 [<a href="/pmc/articles/PMC5266420/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5266420</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27881555" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27881555</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>38.</dt><dd><div class="bk_ref" id="niceng185er7.ref38">Gibson
|
|
WJ, Gibson
|
|
CM, Yee
|
|
MK, Korjian
|
|
S, Daaboul
|
|
Y, Plotnikov
|
|
AN
|
|
et al. Safety and efficacy of rivaroxaban when added to aspirin monotherapy among stabilized post-acute coronary syndrome patients: A pooled analysis study of ATLAS ACS-TIMI 46 and ATLAS ACS 2-TIMI 51. Journal of the American Heart Association. 2019; 8(5):e009451</div></dd></dl><dl class="bkr_refwrap"><dt>39.</dt><dd><div class="bk_ref" id="niceng185er7.ref39">Goette
|
|
A, Merino
|
|
JL, Ezekowitz
|
|
MD, Zamoryakhin
|
|
D, Melino
|
|
M, Jin
|
|
J
|
|
et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): A randomised, open-label, phase 3b trial. Lancet. 2016; 388(10055):1995–2003 [<a href="https://pubmed.ncbi.nlm.nih.gov/27590218" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27590218</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>40.</dt><dd><div class="bk_ref" id="niceng185er7.ref40">Golwala
|
|
HB, Cannon
|
|
CP, Steg
|
|
PG, Doros
|
|
G, Qamar
|
|
A, Ellis
|
|
SG
|
|
et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials. European Heart Journal. 2018; 39(19):1726–1735 [<a href="/pmc/articles/PMC5951099/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5951099</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29668889" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29668889</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>41.</dt><dd><div class="bk_ref" id="niceng185er7.ref41">Greenberg
|
|
B, Neaton
|
|
JD, Anker
|
|
SD, Byra
|
|
WM, Cleland
|
|
JGF, Deng
|
|
H
|
|
et al. Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: A post hoc analysis of the COMMANDER HF trial. JAMA Cardiology. 2019; 4(6):515–523 [<a href="/pmc/articles/PMC6487904/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6487904</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31017637" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31017637</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>42.</dt><dd><div class="bk_ref" id="niceng185er7.ref42">Halg
|
|
C, Brunner-La Rocca
|
|
HP, Kaiser
|
|
C, Jeger
|
|
R, Osswald
|
|
S, Pfisterer
|
|
M
|
|
et al. Early and late increased bleeding rates after angioplasty and stenting due to combined antiplatelet and anticoagulant therapy. EuroIntervention. 2009; 5(4):425–431 [<a href="https://pubmed.ncbi.nlm.nih.gov/19755328" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19755328</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>43.</dt><dd><div class="bk_ref" id="niceng185er7.ref43">Haller
|
|
PM, Sulzgruber
|
|
P, Kaufmann
|
|
C, Geelhoed
|
|
B, Tamargo
|
|
J, Wassmann
|
|
S
|
|
et al. Bleeding and ischemic outcomes in patients treated with dual or triple antithrombotic therapy - systematic review and meta-analysis. European Heart Journal Cardiovascular Pharmacotherapy. 2019; 5(4):226–236 [<a href="https://pubmed.ncbi.nlm.nih.gov/31198930" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31198930</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>44.</dt><dd><div class="bk_ref" id="niceng185er7.ref44">Hess
|
|
CN, James
|
|
S, Lopes
|
|
RD, Wojdyla
|
|
DM, Neely
|
|
ML, Liaw
|
|
D
|
|
et al. Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: Insights from the APPRAISE-2 Trial. Journal of the American College of Cardiology. 2015; 66(7):777–787 [<a href="https://pubmed.ncbi.nlm.nih.gov/26271059" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26271059</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>45.</dt><dd><div class="bk_ref" id="niceng185er7.ref45">Hoshi
|
|
T, Sato
|
|
A, Nogami
|
|
A, Gosho
|
|
M, Aonuma
|
|
K, Safe-A Investigators. Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Journal of Cardiology. 2017; 69(4):648–651 [<a href="https://pubmed.ncbi.nlm.nih.gov/27443596" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27443596</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>46.</dt><dd><div class="bk_ref" id="niceng185er7.ref46">Jackson
|
|
LR, 2nd, Ju
|
|
C, Zettler
|
|
M, Messenger
|
|
JC, Cohen
|
|
DJ, Stone
|
|
GW
|
|
et al. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: A comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study. JACC: Cardiovascular Interventions. 2015; 8(14):1880–9 [<a href="https://pubmed.ncbi.nlm.nih.gov/26718518" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26718518</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>47.</dt><dd><div class="bk_ref" id="niceng185er7.ref47">Jackson
|
|
LR, 2nd, Piccini
|
|
JP, Cyr
|
|
DD, Roe
|
|
MT, Neely
|
|
ML, Martinez
|
|
F
|
|
et al. Dual antiplatelet therapy and outcomes in patients with atrial fibrillation and acute coronary syndromes managed medically without revascularization: Insights from the TRILOGY ACS trial. Clinical Cardiology. 2016; 39(9):497–506 [<a href="/pmc/articles/PMC6490848/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6490848</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27468086" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27468086</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>48.</dt><dd><div class="bk_ref" id="niceng185er7.ref48">Joint Formulary Committee. British National Formulary (BNF) Online. Available from: <a href="http://www.medicinescomplete.com" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.medicinescomplete.com</a> Last accessed: 08/11/2019</div></dd></dl><dl class="bkr_refwrap"><dt>49.</dt><dd><div class="bk_ref" id="niceng185er7.ref49">Kerneis
|
|
M, Gibson
|
|
CM, Chi
|
|
G, Mehran
|
|
R, AlKhalfan
|
|
F, Talib
|
|
U
|
|
et al. Effect of procedure and coronary lesion characteristics on clinical outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: Insights from the PIONEER AF-PCI trial. JACC: Cardiovascular Interventions. 2018; 11(7):626–634 [<a href="https://pubmed.ncbi.nlm.nih.gov/29550085" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29550085</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>50.</dt><dd><div class="bk_ref" id="niceng185er7.ref50">Kerneis
|
|
M, Yee
|
|
MK, Mehran
|
|
R, Nafee
|
|
T, Bode
|
|
C, Halperin
|
|
JL
|
|
et al. Association of international normalized ratio stability and bleeding outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention. Circulation: Cardiovascular Interventions. 2019; 12(2):e007124 [<a href="https://pubmed.ncbi.nlm.nih.gov/30704287" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30704287</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>51.</dt><dd><div class="bk_ref" id="niceng185er7.ref51">Khan
|
|
SU, Arshad
|
|
A, Riaz
|
|
IB, Talluri
|
|
S, Nasir
|
|
F, Kaluski
|
|
E. Meta-analysis of the safety and efficacy of the oral anticoagulant agents (apixaban, rivaroxaban, dabigatran) in patients with acute coronary syndrome. American Journal of Cardiology. 2018; 121(3):301–307 [<a href="/pmc/articles/PMC7453967/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7453967</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29195825" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29195825</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>52.</dt><dd><div class="bk_ref" id="niceng185er7.ref52">Khan
|
|
SU, Khan
|
|
MU, Ghani
|
|
AR, Lone
|
|
AN, Arshad
|
|
A, Kaluski
|
|
E. Meta-analysis of antithrombotic therapy in atrial fibrillation after percutaneous coronary intervention. American Journal of Cardiology. 2018; 121(10):1200–1206 [<a href="https://pubmed.ncbi.nlm.nih.gov/29548674" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29548674</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>53.</dt><dd><div class="bk_ref" id="niceng185er7.ref53">Korjian
|
|
S, Braunwald
|
|
E, Daaboul
|
|
Y, Verheugt
|
|
F, Bode
|
|
C, Tendera
|
|
M
|
|
et al. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. European Heart Journal: Acute Cardiovascular Care. 2019; 8(2):186–193 [<a href="https://pubmed.ncbi.nlm.nih.gov/29249166" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29249166</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>54.</dt><dd><div class="bk_ref" id="niceng185er7.ref54">Lamy
|
|
A, Eikelboom
|
|
J, Sheth
|
|
T, Connolly
|
|
S, Bosch
|
|
J, Fox
|
|
KAA
|
|
et al. Rivaroxaban, aspirin, or both to prevent early coronary bypass graft occlusion: The COMPASS-CABG study. Journal of the American College of Cardiology. 2019; 73(2):121–130 [<a href="https://pubmed.ncbi.nlm.nih.gov/30654882" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30654882</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>55.</dt><dd><div class="bk_ref" id="niceng185er7.ref55">Li
|
|
JX, Li
|
|
Y, Yan
|
|
SJ, Han
|
|
BH, Song
|
|
ZY, Song
|
|
W
|
|
et al. Optimal antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systemic review and meta-analysis. Biomedical Reports. 2018; 8(2):138–147 [<a href="/pmc/articles/PMC5778825/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5778825</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29435272" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29435272</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>56.</dt><dd><div class="bk_ref" id="niceng185er7.ref56">Liang
|
|
GZ, Zhang
|
|
FX, Luo
|
|
XY, Zhang
|
|
CM, Hu
|
|
L, Feng
|
|
YP
|
|
et al. A prospective randomized control clinical trial about clopidogrel combined with warfarin versus clopidogrel alone in the prevention of restenosis after femoral-popliteal artery angioplasty. Chinese Journal of Surgery. 2012; 50(8):704–708 [<a href="https://pubmed.ncbi.nlm.nih.gov/23157902" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23157902</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>57.</dt><dd><div class="bk_ref" id="niceng185er7.ref57">Lip
|
|
GYH, Al-Saady
|
|
N, Ezekowitz
|
|
MD, Banach
|
|
M, Goette
|
|
A. The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. American Heart Journal. 2017; 193:16–22 [<a href="https://pubmed.ncbi.nlm.nih.gov/29129251" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29129251</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>58.</dt><dd><div class="bk_ref" id="niceng185er7.ref58">Lip
|
|
GYH, Al-Saady
|
|
N, Jin
|
|
J, Sun
|
|
M, Melino
|
|
M, Winters
|
|
SM
|
|
et al. Anticoagulation control in warfarin-treated patients undergoing cardioversion of atrial fibrillation (from the edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation trial). American Journal of Cardiology. 2017; 120(5):792–796 [<a href="https://pubmed.ncbi.nlm.nih.gov/28709650" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28709650</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>59.</dt><dd><div class="bk_ref" id="niceng185er7.ref59">Lip
|
|
GYH, Mauri
|
|
L, Montalescot
|
|
G, Ozkor
|
|
M, Vardas
|
|
P, Steg
|
|
PG
|
|
et al. Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. American Heart Journal. 2019; 212:13–22 [<a href="https://pubmed.ncbi.nlm.nih.gov/30928824" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30928824</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>60.</dt><dd><div class="bk_ref" id="niceng185er7.ref60">Lopes
|
|
RD, Heizer
|
|
G, Aronson
|
|
R, Vora
|
|
AN, Massaro
|
|
T, Mehran
|
|
R
|
|
et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. New England Journal of Medicine. 2019; 380(16):1509–1524 [<a href="https://pubmed.ncbi.nlm.nih.gov/30883055" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30883055</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>61.</dt><dd><div class="bk_ref" id="niceng185er7.ref61">Lopes
|
|
RD, Hong
|
|
H, Harskamp
|
|
RE, Bhatt
|
|
DL, Mehran
|
|
R, Cannon
|
|
CP
|
|
et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: A network meta-analysis of randomized controlled trials. JAMA Cardiology. 2019; 4(8):747–755 [<a href="/pmc/articles/PMC6584885/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6584885</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31215979" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31215979</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>62.</dt><dd><div class="bk_ref" id="niceng185er7.ref62">Lopes
|
|
RD, Vora
|
|
AN, Liaw
|
|
D, Granger
|
|
CB, Darius
|
|
H, Goodman
|
|
SG
|
|
et al. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. American Heart Journal. 2018; 200:17–23 [<a href="https://pubmed.ncbi.nlm.nih.gov/29898844" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29898844</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>63.</dt><dd><div class="bk_ref" id="niceng185er7.ref63">Lou
|
|
B, Liang
|
|
X, Wu
|
|
Y, Deng
|
|
Y, Zhou
|
|
B, Yuan
|
|
Z
|
|
et al. Meta-analysis comparing dual versus single antiplatelet therapy in combination with antithrombotic therapy in patients with atrial fibrillation who underwent percutaneous coronary intervention with stent implantation. American Journal of Cardiology. 2018; 122(4):604–611 [<a href="https://pubmed.ncbi.nlm.nih.gov/30205887" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30205887</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>64.</dt><dd><div class="bk_ref" id="niceng185er7.ref64">Lu
|
|
W, Chen
|
|
L, Wang
|
|
Y, Yao
|
|
Y, Fu
|
|
C, Zuo
|
|
P
|
|
et al. Rationale and design of MANJUSRI trial: A randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. Contemporary Clinical Trials. 2015; 40:166–71 [<a href="https://pubmed.ncbi.nlm.nih.gov/25513965" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25513965</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>65.</dt><dd><div class="bk_ref" id="niceng185er7.ref65">Maegdefessel
|
|
L, Schlitt
|
|
A, Faerber
|
|
J, Bond
|
|
SP, Messow
|
|
CM, Buerke
|
|
M
|
|
et al. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience. Medizinische Klinik. 2008; 103(9):628–32 [<a href="https://pubmed.ncbi.nlm.nih.gov/18813885" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18813885</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>66.</dt><dd><div class="bk_ref" id="niceng185er7.ref66">Massie
|
|
BM, Collins
|
|
JF, Ammon
|
|
SE, Armstrong
|
|
PW, Cleland
|
|
JG, Ezekowitz
|
|
M
|
|
et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009; 119(12):1616–24 [<a href="https://pubmed.ncbi.nlm.nih.gov/19289640" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19289640</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>67.</dt><dd><div class="bk_ref" id="niceng185er7.ref67">Matsumura-Nakano
|
|
Y, Shizuta
|
|
S, Komasa
|
|
A, Morimoto
|
|
T, Masuda
|
|
H, Shiomi
|
|
H
|
|
et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation. 2019; 139(5):604–616 [<a href="https://pubmed.ncbi.nlm.nih.gov/30586700" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30586700</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>68.</dt><dd><div class="bk_ref" id="niceng185er7.ref68">Mega
|
|
JL, Braunwald
|
|
E, Mohanavelu
|
|
S, Burton
|
|
P, Poulter
|
|
R, Misselwitz
|
|
F
|
|
et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet. 2009; 374(9683):29–38 [<a href="https://pubmed.ncbi.nlm.nih.gov/19539361" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19539361</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>69.</dt><dd><div class="bk_ref" id="niceng185er7.ref69">Mo
|
|
F, Li
|
|
J, Yan
|
|
Y, Wu
|
|
W, Lai
|
|
S. Effect and safety of antithrombotic therapies for secondary prevention after acute coronary syndrome: A network meta-analysis. Drug Design, Development and Therapy. 2018; 12:3583–3594 [<a href="/pmc/articles/PMC6207225/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6207225</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30498334" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30498334</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>70.</dt><dd><div class="bk_ref" id="niceng185er7.ref70">National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [updated October 2018]. London. National Institute for Health and Care Excellence, 2014. Available from: <a href="http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.nice.org.uk<wbr style="display:inline-block"></wbr>​/article/PMG20/chapter<wbr style="display:inline-block"></wbr>​/1%20Introduction%20and%20overview</a></div></dd></dl><dl class="bkr_refwrap"><dt>71.</dt><dd><div class="bk_ref" id="niceng185er7.ref71">Nijenhuis
|
|
VJ, Bennaghmouch
|
|
N, Hassell
|
|
M, Baan
|
|
J, Jr., van Kuijk
|
|
JP, Agostoni
|
|
P
|
|
et al. Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation. American Heart Journal. 2016; 173:77–85 [<a href="https://pubmed.ncbi.nlm.nih.gov/26920599" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26920599</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>72.</dt><dd><div class="bk_ref" id="niceng185er7.ref72">Ogawa
|
|
H, Goto
|
|
S, Matsuzaki
|
|
M, Hiro
|
|
S, Shima
|
|
D, investigators A-J. Randomized, double-blind trial to evaluate the safety of apixaban with antiplatelet therapy after acute coronary syndrome in Japanese patients (APPRAISE-J). Circulation Journal. 2013; 77(9):2341–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/23748920" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23748920</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>73.</dt><dd><div class="bk_ref" id="niceng185er7.ref73">Ohman
|
|
EM, Roe
|
|
MT, Steg
|
|
PG, James
|
|
SK, Povsic
|
|
TJ, White
|
|
J
|
|
et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): Adouble-blind, multicentre, randomised trial. Lancet. 2017; 389(10081):1799–1808 [<a href="https://pubmed.ncbi.nlm.nih.gov/28325638" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28325638</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>74.</dt><dd><div class="bk_ref" id="niceng185er7.ref74">Oldgren
|
|
J, Budaj
|
|
A, Granger
|
|
CB, Khder
|
|
Y, Roberts
|
|
J, Siegbahn
|
|
A
|
|
et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial. European Heart Journal. 2011; 32(22):2781–2789 [<a href="https://pubmed.ncbi.nlm.nih.gov/21551462" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21551462</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>75.</dt><dd><div class="bk_ref" id="niceng185er7.ref75">Oldgren
|
|
J, Steg
|
|
PG, Hohnloser
|
|
SH, Lip
|
|
GYH, Kimura
|
|
T, Nordaby
|
|
M
|
|
et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: A subgroup analysis from the RE-DUAL PCI trial. European Heart Journal. 2019; 40(19):1553–1562 [<a href="/pmc/articles/PMC6514838/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6514838</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30793734" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30793734</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>76.</dt><dd><div class="bk_ref" id="niceng185er7.ref76">Özdemir
|
|
M. PIONEER AF-PCI trial. Turk Kardiyoloji Dernegi Arsivi. 2017; 45:(Suppl 4):10–14 [<a href="https://pubmed.ncbi.nlm.nih.gov/28947725" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28947725</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>77.</dt><dd><div class="bk_ref" id="niceng185er7.ref77">Palla
|
|
M, Briasoulis
|
|
A, Kondur
|
|
A. Oral anticoagulants with dual antiplatelet therapy versus clopidogrel in patients after percutaneous coronary intervention: A meta-analysis. American Journal of Therapeutics. 2019; 26(1):e143–e150 [<a href="https://pubmed.ncbi.nlm.nih.gov/27340910" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27340910</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>78.</dt><dd><div class="bk_ref" id="niceng185er7.ref78">Pandor
|
|
A, Pollard
|
|
D, Chico
|
|
T, Henderson
|
|
R, Stevenson
|
|
M. Rivaroxaban for preventing atherothrombotic events in people with acute coronary syndrome and elevated cardiac biomarkers: An evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2016; 34(5):463–77 [<a href="https://pubmed.ncbi.nlm.nih.gov/26689783" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26689783</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>79.</dt><dd><div class="bk_ref" id="niceng185er7.ref79">Patti
|
|
G, Pecen
|
|
L, Lucerna
|
|
M, Huber
|
|
K, Rohla
|
|
M, Renda
|
|
G
|
|
et al. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. International Journal of Cardiology. 2018; 270:160–166 [<a href="https://pubmed.ncbi.nlm.nih.gov/30220376" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30220376</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>80.</dt><dd><div class="bk_ref" id="niceng185er7.ref80">Povsic
|
|
TJ, Roe
|
|
MT, Ohman
|
|
EM, Steg
|
|
PG, James
|
|
S, Plotnikov
|
|
A
|
|
et al. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. American Heart Journal. 2016; 174:120–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/26995378" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26995378</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>81.</dt><dd><div class="bk_ref" id="niceng185er7.ref81">Sambola
|
|
A, Montoro
|
|
JB, Del Blanco
|
|
BG, Llavero
|
|
N, Barrabes
|
|
JA, Alfonso
|
|
F
|
|
et al. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial. American Heart Journal. 2013; 166(4):669–75 [<a href="https://pubmed.ncbi.nlm.nih.gov/24093846" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24093846</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>82.</dt><dd><div class="bk_ref" id="niceng185er7.ref82">Schwalm
|
|
JD, Ahmad
|
|
M, Salehian
|
|
O, Eikelboom
|
|
JW, Natarajan
|
|
MK. Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: A randomized feasibility trial. Journal of Thrombosis and Thrombolysis. 2010; 30(2):127–132 [<a href="https://pubmed.ncbi.nlm.nih.gov/20157843" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20157843</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>83.</dt><dd><div class="bk_ref" id="niceng185er7.ref83">Shin
|
|
D, Mohanty
|
|
BD, Lee
|
|
ES. Dual versus triple antithrombotic therapy after percutaneous coronary intervention or acute coronary syndrome in patients with indication for anticoagulation: an updated meta-analysis. Coronary Artery Disease. 2018; 29(8):670–680 [<a href="https://pubmed.ncbi.nlm.nih.gov/30222595" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30222595</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>84.</dt><dd><div class="bk_ref" id="niceng185er7.ref84">Steg
|
|
PG, Mehta
|
|
SR, Jukema
|
|
JW, Lip
|
|
GY, Gibson
|
|
CM, Kovar
|
|
F
|
|
et al. RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. European Heart Journal. 2011; 32(20):2541–54 [<a href="/pmc/articles/PMC3295208/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3295208</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21878434" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21878434</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>85.</dt><dd><div class="bk_ref" id="niceng185er7.ref85">Tan
|
|
JY, Shi
|
|
WH, He
|
|
J, Zhu
|
|
L, Wang
|
|
TP, Yu
|
|
B. A clinical trial of using antiplatelet therapy to prevent restenosis following peripheral artery angioplasty and stenting. Chinese Journal of Medical Genetics. 2008; 88(12):812–815 [<a href="https://pubmed.ncbi.nlm.nih.gov/18756983" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18756983</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>86.</dt><dd><div class="bk_ref" id="niceng185er7.ref86">Vafaey
|
|
HR, Omran
|
|
MTS, Abbaspour
|
|
S, Banihashem
|
|
N, Ganji
|
|
GF. Anti-coagulation therapy following coronary endarterectomy in patient with coronary artery bypass graft. Caspian Journal of Internal Medicine. 2018; 9(1):27–31 [<a href="/pmc/articles/PMC5771357/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5771357</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29387316" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29387316</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>87.</dt><dd><div class="bk_ref" id="niceng185er7.ref87">Vranckx
|
|
P, Lewalter
|
|
T, Valgimigli
|
|
M, Tijssen
|
|
JG, Reimitz
|
|
PE, Eckardt
|
|
L
|
|
et al. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. American Heart Journal. 2018; 196:105–112 [<a href="https://pubmed.ncbi.nlm.nih.gov/29421002" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29421002</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>88.</dt><dd><div class="bk_ref" id="niceng185er7.ref88">Vranckx
|
|
P, Valgimigli
|
|
M, Eckardt
|
|
L, Tijssen
|
|
J, Lewalter
|
|
T, Gargiulo
|
|
G
|
|
et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019; 394(10206):P1335–1343 [<a href="https://pubmed.ncbi.nlm.nih.gov/31492505" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31492505</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>89.</dt><dd><div class="bk_ref" id="niceng185er7.ref89">Windecker
|
|
S, Tijssen
|
|
J, Giustino
|
|
G, Guimaraes
|
|
AH, Mehran
|
|
R, Valgimigli
|
|
M
|
|
et al. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. American Heart Journal. 2017; 184:81–87 [<a href="https://pubmed.ncbi.nlm.nih.gov/27892890" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27892890</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>90.</dt><dd><div class="bk_ref" id="niceng185er7.ref90">Yasuda
|
|
S, Kaikita
|
|
K, Ogawa
|
|
H, Akao
|
|
M, Ako
|
|
J, Matoba
|
|
T
|
|
et al. Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study. International Journal of Cardiology. 2018; 265:108–112 [<a href="https://pubmed.ncbi.nlm.nih.gov/29764706" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29764706</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>91.</dt><dd><div class="bk_ref" id="niceng185er7.ref91">Yuan
|
|
J. Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. BMC Pharmacology & Toxicology. 2018; 19:19 [<a href="/pmc/articles/PMC5932859/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5932859</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29720261" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29720261</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>92.</dt><dd><div class="bk_ref" id="niceng185er7.ref92">Zhang
|
|
J, Wang
|
|
Z, Sang
|
|
W, Wei
|
|
M, Xu
|
|
F, Chen
|
|
Y. Omission of aspirin in patients taking oral anticoagulation after percutaneous coronary intervention: A systematic review and meta-analysis. Coronary Artery Disease. 2019; 30(2):109–115 [<a href="https://pubmed.ncbi.nlm.nih.gov/30629002" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30629002</span></a>]</div></dd></dl></dl></div><div id="appendixesappgroup1"><h2 id="_appendixesappgroup1_">Appendices</h2><div id="niceng185er7.appa"><h3>Appendix A. Review protocols</h3><p id="niceng185er7.appa.et1"><a href="/books/NBK565359/bin/niceng185er7-appa-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 15. Review protocol: Combination therapy</a><span class="small"> (PDF, 412K)</span></p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appatab1"><a href="/books/NBK565359/table/niceng185er7.appa.tab1/?report=objectonly" target="object" title="Table 16" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appatab1" rid-ob="figobniceng185er7appatab1"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appa.tab1/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appa.tab1/?report=previmg" alt="Table 16. Health economic review protocol." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appa.tab1"><a href="/books/NBK565359/table/niceng185er7.appa.tab1/?report=objectonly" target="object" rid-ob="figobniceng185er7appatab1">Table 16</a></h4><p class="float-caption no_bottom_margin">Health economic review protocol. </p></div></div></div><div id="niceng185er7.appb"><h3>Appendix B. Literature search strategies</h3><p>The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.<a class="bibr" href="#niceng185er7.ref70" rid="niceng185er7.ref70"><sup>70</sup></a></p><p>For more information, please see the Methods report published as part of the accompanying documents for this guideline.</p><div id="niceng185er7.appb.s1"><h4>B.1. Clinical search literature search strategy</h4><p>Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appbtab1"><a href="/books/NBK565359/table/niceng185er7.appb.tab1/?report=objectonly" target="object" title="Table 17" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appbtab1" rid-ob="figobniceng185er7appbtab1"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appb.tab1/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appb.tab1/?report=previmg" alt="Table 17. Database date parameters and filters used." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appb.tab1"><a href="/books/NBK565359/table/niceng185er7.appb.tab1/?report=objectonly" target="object" rid-ob="figobniceng185er7appbtab1">Table 17</a></h4><p class="float-caption no_bottom_margin">Database date parameters and filters used. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appbtab2"><a href="/books/NBK565359/table/niceng185er7.appb.tab2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appbtab2" rid-ob="figobniceng185er7appbtab2"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appb.tab2/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appb.tab2/?report=previmg" alt="Medline (Ovid) search terms." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appb.tab2"><a href="/books/NBK565359/table/niceng185er7.appb.tab2/?report=objectonly" target="object" rid-ob="figobniceng185er7appbtab2">Table</a></h4><p class="float-caption no_bottom_margin">Medline (Ovid) search terms. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appbtab3"><a href="/books/NBK565359/table/niceng185er7.appb.tab3/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appbtab3" rid-ob="figobniceng185er7appbtab3"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appb.tab3/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appb.tab3/?report=previmg" alt="Embase (Ovid) search terms." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appb.tab3"><a href="/books/NBK565359/table/niceng185er7.appb.tab3/?report=objectonly" target="object" rid-ob="figobniceng185er7appbtab3">Table</a></h4><p class="float-caption no_bottom_margin">Embase (Ovid) search terms. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appbtab4"><a href="/books/NBK565359/table/niceng185er7.appb.tab4/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appbtab4" rid-ob="figobniceng185er7appbtab4"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appb.tab4/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appb.tab4/?report=previmg" alt="Cochrane Library (Wiley) search terms." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appb.tab4"><a href="/books/NBK565359/table/niceng185er7.appb.tab4/?report=objectonly" target="object" rid-ob="figobniceng185er7appbtab4">Table</a></h4><p class="float-caption no_bottom_margin">Cochrane Library (Wiley) search terms. </p></div></div></div><div id="niceng185er7.appb.s2"><h4>B.2. Health Economics literature search strategy</h4><p>Health economic evidence was identified by conducting a search relating to acute coronary syndromes population combined with terms for interventions in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional searches were run on Medline and Embase using a filter for health economics studies.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appbtab5"><a href="/books/NBK565359/table/niceng185er7.appb.tab5/?report=objectonly" target="object" title="Table 18" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appbtab5" rid-ob="figobniceng185er7appbtab5"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appb.tab5/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appb.tab5/?report=previmg" alt="Table 18. Database date parameters and filters used." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appb.tab5"><a href="/books/NBK565359/table/niceng185er7.appb.tab5/?report=objectonly" target="object" rid-ob="figobniceng185er7appbtab5">Table 18</a></h4><p class="float-caption no_bottom_margin">Database date parameters and filters used. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appbtab6"><a href="/books/NBK565359/table/niceng185er7.appb.tab6/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appbtab6" rid-ob="figobniceng185er7appbtab6"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appb.tab6/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appb.tab6/?report=previmg" alt="Medline (Ovid) search terms." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appb.tab6"><a href="/books/NBK565359/table/niceng185er7.appb.tab6/?report=objectonly" target="object" rid-ob="figobniceng185er7appbtab6">Table</a></h4><p class="float-caption no_bottom_margin">Medline (Ovid) search terms. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appbtab7"><a href="/books/NBK565359/table/niceng185er7.appb.tab7/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appbtab7" rid-ob="figobniceng185er7appbtab7"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appb.tab7/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appb.tab7/?report=previmg" alt="Embase (Ovid) search terms." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appb.tab7"><a href="/books/NBK565359/table/niceng185er7.appb.tab7/?report=objectonly" target="object" rid-ob="figobniceng185er7appbtab7">Table</a></h4><p class="float-caption no_bottom_margin">Embase (Ovid) search terms. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appbtab8"><a href="/books/NBK565359/table/niceng185er7.appb.tab8/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appbtab8" rid-ob="figobniceng185er7appbtab8"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appb.tab8/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appb.tab8/?report=previmg" alt="NHS EED and HTA (CRD) search terms." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appb.tab8"><a href="/books/NBK565359/table/niceng185er7.appb.tab8/?report=objectonly" target="object" rid-ob="figobniceng185er7appbtab8">Table</a></h4><p class="float-caption no_bottom_margin">NHS EED and HTA (CRD) search terms. </p></div></div></div></div><div id="niceng185er7.appc"><h3>Appendix C. Clinical evidence selection</h3><p id="niceng185er7.appc.fig1"><a href="/books/NBK565359/figure/niceng185er7.appc.fig1/?report=objectonly" target="object" rid-ob="figobniceng185er7appcfig1" class="figpopup">Figure 1. Flow chart of clinical study selection for the review of combination therapy</a></p></div><div id="niceng185er7.appd"><h3>Appendix D. Clinical evidence tables</h3><p id="niceng185er7.appd.et1"><a href="/books/NBK565359/bin/niceng185er7-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (354K)</span></p></div><div id="niceng185er7.appe"><h3>Appendix E. Forest plots</h3><div id="niceng185er7.appe.s1"><h4>E.1. Warfarin + clopidogrel + aspirin versus warfarin + clopidogrel</h4></div><div id="niceng185er7.appe.s2"><h4>E.2. AUGUSTUS data only</h4><p id="niceng185er7.appe.fig1"><a href="/books/NBK565359/figure/niceng185er7.appe.fig1/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig1" class="figpopup">Figure 2. All-cause mortality (6 months)</a></p><p id="niceng185er7.appe.fig2"><a href="/books/NBK565359/figure/niceng185er7.appe.fig2/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig2" class="figpopup">Figure 3. Myocardial infarction (6 months)</a></p><p id="niceng185er7.appe.fig3"><a href="/books/NBK565359/figure/niceng185er7.appe.fig3/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig3" class="figpopup">Figure 4. Stroke (6 months)</a></p><p id="niceng185er7.appe.fig4"><a href="/books/NBK565359/figure/niceng185er7.appe.fig4/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig4" class="figpopup">Figure 5. Any stent thrombosis (6 months)</a></p><p id="niceng185er7.appe.fig5"><a href="/books/NBK565359/figure/niceng185er7.appe.fig5/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig5" class="figpopup">Figure 6. Complications relating to bleeding (6 months)</a></p></div><div id="niceng185er7.appe.s3"><h4>E.3. Warfarin + clopidogrel + aspirin versus dabigatran + clopidogrel</h4><p id="niceng185er7.appe.fig6"><a href="/books/NBK565359/figure/niceng185er7.appe.fig6/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig6" class="figpopup">Figure 7. All-cause mortality (14 months)</a></p><p id="niceng185er7.appe.fig7"><a href="/books/NBK565359/figure/niceng185er7.appe.fig7/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig7" class="figpopup">Figure 8. Myocardial infarction (14 months)</a></p><p id="niceng185er7.appe.fig8"><a href="/books/NBK565359/figure/niceng185er7.appe.fig8/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig8" class="figpopup">Figure 9. Stroke (14 months)</a></p><p id="niceng185er7.appe.fig9"><a href="/books/NBK565359/figure/niceng185er7.appe.fig9/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig9" class="figpopup">Figure 10. Definite stent thrombosis (14 months)</a></p><p id="niceng185er7.appe.fig10"><a href="/books/NBK565359/figure/niceng185er7.appe.fig10/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig10" class="figpopup">Figure 11. Complications relating to bleeding (14 months)</a></p></div><div id="niceng185er7.appe.s4"><h4>E.4. Rivaroxaban + clopidogrel + aspirin versus rivaroxaban + clopidogrel</h4><p id="niceng185er7.appe.fig11"><a href="/books/NBK565359/figure/niceng185er7.appe.fig11/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig11" class="figpopup">Figure 12. All cause mortality (12 months)</a></p><p id="niceng185er7.appe.fig12"><a href="/books/NBK565359/figure/niceng185er7.appe.fig12/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig12" class="figpopup">Figure 13. Myocardial infarction (12 months)</a></p><p id="niceng185er7.appe.fig13"><a href="/books/NBK565359/figure/niceng185er7.appe.fig13/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig13" class="figpopup">Figure 14. Stroke (12 months)</a></p><p id="niceng185er7.appe.fig14"><a href="/books/NBK565359/figure/niceng185er7.appe.fig14/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig14" class="figpopup">Figure 15. Stent thrombosis (12 months)</a></p><p id="niceng185er7.appe.fig15"><a href="/books/NBK565359/figure/niceng185er7.appe.fig15/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig15" class="figpopup">Figure 16. Complications relating to bleeding (12 months)</a></p></div><div id="niceng185er7.appe.s5"><h4>E.5. Rivaroxaban + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin</h4><p id="niceng185er7.appe.fig16"><a href="/books/NBK565359/figure/niceng185er7.appe.fig16/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig16" class="figpopup">Figure 17. All-cause mortality (12 months)</a></p><p id="niceng185er7.appe.fig17"><a href="/books/NBK565359/figure/niceng185er7.appe.fig17/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig17" class="figpopup">Figure 18. Myocardial infarction (12 months)</a></p><p id="niceng185er7.appe.fig18"><a href="/books/NBK565359/figure/niceng185er7.appe.fig18/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig18" class="figpopup">Figure 19. Stroke (12 months)</a></p><p id="niceng185er7.appe.fig19"><a href="/books/NBK565359/figure/niceng185er7.appe.fig19/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig19" class="figpopup">Figure 20. Stent thrombosis (12 months)</a></p><p id="niceng185er7.appe.fig20"><a href="/books/NBK565359/figure/niceng185er7.appe.fig20/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig20" class="figpopup">Figure 21. Complications relating to bleeding (12 months)</a></p></div><div id="niceng185er7.appe.s6"><h4>E.6. Warfarin + clopidogrel + aspirin versus rivaroxaban + clopidogrel</h4><p id="niceng185er7.appe.fig21"><a href="/books/NBK565359/figure/niceng185er7.appe.fig21/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig21" class="figpopup">Figure 22. All-cause mortality (12 months)</a></p><p id="niceng185er7.appe.fig22"><a href="/books/NBK565359/figure/niceng185er7.appe.fig22/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig22" class="figpopup">Figure 23. Myocardial infarction (12 months)</a></p><p id="niceng185er7.appe.fig23"><a href="/books/NBK565359/figure/niceng185er7.appe.fig23/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig23" class="figpopup">Figure 24. Stroke (12 months)</a></p><p id="niceng185er7.appe.fig24"><a href="/books/NBK565359/figure/niceng185er7.appe.fig24/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig24" class="figpopup">Figure 25. Stent thrombosis (12 months)</a></p><p id="niceng185er7.appe.fig25"><a href="/books/NBK565359/figure/niceng185er7.appe.fig25/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig25" class="figpopup">Figure 26. Complications relating to bleeding (12 months)</a></p></div><div id="niceng185er7.appe.s7"><h4>E.7. AUGUSTUS – Apixaban + clopidogrel + aspirin versus apixaban + clopidogrel</h4><p id="niceng185er7.appe.fig26"><a href="/books/NBK565359/figure/niceng185er7.appe.fig26/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig26" class="figpopup">Figure 27. All-cause mortality (6 months)</a></p><p id="niceng185er7.appe.fig27"><a href="/books/NBK565359/figure/niceng185er7.appe.fig27/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig27" class="figpopup">Figure 28. Myocardial infarction (6 months)</a></p><p id="niceng185er7.appe.fig28"><a href="/books/NBK565359/figure/niceng185er7.appe.fig28/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig28" class="figpopup">Figure 29. Stroke (6 months)</a></p><p id="niceng185er7.appe.fig29"><a href="/books/NBK565359/figure/niceng185er7.appe.fig29/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig29" class="figpopup">Figure 30. Any stent thrombosis (6 months)</a></p><p id="niceng185er7.appe.fig30"><a href="/books/NBK565359/figure/niceng185er7.appe.fig30/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig30" class="figpopup">Figure 31. Complications related to bleeding (6 months)</a></p></div><div id="niceng185er7.appe.s8"><h4>E.8. AUGUSTUS – Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin</h4><p id="niceng185er7.appe.fig31"><a href="/books/NBK565359/figure/niceng185er7.appe.fig31/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig31" class="figpopup">Figure 32. All-cause mortality (6 months)</a></p><p id="niceng185er7.appe.fig32"><a href="/books/NBK565359/figure/niceng185er7.appe.fig32/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig32" class="figpopup">Figure 33. Myocardial infarction (6 months)</a></p><p id="niceng185er7.appe.fig33"><a href="/books/NBK565359/figure/niceng185er7.appe.fig33/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig33" class="figpopup">Figure 34. Stroke (6 months)</a></p><p id="niceng185er7.appe.fig34"><a href="/books/NBK565359/figure/niceng185er7.appe.fig34/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig34" class="figpopup">Figure 35. Any stent thrombosis (6 months)</a></p><p id="niceng185er7.appe.fig35"><a href="/books/NBK565359/figure/niceng185er7.appe.fig35/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig35" class="figpopup">Figure 36. Complications related to bleeding (6 months)</a></p></div><div id="niceng185er7.appe.s9"><h4>E.9. AUGUSTUS – Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel</h4><p id="niceng185er7.appe.fig36"><a href="/books/NBK565359/figure/niceng185er7.appe.fig36/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig36" class="figpopup">Figure 37. All-cause mortality (6 months)</a></p><p id="niceng185er7.appe.fig37"><a href="/books/NBK565359/figure/niceng185er7.appe.fig37/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig37" class="figpopup">Figure 38. Myocardial infarction (6 months)</a></p><p id="niceng185er7.appe.fig38"><a href="/books/NBK565359/figure/niceng185er7.appe.fig38/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig38" class="figpopup">Figure 39. Stroke (6 months)</a></p><p id="niceng185er7.appe.fig39"><a href="/books/NBK565359/figure/niceng185er7.appe.fig39/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig39" class="figpopup">Figure 40. Any stent thrombosis (6 months)</a></p><p id="niceng185er7.appe.fig40"><a href="/books/NBK565359/figure/niceng185er7.appe.fig40/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig40" class="figpopup">Figure 41. Complications related to bleeding (6 months)</a></p></div><div id="niceng185er7.appe.s10"><h4>E.10. AUGUSTUS – Warfarin + clopidogrel + aspirin versus apixaban + clopidogrel</h4><p id="niceng185er7.appe.fig41"><a href="/books/NBK565359/figure/niceng185er7.appe.fig41/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig41" class="figpopup">Figure 42. All-cause mortality (6 months)</a></p><p id="niceng185er7.appe.fig42"><a href="/books/NBK565359/figure/niceng185er7.appe.fig42/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig42" class="figpopup">Figure 43. Myocardial infarction (6 months)</a></p><p id="niceng185er7.appe.fig43"><a href="/books/NBK565359/figure/niceng185er7.appe.fig43/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig43" class="figpopup">Figure 44. Stroke (6 months)</a></p><p id="niceng185er7.appe.fig44"><a href="/books/NBK565359/figure/niceng185er7.appe.fig44/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig44" class="figpopup">Figure 45. Any stent thrombosis (6 months)</a></p><p id="niceng185er7.appe.fig45"><a href="/books/NBK565359/figure/niceng185er7.appe.fig45/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig45" class="figpopup">Figure 46. Complications relating to bleeding (6 months)</a></p></div><div id="niceng185er7.appe.s11"><h4>E.11. AUGUSTUS – Apixaban + clopidogrel versus warfarin + clopidogrel</h4><p id="niceng185er7.appe.fig46"><a href="/books/NBK565359/figure/niceng185er7.appe.fig46/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig46" class="figpopup">Figure 47. All-cause mortality (6 months)</a></p><p id="niceng185er7.appe.fig47"><a href="/books/NBK565359/figure/niceng185er7.appe.fig47/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig47" class="figpopup">Figure 48. Myocardial infarction (6 months)</a></p><p id="niceng185er7.appe.fig48"><a href="/books/NBK565359/figure/niceng185er7.appe.fig48/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig48" class="figpopup">Figure 49. Stroke (6 months)</a></p><p id="niceng185er7.appe.fig49"><a href="/books/NBK565359/figure/niceng185er7.appe.fig49/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig49" class="figpopup">Figure 50. Any stent thrombosis (6 months)</a></p><p id="niceng185er7.appe.fig50"><a href="/books/NBK565359/figure/niceng185er7.appe.fig50/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig50" class="figpopup">Figure 51. Complications related to bleeding (6 months)</a></p></div><div id="niceng185er7.appe.s12"><h4>E.12. VKA + clopidogrel + aspirin versus edoxaban + clopidogrel</h4><p id="niceng185er7.appe.fig51"><a href="/books/NBK565359/figure/niceng185er7.appe.fig51/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig51" class="figpopup">Figure 52. Complications relating to bleeding (12 months)</a></p></div><div id="niceng185er7.appe.s13"><h4>E.13. Edoxaban + clopidogrel versus VKA + clopidogrel + aspirin</h4><p id="niceng185er7.appe.fig52"><a href="/books/NBK565359/figure/niceng185er7.appe.fig52/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig52" class="figpopup">Figure 53. All-cause mortality (12 months)</a></p><p id="niceng185er7.appe.fig53"><a href="/books/NBK565359/figure/niceng185er7.appe.fig53/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig53" class="figpopup">Figure 54. Stroke (12 months)</a></p><p id="niceng185er7.appe.fig54"><a href="/books/NBK565359/figure/niceng185er7.appe.fig54/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig54" class="figpopup">Figure 55. Myocardial infarction (12 months)</a></p><p id="niceng185er7.appe.fig55"><a href="/books/NBK565359/figure/niceng185er7.appe.fig55/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig55" class="figpopup">Figure 56. Stent thrombosis (12 months)</a></p><p id="niceng185er7.appe.fig56"><a href="/books/NBK565359/figure/niceng185er7.appe.fig56/?report=objectonly" target="object" rid-ob="figobniceng185er7appefig56" class="figpopup">Figure 57. Complications relating to bleeding (12 months)</a></p></div></div><div id="niceng185er7.appf"><h3>Appendix F. GRADE tables</h3><p id="niceng185er7.appf.tab1"><a href="/books/NBK565359/table/niceng185er7.appf.tab1/?report=objectonly" target="object" rid-ob="figobniceng185er7appftab1" class="figpopup">Table 19. Clinical evidence profile: Warfarin + clopidogrel + aspirin versus warfarin + clopidogrel (AUGUSTUS data only)</a></p><p id="niceng185er7.appf.tab2"><a href="/books/NBK565359/table/niceng185er7.appf.tab2/?report=objectonly" target="object" rid-ob="figobniceng185er7appftab2" class="figpopup">Table 20. Clinical evidence profile: Warfarin + clopidogrel + aspirin versus dabigatran + clopidogrel</a></p><p id="niceng185er7.appf.tab3"><a href="/books/NBK565359/table/niceng185er7.appf.tab3/?report=objectonly" target="object" rid-ob="figobniceng185er7appftab3" class="figpopup">Table 21. Clinical evidence profile: Rivaroxaban + clopidogrel + aspirin versus rivaroxaban + clopidogrel</a></p><p id="niceng185er7.appf.tab4"><a href="/books/NBK565359/table/niceng185er7.appf.tab4/?report=objectonly" target="object" rid-ob="figobniceng185er7appftab4" class="figpopup">Table 22. Clinical evidence profile: Rivaroxaban + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin</a></p><p id="niceng185er7.appf.tab5"><a href="/books/NBK565359/table/niceng185er7.appf.tab5/?report=objectonly" target="object" rid-ob="figobniceng185er7appftab5" class="figpopup">Table 23. Clinical evidence profile: Warfarin + clopidogrel + aspirin versus Rivaroxaban + clopidogrel</a></p><p id="niceng185er7.appf.tab6"><a href="/books/NBK565359/table/niceng185er7.appf.tab6/?report=objectonly" target="object" rid-ob="figobniceng185er7appftab6" class="figpopup">Table 24. Clinical evidence profile: AUGUSTUS – apixaban + clopidogrel + aspirin versus apixaban + clopidogrel</a></p><p id="niceng185er7.appf.tab7"><a href="/books/NBK565359/table/niceng185er7.appf.tab7/?report=objectonly" target="object" rid-ob="figobniceng185er7appftab7" class="figpopup">Table 25. Clinical evidence profile: AUGUSTUS – Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin</a></p><p id="niceng185er7.appf.tab8"><a href="/books/NBK565359/table/niceng185er7.appf.tab8/?report=objectonly" target="object" rid-ob="figobniceng185er7appftab8" class="figpopup">Table 26. Clinical evidence profile: AUGUSTUS – Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel</a></p><p id="niceng185er7.appf.tab9"><a href="/books/NBK565359/table/niceng185er7.appf.tab9/?report=objectonly" target="object" rid-ob="figobniceng185er7appftab9" class="figpopup">Table 27. Clinical evidence profile: AUGUSTUS – Warfarin + clopidogrel + aspirin versus apixaban + clopidogrel</a></p><p id="niceng185er7.appf.tab10"><a href="/books/NBK565359/table/niceng185er7.appf.tab10/?report=objectonly" target="object" rid-ob="figobniceng185er7appftab10" class="figpopup">Table 28. Clinical evidence profile: AUGUSTUS – Apixaban + clopidogrel versus warfarin + clopidogrel</a></p><p id="niceng185er7.appf.tab11"><a href="/books/NBK565359/table/niceng185er7.appf.tab11/?report=objectonly" target="object" rid-ob="figobniceng185er7appftab11" class="figpopup">Table 29. Clinical evidence profile: VKA + clopidogrel + aspirin versus edoxaban + clopidogrel (ENTRUST-AF PCI)</a></p><p id="niceng185er7.appf.tab12"><a href="/books/NBK565359/table/niceng185er7.appf.tab12/?report=objectonly" target="object" rid-ob="figobniceng185er7appftab12" class="figpopup">Table 30. Clinical evidence summary: edoxaban + clopidogrel versus VKA + clopidogrel + aspirin (ENTRUST-AF PCI)</a></p></div><div id="niceng185er7.appg"><h3>Appendix G. Network meta-analysis: Sensitivity analyses using Lopes 2019</h3><div id="niceng185er7.appg.s1"><h4>Introduction</h4><p>Whilst reviewing the pairwise outcome data, the committee found it difficult to reach an over-arching conclusion about the most clinically effective treatment/s. The committee considered the proposal of conducting network meta-analyses (NMAs) in this evidence review to inform decision-making. Traditionally, an NMA can provide some clarity around the relative effects for treatments within a network and aid decision-making.</p><p>A recently published NMA was identified as being relevant for this review (Lopes 2019) <a class="bibr" href="#niceng185er7.ref61" rid="niceng185er7.ref61"><sup>61</sup></a>. Whilst reviewing this publication some differences between the evidence-base of Lopes 2019 and this guideline evidence-base were highlighted:
|
|
<ul><li class="half_rhythm"><div>The committee agreed a threshold of >60% ACS (with 50-60% being acceptable but downgraded) for inclusion in this review, Lopes 2019 did not have a threshold for ACS</div></li><li class="half_rhythm"><div>One of the studies (included in Lopes 2019) was excluded from this evidence review as the population of ACS was only 28% <a class="bibr" href="#niceng185er7.ref27" rid="niceng185er7.ref27"><sup>27</sup></a></div></li><li class="half_rhythm"><div>A recent additional study was included this evidence review but was not included in the published NMA <a class="bibr" href="#niceng185er7.ref88" rid="niceng185er7.ref88"><sup>88</sup></a></div></li><li class="half_rhythm"><div>This review has analysed drugs separately, Lopes 2019 has combined drugs into their classes in their analyses, e.g. apixaban and rivaroxaban are classified as NOACs</div></li></ul></p></div><div id="niceng185er7.appg.s2"><h4>Objective</h4><p>Sensitivity analyses were conducted to assess if it was appropriate to use Lopes 2019 to inform decision-making. The sensitivity analyses took into account the current guideline evidence-base for the question on the most clinically and cost effective combination of antiplatelet and anticoagulant therapies for people who have had an ACS and a separate indication for anticoagulation.</p></div><div id="niceng185er7.appg.s3"><h4>Statistical Methods</h4><p>The description of the statistical methods used is described elsewhere in the guideline, see NMA document. Whilst relative risk values have been reported in this evidence review for pairwise meta-analyses, odd ratios have been used to be consistent with the summary statistics reported in Lopes 2019.</p></div><div id="niceng185er7.appg.s4"><h4>Results</h4><p>Network meta-analyses were conducted for three outcomes (all-cause mortality, myocardial infarction and major bleeding). All of the networks were informed by outcome data from the four trials included in this evidence review. Outcome data for all-cause mortality, myocardial infarction and major bleeding can be found in <a class="figpopup" href="/books/NBK565359/table/niceng185er7.appg.tab1/?report=objectonly" target="object" rid-figpopup="figniceng185er7appgtab1" rid-ob="figobniceng185er7appgtab1">Table 31</a>, <a class="figpopup" href="/books/NBK565359/table/niceng185er7.appg.tab2/?report=objectonly" target="object" rid-figpopup="figniceng185er7appgtab2" rid-ob="figobniceng185er7appgtab2">Table 32</a>, <a class="figpopup" href="/books/NBK565359/table/niceng185er7.appg.tab3/?report=objectonly" target="object" rid-figpopup="figniceng185er7appgtab3" rid-ob="figobniceng185er7appgtab3">Table 33</a>, respectively. The network diagram for all of the outcomes is displayed in <a class="figpopup" href="/books/NBK565359/figure/niceng185er7.appg.fig1/?report=objectonly" target="object" rid-figpopup="figniceng185er7appgfig1" rid-ob="figobniceng185er7appgfig1">Figure 58</a>.</p><p>The results (odd ratios) for the network meta-analyses were compared in plots for each of the outcomes, as seen in <a class="figpopup" href="/books/NBK565359/figure/niceng185er7.appg.fig2/?report=objectonly" target="object" rid-figpopup="figniceng185er7appgfig2" rid-ob="figobniceng185er7appgfig2">Figure 59</a>, <a class="figpopup" href="/books/NBK565359/figure/niceng185er7.appg.fig3/?report=objectonly" target="object" rid-figpopup="figniceng185er7appgfig3" rid-ob="figobniceng185er7appgfig3">Figure 60</a>, <a class="figpopup" href="/books/NBK565359/figure/niceng185er7.appg.fig4/?report=objectonly" target="object" rid-figpopup="figniceng185er7appgfig4" rid-ob="figobniceng185er7appgfig4">Figure 61</a>. Checks for inconsistency were conducted following methods described in the NMA chapter. No inconsistency was identified in the three networks.</p><div id="niceng185er7.appg.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2058.%20Network%20diagram%20for%20the%20three%20outcomes%20(all-cause%20mortality%2C%20myocardial%20infarction%20and%20major%20bleeding).&p=BOOKS&id=565359_niceng185er7appgf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK565359/bin/niceng185er7appgf1.jpg" alt="Figure 58. Network diagram for the three outcomes (all-cause mortality, myocardial infarction and major bleeding)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 58</span><span class="title">Network diagram for the three outcomes (all-cause mortality, myocardial infarction and major bleeding)</span></h3></div></div><div id="niceng185er7.appg.s5"><h4>All-cause mortality</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appgtab1"><a href="/books/NBK565359/table/niceng185er7.appg.tab1/?report=objectonly" target="object" title="Table 31" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appgtab1" rid-ob="figobniceng185er7appgtab1"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appg.tab1/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appg.tab1/?report=previmg" alt="Table 31. Study data for all-cause mortality network meta-analysis – guideline review evidence-base." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appg.tab1"><a href="/books/NBK565359/table/niceng185er7.appg.tab1/?report=objectonly" target="object" rid-ob="figobniceng185er7appgtab1">Table 31</a></h4><p class="float-caption no_bottom_margin">Study data for all-cause mortality network meta-analysis – guideline review evidence-base. </p></div></div><div id="niceng185er7.appg.fig2" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2059.%20Sensitivity%20analysis%20results%20(odds%20ratios)%20%02013%20NMA%20conducted%20for%20this%20evidence%20review%20compared%20with%20Lopes%202019%20results%20%02013%20all-cause%20mortality.&p=BOOKS&id=565359_niceng185er7appgf2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK565359/bin/niceng185er7appgf2.jpg" alt="Figure 59. Sensitivity analysis results (odds ratios) – NMA conducted for this evidence review compared with Lopes 2019 results – all-cause mortality." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 59</span><span class="title">Sensitivity analysis results (odds ratios) – NMA conducted for this evidence review compared with Lopes 2019 results – all-cause mortality</span></h3><div class="caption"><p>Blue circle = Lopes 2019; Orange circle = National Guideline Centre</p></div></div></div><div id="niceng185er7.appg.s6"><h4>Myocardial infarction</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appgtab2"><a href="/books/NBK565359/table/niceng185er7.appg.tab2/?report=objectonly" target="object" title="Table 32" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appgtab2" rid-ob="figobniceng185er7appgtab2"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appg.tab2/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appg.tab2/?report=previmg" alt="Table 32. Study data for myocardial infarction network meta-analysis – guideline review evidence-base." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appg.tab2"><a href="/books/NBK565359/table/niceng185er7.appg.tab2/?report=objectonly" target="object" rid-ob="figobniceng185er7appgtab2">Table 32</a></h4><p class="float-caption no_bottom_margin">Study data for myocardial infarction network meta-analysis – guideline review evidence-base. </p></div></div><div id="niceng185er7.appg.fig3" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2060.%20Sensitivity%20analysis%20results%20(odds%20ratios)%20%02013%20NMA%20conducted%20for%20this%20evidence%20review%20compared%20with%20Lopes%202019%20results%20%02013%20myocardial%20infarction.&p=BOOKS&id=565359_niceng185er7appgf3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK565359/bin/niceng185er7appgf3.jpg" alt="Figure 60. Sensitivity analysis results (odds ratios) – NMA conducted for this evidence review compared with Lopes 2019 results – myocardial infarction." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 60</span><span class="title">Sensitivity analysis results (odds ratios) – NMA conducted for this evidence review compared with Lopes 2019 results – myocardial infarction</span></h3><div class="caption"><p>Blue circle = Lopes 2019; Orange circle = National Guideline Centre</p></div></div></div><div id="niceng185er7.appg.s7"><h4>Major bleeding</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appgtab3"><a href="/books/NBK565359/table/niceng185er7.appg.tab3/?report=objectonly" target="object" title="Table 33" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appgtab3" rid-ob="figobniceng185er7appgtab3"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appg.tab3/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appg.tab3/?report=previmg" alt="Table 33. Study data for major bleeding network meta-analysis – guideline review evidence-base." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appg.tab3"><a href="/books/NBK565359/table/niceng185er7.appg.tab3/?report=objectonly" target="object" rid-ob="figobniceng185er7appgtab3">Table 33</a></h4><p class="float-caption no_bottom_margin">Study data for major bleeding network meta-analysis – guideline review evidence-base. </p></div></div><div id="niceng185er7.appg.fig4" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2061.%20Sensitivity%20analysis%20results%20(odds%20ratios)%20%02013%20NMA%20conducted%20for%20this%20evidence%20review%20compared%20with%20Lopes%202019%20results%20%02013%20major%20bleeding.&p=BOOKS&id=565359_niceng185er7appgf4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK565359/bin/niceng185er7appgf4.jpg" alt="Figure 61. Sensitivity analysis results (odds ratios) – NMA conducted for this evidence review compared with Lopes 2019 results – major bleeding." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 61</span><span class="title">Sensitivity analysis results (odds ratios) – NMA conducted for this evidence review compared with Lopes 2019 results – major bleeding</span></h3><div class="caption"><p>Blue circle = Lopes 2019; Orange circle = National Guideline Centre</p></div></div></div><div id="niceng185er7.appg.s8"><h4>Conclusion</h4><p>The sensitivity analyses showed that there seemed to be good agreement between the results for major bleeding, but there are some differences in the point estimates for the other two outcomes. Since there were some differences in the direction of relative effectiveness estimated from the two evidence bases, the committee concluded that Lopes 2019 is not representative of the guideline’s evidence base and its results did not influence decision-making. Nevertheless, based on the guideline-specific results for the three outcomes considered, there was not enough evidence to conclude any differences between the clinical effectiveness and harms of these treatments. There is a lot of uncertainty in the relative effects, with overlapping credible intervals. The committee concluded that there is not enough evidence to conclude these treatments are more effective or safer than the others.</p><p>See <a href="#niceng185er7.s1.8">section 1.8</a> for full details on the committee’s discussion of the evidence.</p></div></div><div id="niceng185er7.apph"><h3>Appendix H. Health economic evidence selection</h3><p id="niceng185er7.apph.fig1"><a href="/books/NBK565359/figure/niceng185er7.apph.fig1/?report=objectonly" target="object" rid-ob="figobniceng185er7apphfig1" class="figpopup">Figure 62. Flow chart of health economic study selection for the guideline</a></p></div><div id="niceng185er7.appi"><h3>Appendix I. Health economic evidence tables</h3><p>None.</p></div><div id="niceng185er7.appj"><h3>Appendix J. Excluded studies</h3><div id="niceng185er7.appj.s1"><h4>J.1. Excluded clinical studies</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appjtab1"><a href="/books/NBK565359/table/niceng185er7.appj.tab1/?report=objectonly" target="object" title="Table 34" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appjtab1" rid-ob="figobniceng185er7appjtab1"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appj.tab1/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appj.tab1/?report=previmg" alt="Table 34. Studies excluded from the clinical review." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appj.tab1"><a href="/books/NBK565359/table/niceng185er7.appj.tab1/?report=objectonly" target="object" rid-ob="figobniceng185er7appjtab1">Table 34</a></h4><p class="float-caption no_bottom_margin">Studies excluded from the clinical review. </p></div></div></div><div id="niceng185er7.appj.s2"><h4>J.2. Excluded health economic studies</h4><p>Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2003 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er7appjtab2"><a href="/books/NBK565359/table/niceng185er7.appj.tab2/?report=objectonly" target="object" title="Table 35" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er7appjtab2" rid-ob="figobniceng185er7appjtab2"><img class="small-thumb" src="/books/NBK565359/table/niceng185er7.appj.tab2/?report=thumb" src-large="/books/NBK565359/table/niceng185er7.appj.tab2/?report=previmg" alt="Table 35. Studies excluded from the health economic review." /></a><div class="icnblk_cntnt"><h4 id="niceng185er7.appj.tab2"><a href="/books/NBK565359/table/niceng185er7.appj.tab2/?report=objectonly" target="object" rid-ob="figobniceng185er7appjtab2">Table 35</a></h4><p class="float-caption no_bottom_margin">Studies excluded from the health economic review. </p></div></div></div></div></div><div style="display:none"><div style="display:none" id="figniceng185er7appgfig1"><img alt="Image niceng185er7appgf1" src-large="/books/NBK565359/bin/niceng185er7appgf1.jpg" /></div><div style="display:none" id="figniceng185er7appgfig2"><img alt="Image niceng185er7appgf2" src-large="/books/NBK565359/bin/niceng185er7appgf2.jpg" /></div><div style="display:none" id="figniceng185er7appgfig3"><img alt="Image niceng185er7appgf3" src-large="/books/NBK565359/bin/niceng185er7appgf3.jpg" /></div><div style="display:none" id="figniceng185er7appgfig4"><img alt="Image niceng185er7appgf4" src-large="/books/NBK565359/bin/niceng185er7appgf4.jpg" /></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Intervention evidence review</p><p>This evidence review was developed by the National Guideline Centre based at the Royal College of Physicians</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.</p><p>Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2020.</div><div class="small"><span class="label">Bookshelf ID: NBK565359</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33301268" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">33301268</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobniceng185er7tab1"><div id="niceng185er7.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO characteristics of review question</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng185er7.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_niceng185er7.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Adults (≥ 18 years) who have had ACS and a comorbid condition needing oral anticoagulation.</div></li></ul>
|
|
The following groups may be included:
|
|
<ul><li class="half_rhythm"><div>Patients with mechanical valve replacements</div></li><li class="half_rhythm"><div>Patients with VTE needing continuing treatment</div></li><li class="half_rhythm"><div>Patients who have left ventricular thrombus</div></li><li class="half_rhythm"><div>Patients with atrial fibrillation (AF) who have had an MI and are taking anticoagulant agents</div></li><li class="half_rhythm"><div>Mixed populations (ACS and stable) may be included if > 60% ACS</div></li><li class="half_rhythm"><div>Papers including between 50-60% ACS may be included and downgraded for indirectness except for bleeding outcomes as these are not likely to be different in stable and unstable patients</div></li></ul></td></tr><tr><th id="hd_b_niceng185er7.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Interventions</th><td headers="hd_b_niceng185er7.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p><b>Intervention = Post discharge treatment</b> (may be initiated in hospital but should not be stopped before discharge).
|
|
<ul><li class="half_rhythm"><div>Dual antiplatelet therapy + warfarin</div></li><li class="half_rhythm"><div>Dual antiplatelet therapy + rivaroaiban</div></li><li class="half_rhythm"><div>Dual antiplatelet therapy + dabigatran</div></li><li class="half_rhythm"><div>Dual antiplatelet therapy + apixaban</div></li><li class="half_rhythm"><div>Dual antiplatelet therapy + edoxaban</div></li><li class="half_rhythm"><div>Asprin + apixaban</div></li><li class="half_rhythm"><div>Aspirin + warfarin</div></li><li class="half_rhythm"><div>Aspirin + rivaroxaban</div></li><li class="half_rhythm"><div>Aspirin + dabigatran</div></li><li class="half_rhythm"><div>Aspirin + edoxaban</div></li><li class="half_rhythm"><div>Clopidogrel/prasugrel/ticagrelor + warfarin</div></li><li class="half_rhythm"><div>Clopidogrel/prasugrel/ticagrelor + rivaroxaban</div></li><li class="half_rhythm"><div>Clopidogrel/prasugrel/ticagrelor + dabigatran</div></li><li class="half_rhythm"><div>Clopidogrel/prasugrel/ticagrelor + apixaban</div></li><li class="half_rhythm"><div>Clopidogrel/prasugrel/ticagrelor + edoxaban</div></li></ul></p>
|
|
<p>Note</p>
|
|
<p>Dual antiplatelet therapy = aspirin + clopidogrel/ticagrelor/prasugrel</p>
|
|
<p><b>Duration</b></p>
|
|
<p>Studies with durations of follow up of up to 2 years will be included in the review. The duration of treatment and follow up will be considered when evaluating the benefits and risks for these therapies:</p></td></tr><tr><th id="hd_b_niceng185er7.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparisons</th><td headers="hd_b_niceng185er7.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b>Comparison</b>
|
|
<ul><li class="half_rhythm"><div>Dual antiplatelet therapy alone</div></li><li class="half_rhythm"><div>Warfarin alone</div></li><li class="half_rhythm"><div>Rivaroxaban alone</div></li><li class="half_rhythm"><div>Dabigatran alone</div></li><li class="half_rhythm"><div>apixaban alone</div></li><li class="half_rhythm"><div>Aspirin alone</div></li><li class="half_rhythm"><div>Clopidogrel/prasugrel/ticagrelor alone</div></li><li class="half_rhythm"><div>Edoxaban</div></li></ul></td></tr><tr><th id="hd_b_niceng185er7.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_niceng185er7.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b>CRITICAL</b>
|
|
<ul><li class="half_rhythm"><div>All cause mortality - short term (≤30 days)</div></li><li class="half_rhythm"><div>All cause mortality- intermediate term (up to 1 year)</div></li><li class="half_rhythm"><div>All cause mortality- long term (>1 year)</div></li><li class="half_rhythm"><div>Myocardial re-infarction - short term (≤30 days)</div></li><li class="half_rhythm"><div>Myocardial re-infarction - intermediate term (up to 1 year)</div></li><li class="half_rhythm"><div>Myocardial re-infarction - short term (≤30 days)</div></li><li class="half_rhythm"><div>stroke - short term (≤30 days)</div></li><li class="half_rhythm"><div>stroke - long term (>1 year)</div></li><li class="half_rhythm"><div>stroke - short term (≤30 days)</div></li><li class="half_rhythm"><div>Complications related to bleeding short term (≤30 days), intermediate term (up to 1 year), and long term (>1 year) including haemorrhagic stroke – (access bleeding and non-access bleeding need to be differentiated)- the following hierarchy of bleeding scales will be used:
|
|
<ul class="circle"><li class="half_rhythm"><div>BARC</div></li><li class="half_rhythm"><div>Author’s definition</div></li><li class="half_rhythm"><div>TIMI</div></li><li class="half_rhythm"><div>GUSTO</div></li></ul>
|
|
Where possible, bleeding outcomes will be categorised into:
|
|
<ul class="circle"><li class="half_rhythm"><div>Major bleeding (including BARC 3-5 and as reported by author)</div></li><li class="half_rhythm"><div>Minor bleeding (including BARC 2, TIMI and as reported by author). – 1 year</div></li></ul></div></li><li class="half_rhythm"><div>Health-related quality of life including EQ5D and SF-36. All data for the stated quality of life measures will be collected. Only overall scores will be reported for meta-analysis and GRADE.</div></li></ul>
|
|
<b>IMPORTANT</b>
|
|
<ul><li class="half_rhythm"><div>withdrawal of study drug due to any side effect</div></li><li class="half_rhythm"><div>Probable and/or definite stent thrombosis at 1 year</div></li></ul></td></tr><tr><th id="hd_b_niceng185er7.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_niceng185er7.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Randomised Controlled Trials (RCT)</div></li><li class="half_rhythm"><div>Systematic Reviews (SR) of RCTs</div></li></ul></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er7tab2"><div id="niceng185er7.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Summary of studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng185er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention and comparison</th><th id="hd_h_niceng185er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><th id="hd_h_niceng185er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><th id="hd_h_niceng185er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p><b>REDUAL</b></p>
|
|
<p>Cannon 2016<a class="bibr" href="#niceng185er7.ref20" rid="niceng185er7.ref20"><sup>20</sup></a></p>
|
|
<p>Cannon 2017<a class="bibr" href="#niceng185er7.ref19" rid="niceng185er7.ref19"><sup>19</sup></a></p>
|
|
<p>Oldgren 2019<a class="bibr" href="#niceng185er7.ref75" rid="niceng185er7.ref75"><sup>75</sup></a></p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Warfarin (INR 2-3) plus a P2Y12 inhibitor (clopidogrel 75 mg daily or ticagrelor 90 mg twice daily) plus aspirin (≤100 mg daily)</p>
|
|
<p>Dabigatran (110 mg twice daily) plus a P2Y12 inhibitor (clopidogrel 75 mg daily or ticagrelor 90 mg twice daily)</p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>2725 people with atrial fibrillation who had undergone PCI</p>
|
|
<p>PCI population who also had AF</p>
|
|
<p>Stable angina: 43%; ACS: 50%; other: 6%</p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Death</p>
|
|
<p>Myocardial infarction</p>
|
|
<p>Stroke</p>
|
|
<p>Definite stent thrombosis</p>
|
|
<p>Complications related to bleeding
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">TIMI major bleeding</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">TIMI major or minor bleeding</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Intracranial haemorrhage</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Total bleeding</p></dd></dl></dl></p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Most of the patients received clopidogrel; only 12.0% received ticagrelor</td></tr><tr><td headers="hd_h_niceng185er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p><b>PIONEER AF PCI</b></p>
|
|
<p>Gibson 2016<a class="bibr" href="#niceng185er7.ref36" rid="niceng185er7.ref36"><sup>36</sup></a>,</p>
|
|
<p>Gibson 2015<a class="bibr" href="#niceng185er7.ref35" rid="niceng185er7.ref35"><sup>35</sup></a>,</p>
|
|
<p>Gibson 2017<a class="bibr" href="#niceng185er7.ref37" rid="niceng185er7.ref37"><sup>37</sup></a>,</p>
|
|
<p>Kerneis 2018<a class="bibr" href="#niceng185er7.ref49" rid="niceng185er7.ref49"><sup>49</sup></a></p>
|
|
<p>Kerneis 2019<a class="bibr" href="#niceng185er7.ref50" rid="niceng185er7.ref50"><sup>50</sup></a></p>
|
|
<p>Chi 2018<a class="bibr" href="#niceng185er7.ref23" rid="niceng185er7.ref23"><sup>23</sup></a></p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Rivaroxaban (15 mg once daily) plus clopidogrel (75 mg once daily) (or ticagrelor at a dose of 90 mg twice daily or prasugrel at a dose of 10 mg once daily in ≤15% of participants)</p>
|
|
<p>Rivaroxaban (2.5 mg twice daily) plus clopidogrel (75 mg once daily) (or ticagrelor at a dose of 90 mg twice daily or prasugrel at a dose of 10 mg once daily in ≤15% of participants) plus aspirin (75 to 100 mg per day)</p>
|
|
<p>Warfarin (INR 2-3) plus clopidogrel (75 mg once daily) (or ticagrelor at a dose of 90 mg twice daily or prasugrel at a dose of 10 mg once daily in ≤15% of participants+ aspirin) plus aspirin (75 to 100 mg per day)</p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>2124 people with paroxysmal, persistent, or permanent non-valvular atrial fibrillation who had undergone PCI with stenting</p>
|
|
<p>NSTEMI: 18%; STEMI: 12%; unstable angina: 22%</p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Death</p>
|
|
<p>Myocardial infarction</p>
|
|
<p>Stroke</p>
|
|
<p>Stent thrombosis</p>
|
|
<p>Complications related to bleeding
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Major bleeding</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Minor bleeding</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Bleeding requiring medical attention</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Clinically significant bleeding</p></dd></dl></dl></p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Approximately 94% of participants had clopidogrel</td></tr><tr><td headers="hd_h_niceng185er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p><b>AUGUSTUS</b></p>
|
|
<p>Lopes 2018<a class="bibr" href="#niceng185er7.ref62" rid="niceng185er7.ref62"><sup>62</sup></a></p>
|
|
<p>Lopes 2019<a class="bibr" href="#niceng185er7.ref60" rid="niceng185er7.ref60"><sup>60</sup></a></p>
|
|
<p>Haller 2019<a class="bibr" href="#niceng185er7.ref43" rid="niceng185er7.ref43"><sup>43</sup></a></p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Apixaban plus aspirin plus P2Y12 inhibitor</p>
|
|
<p>Warfarin plus aspirin plus P2Y12 inhibitor</p>
|
|
<p>Apixaban plus P2Y12 inhibitor plus placebo</p>
|
|
<p>Warfarin plus P2Y12 inhibitor plus placebo</p>
|
|
<p>The P2Y12 inhibitor was clopidogrel in >90% of participants</p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4614 people with atrial fibrillation who had an acute coronary syndrome or had undergone PCI</td><td headers="hd_h_niceng185er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Death</p>
|
|
<p>Stroke</p>
|
|
<p>Myocardial infarction</p>
|
|
<p>Complications related to bleeding
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Intracranial haemorrhage</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">GUSTO severe bleeding</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">GUSTO moderate bleeding</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">TIMI major bleeding</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">TIMI minor bleeding</p></dd></dl></dl></p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng185er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p><b>ENTRUST-AF PCI</b></p>
|
|
<p>Vranckx 2019<a class="bibr" href="#niceng185er7.ref88" rid="niceng185er7.ref88"><sup>88</sup></a></p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Edoxaban (60mg once daily) plus a P2Y12 inhibitor (clopidogrel 75mg once daily) for 12 months</p>
|
|
<p>Vitamin K antagonist (INR 2-3) plus a P2Y12 inhibitor (clopidogrel 75mg once daily) plus aspirin (100mg once daily for 1-12 months)</p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1506 people with atrial fibrillation requiring oral anticoagulation who were at least 18 years old and had successful PCI for stable coronary artery disease (48%) or ACS (52%)</td><td headers="hd_h_niceng185er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Death</p>
|
|
<p>Stroke</p>
|
|
<p>Myocardial infarction</p>
|
|
<p>Stent thrombosis</p>
|
|
<p>Complications related to bleeding
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Major or clinically relevant non-major bleeding</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Major bleeding</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Intracranial haemorrhage</p></dd></dl></dl></p></td><td headers="hd_h_niceng185er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not clear which VKA used</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er7tab3"><div id="niceng185er7.tab3" class="table"><h3><span class="label">Table 3</span><span class="title">Clinical evidence summary: Warfarin + clopidogrel + aspirin versus warfarin + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.tab3_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab3_1_1_1_1" style="text-align:left;vertical-align:bottom;">
|
|
<p>Outcomes</p>
|
|
<p>Follow up</p>
|
|
</th><th id="hd_h_niceng185er7.tab3_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab3_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies)</th><th id="hd_h_niceng185er7.tab3_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab3_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_niceng185er7.tab3_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab3_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng185er7.tab3_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng185er7.tab3_1_1_1_5" id="hd_h_niceng185er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with warfarin + clopidogrel</th><th headers="hd_h_niceng185er7.tab3_1_1_1_5" id="hd_h_niceng185er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Warfarin + clopidogrel + aspirin (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All cause mortality - 6 months</td><td headers="hd_h_niceng185er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2308</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.85</p>
|
|
<p>(0.54 to 1.33)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 per 1000</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>5 fewer per 1000</p>
|
|
<p>(from 16 fewer to 12 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction - 6 months</td><td headers="hd_h_niceng185er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2308</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.74</p>
|
|
<p>(0.48 to 1.14)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40 per 1000</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>10 fewer per 1000</p>
|
|
<p>(from 21 fewer to 6 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stroke - 6 months</td><td headers="hd_h_niceng185er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2308</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.86</p>
|
|
<p>(0.4 to 1.85)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 per 1000</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2 fewer per 1000</p>
|
|
<p>(from 7 fewer to 10 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Any stent thrombosis - 6 months</td><td headers="hd_h_niceng185er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2308</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.63</p>
|
|
<p>(0.31 to 1.3)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 per 1000</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>6 fewer per 1000</p>
|
|
<p>(from 12 fewer to 5 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - TIMI major 6 months</td><td headers="hd_h_niceng185er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2249</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.62</p>
|
|
<p>(0.9 to 2.89)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 per 1000</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>10 more per 1000</p>
|
|
<p>(from 2 fewer to 30 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - TIMI major and minor - 6 months</td><td headers="hd_h_niceng185er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2249</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.57</p>
|
|
<p>(1.12 to 2.21)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45 per 1000</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>26 more per 1000</p>
|
|
<p>(from 5 more to 54 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - Intracranial haemorrhage - 6 months</td><td headers="hd_h_niceng185er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2249</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.5</p>
|
|
<p>(0.15 to 1.66)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 per 1000</td><td headers="hd_h_niceng185er7.tab3_1_1_1_5 hd_h_niceng185er7.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3 fewer per 1000</p>
|
|
<p>(from 6 fewer to 5 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.tab3_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7tab4"><div id="niceng185er7.tab4" class="table"><h3><span class="label">Table 4</span><span class="title">Clinical evidence summary: Warfarin + clopidogrel + aspirin versus dabigatran + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.tab4_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab4_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng185er7.tab4_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab4_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_niceng185er7.tab4_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab4_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_niceng185er7.tab4_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab4_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng185er7.tab4_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng185er7.tab4_1_1_1_5" id="hd_h_niceng185er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with dabigatran + clopidogrel</th><th headers="hd_h_niceng185er7.tab4_1_1_1_5" id="hd_h_niceng185er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Warfarin + clopidogrel + aspirin (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality - 14 months</td><td headers="hd_h_niceng185er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1962</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.87</p>
|
|
<p>(0.6 to 1.27)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56 per 1000</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>7 fewer per 1000</p>
|
|
<p>(from 22 fewer to 15 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction - 14 months</td><td headers="hd_h_niceng185er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1962</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.66</p>
|
|
<p>(0.42 to 1.04)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45 per 1000</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>15 fewer per 1000</p>
|
|
<p>(from 26 fewer to 2 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stroke - 14 months</td><td headers="hd_h_niceng185er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1962</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.76</p>
|
|
<p>(0.37 to 1.57)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 per 1000</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>4 fewer per 1000</p>
|
|
<p>(from 11 fewer to 10 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Definite stent thrombosis - 14 months</td><td headers="hd_h_niceng185er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1962</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.53</p>
|
|
<p>(0.23 to 1.25)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 per 1000</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>7 fewer per 1000</p>
|
|
<p>(from 12 fewer to 4 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - Intracranial haemorrhage - 14 months</td><td headers="hd_h_niceng185er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1962</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 3.33</p>
|
|
<p>(0.92 to 12.08)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 per 1000</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>7 more per 1000</p>
|
|
<p>(from 0 fewer to 33 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - TIMI major bleeding - 14 months</td><td headers="hd_h_niceng185er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1962</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to risk of bias</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 2.64</p>
|
|
<p>(1.44 to 4.86)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 per 1000</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>23 more per 1000</p>
|
|
<p>(from 6 more to 54 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - TIMI major and minor bleeding 14 months</td><td headers="hd_h_niceng185er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1962</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to risk of bias</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 2.38</p>
|
|
<p>(1.56 to 3.64)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30 per 1000</td><td headers="hd_h_niceng185er7.tab4_1_1_1_5 hd_h_niceng185er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>41 more per 1000</p>
|
|
<p>(from 17 more to 79 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.tab4_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng185er7.tab4_2"><p class="no_margin">Downgraded once for serious imprecision, and twice for very serious imprecision</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7tab5"><div id="niceng185er7.tab5" class="table"><h3><span class="label">Table 5</span><span class="title">Clinical evidence summary: Rivaroxaban (2.5 mg bd) + clopidogrel + aspirin versus rivaroxaban (15 mg od) + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.tab5_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab5_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng185er7.tab5_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab5_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_niceng185er7.tab5_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab5_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_niceng185er7.tab5_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab5_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng185er7.tab5_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng185er7.tab5_1_1_1_5" id="hd_h_niceng185er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with rivaroxaban + clopidogrel</th><th headers="hd_h_niceng185er7.tab5_1_1_1_5" id="hd_h_niceng185er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Rivaroxaban + clopidogrel + aspirin (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality - 12 months</td><td headers="hd_h_niceng185er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1398</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.05</p>
|
|
<p>(0.53 to 2.06)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 per 1000</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1 more per 1000</p>
|
|
<p>(from 11 fewer to 24 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction - 12 months</td><td headers="hd_h_niceng185er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1398</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.88</p>
|
|
<p>(0.46 to 1.68)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27 per 1000</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3 fewer per 1000</p>
|
|
<p>(from 15 fewer to 18 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stroke - 12 months</td><td headers="hd_h_niceng185er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1398</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.23</p>
|
|
<p>(0.49 to 3.1)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 per 1000</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3 more per 1000</p>
|
|
<p>(from 6 fewer to 25 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stent thrombosis - 12 months</td><td headers="hd_h_niceng185er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1398</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.18</p>
|
|
<p>(0.36 to 3.86)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 per 1000</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1 more per 1000</p>
|
|
<p>(from 4 fewer to 20 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - Bleeding requiring medical attention - 12 months</td><td headers="hd_h_niceng185er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1402</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.08</p>
|
|
<p>(0.83 to 1.4)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">134 per 1000</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>11 more per 1000</p>
|
|
<p>(from 23 fewer to 54 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - Major bleeding- 12 months</td><td headers="hd_h_niceng185er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1402</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.85</p>
|
|
<p>(0.39 to 1.81)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20 per 1000</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3 fewer per 1000</p>
|
|
<p>(from 12 fewer to 16 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - Minor bleeding 12 months</td><td headers="hd_h_niceng185er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1402</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.99</p>
|
|
<p>(0.35 to 2.8)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 per 1000</td><td headers="hd_h_niceng185er7.tab5_1_1_1_5 hd_h_niceng185er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0 fewer per 1000</p>
|
|
<p>(from 7 fewer to 18 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.tab5_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng185er7.tab5_2"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7tab6"><div id="niceng185er7.tab6" class="table"><h3><span class="label">Table 6</span><span class="title">Clinical evidence summary: Rivaroxaban (2.5 mg bd) + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.tab6_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab6_1_1_1_1" style="text-align:left;vertical-align:bottom;">
|
|
<p>Outcomes</p>
|
|
<p>Follow up</p>
|
|
</th><th id="hd_h_niceng185er7.tab6_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab6_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies)</th><th id="hd_h_niceng185er7.tab6_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab6_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_niceng185er7.tab6_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab6_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng185er7.tab6_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng185er7.tab6_1_1_1_5" id="hd_h_niceng185er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with warfarin + clopidogrel + aspirin</th><th headers="hd_h_niceng185er7.tab6_1_1_1_5" id="hd_h_niceng185er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Rivaroxaban + clopidogrel + aspirin (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality- 12 months</td><td headers="hd_h_niceng185er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1399</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.29</p>
|
|
<p>(0.63 to 2.64)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19 per 1000</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>5 more per 1000</p>
|
|
<p>(from 7 fewer to 31 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction - 12 months</td><td headers="hd_h_niceng185er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1399</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.8</p>
|
|
<p>(0.43 to 1.5)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30 per 1000</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>6 fewer per 1000</p>
|
|
<p>(from 17 fewer to 15 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stroke - 12 months</td><td headers="hd_h_niceng185er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1399</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.41</p>
|
|
<p>(0.54 to 3.68)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 per 1000</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>4 more per 1000</p>
|
|
<p>(from 5 fewer to 27 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stent thrombosis - 12 months</td><td headers="hd_h_niceng185er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1398</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.48</p>
|
|
<p>(0.42 to 5.22)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 per 1000</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3 more per 1000</p>
|
|
<p>(from 3 fewer to 25 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - Bleeding requiring medical attention - 12 months</td><td headers="hd_h_niceng185er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1403</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.72</p>
|
|
<p>(0.57 to 0.91)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">199 per 1000</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>56 fewer per 1000</p>
|
|
<p>(from 18 fewer to 86 fewer)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - Major bleeding 12 months</td><td headers="hd_h_niceng185er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1403</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.59</p>
|
|
<p>(0.29 to 1.2)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29 per 1000</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>12 fewer per 1000</p>
|
|
<p>(from 21 fewer to 6 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - Minor bleeding 12 months</td><td headers="hd_h_niceng185er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1403</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.53</p>
|
|
<p>(0.21 to 1.32)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19 per 1000</td><td headers="hd_h_niceng185er7.tab6_1_1_1_5 hd_h_niceng185er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>9 fewer per 1000</p>
|
|
<p>(from 15 fewer to 6 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.tab6_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng185er7.tab6_2"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7tab7"><div id="niceng185er7.tab7" class="table"><h3><span class="label">Table 7</span><span class="title">Clinical evidence summary: Warfarin + clopidogrel + aspirin versus Rivaroxaban (15 mg od)+ clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab7_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.tab7_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab7_1_1_1_1" style="text-align:left;vertical-align:bottom;">
|
|
<p>Outcomes</p>
|
|
<p>Follow up</p>
|
|
</th><th id="hd_h_niceng185er7.tab7_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab7_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies)</th><th id="hd_h_niceng185er7.tab7_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab7_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_niceng185er7.tab7_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab7_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng185er7.tab7_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng185er7.tab7_1_1_1_5" id="hd_h_niceng185er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with Rivaroxaban + clopidogrel</th><th headers="hd_h_niceng185er7.tab7_1_1_1_5" id="hd_h_niceng185er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Warfarin + clopidogrel + aspirin (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality - 12 months</td><td headers="hd_h_niceng185er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1389</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.81</p>
|
|
<p>(0.39 to 1.67)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 per 1000</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>4 fewer per 1000</p>
|
|
<p>(from 14 fewer to 15 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction - 12 months</td><td headers="hd_h_niceng185er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1389</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.1</p>
|
|
<p>(0.6 to 2.03)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27 per 1000</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3 more per 1000</p>
|
|
<p>(from 11 fewer to 28 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stroke - 12 months</td><td headers="hd_h_niceng185er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1389</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.87</p>
|
|
<p>(0.32 to 2.4)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 per 1000</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2 fewer per 1000</p>
|
|
<p>(from 8 fewer to 17 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stent thrombosis - 12 months</td><td headers="hd_h_niceng185er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1389</p>
|
|
<p>(1 study)</p>
|
|
<p>12 months</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.8</p>
|
|
<p>(0.22 to 2.96)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 per 1000</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1 fewer per 1000</p>
|
|
<p>(from 5 fewer to 14 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - Bleeding requiring medical attention - 12 months</td><td headers="hd_h_niceng185er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1393</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.49</p>
|
|
<p>(1.17 to 1.9)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">134 per 1000</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>66 more per 1000</p>
|
|
<p>(from 23 more to 121 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - Major bleeding 12 months</td><td headers="hd_h_niceng185er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1393</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.43</p>
|
|
<p>(0.73 to 2.8)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20 per 1000</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>9 more per 1000</p>
|
|
<p>(from 5 fewer to 36 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - Minor bleeding 12 months</td><td headers="hd_h_niceng185er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1393</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.85</p>
|
|
<p>(0.74 to 4.62)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 per 1000</td><td headers="hd_h_niceng185er7.tab7_1_1_1_5 hd_h_niceng185er7.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>9 more per 1000</p>
|
|
<p>(from 3 fewer to 36 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.tab7_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng185er7.tab7_2"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7tab8"><div id="niceng185er7.tab8" class="table"><h3><span class="label">Table 8</span><span class="title">Clinical evidence summary: Apixaban + clopidogrel + aspirin versus apixaban + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab8_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.tab8_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab8_1_1_1_1" style="text-align:left;vertical-align:bottom;">
|
|
<p>Outcomes</p>
|
|
<p>Follow up</p>
|
|
</th><th id="hd_h_niceng185er7.tab8_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab8_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies)</th><th id="hd_h_niceng185er7.tab8_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab8_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_niceng185er7.tab8_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab8_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng185er7.tab8_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng185er7.tab8_1_1_1_5" id="hd_h_niceng185er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with apixaban + clopidogrel</th><th headers="hd_h_niceng185er7.tab8_1_1_1_5" id="hd_h_niceng185er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Apixaban + clopidogrel + aspirin (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality - 6 months</td><td headers="hd_h_niceng185er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2306</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.97</p>
|
|
<p>(0.63 to 1.51)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34 per 1000</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1 fewer per 1000</p>
|
|
<p>(from 13 fewer to 17 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction - 6 months</td><td headers="hd_h_niceng185er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2306</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.89</p>
|
|
<p>(0.57 to 1.41)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33 per 1000</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>4 fewer per 1000</p>
|
|
<p>(from 14 fewer to 14 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stroke - 6 months</td><td headers="hd_h_niceng185er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2306</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.6</p>
|
|
<p>(0.52 to 4.88)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 per 1000</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2 more per 1000</p>
|
|
<p>(from 2 fewer to 16 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stent thrombosis - 6 months</td><td headers="hd_h_niceng185er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2306</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.52</p>
|
|
<p>(0.25 to 1.08)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18 per 1000</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>9 fewer per 1000</p>
|
|
<p>(from 13 fewer to 1 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - TIMI major bleeding - 6 months</td><td headers="hd_h_niceng185er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2288</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.92</p>
|
|
<p>(0.99 to 3.73)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 per 1000</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>10 more per 1000</p>
|
|
<p>(from 0 fewer to 30 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - TIMI major and minor bleeding - 6 months</td><td headers="hd_h_niceng185er7.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2288</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊕</p>
|
|
<p>HIGH</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 2</p>
|
|
<p>(1.32 to 3.03)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28 per 1000</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>28 more per 1000</p>
|
|
<p>(from 9 more to 57 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab8_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Complications relating to bleeding - Intracranial haemorrhage - 6 months</td><td headers="hd_h_niceng185er7.tab8_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2288</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 3.99</p>
|
|
<p>(0.45 to 35.67)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_1 hd_h_niceng185er7.tab8_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 per 1000</td><td headers="hd_h_niceng185er7.tab8_1_1_1_5 hd_h_niceng185er7.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3 more per 1000</p>
|
|
<p>(from 1 fewer to 35 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.tab8_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7tab9"><div id="niceng185er7.tab9" class="table"><h3><span class="label">Table 9</span><span class="title">Clinical evidence summary: Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab9_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.tab9_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab9_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng185er7.tab9_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab9_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_niceng185er7.tab9_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab9_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_niceng185er7.tab9_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab9_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng185er7.tab9_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng185er7.tab9_1_1_1_5" id="hd_h_niceng185er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with warfarin + clopidogrel + aspirin</th><th headers="hd_h_niceng185er7.tab9_1_1_1_5" id="hd_h_niceng185er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Apixaban + clopidogrel + aspirin (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality - 6 months</td><td headers="hd_h_niceng185er7.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.12</p>
|
|
<p>(0.71 to 1.76)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30 per 1000</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>4 more per 1000</p>
|
|
<p>(from 9 fewer to 23 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction - 6 months</td><td headers="hd_h_niceng185er7.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1</p>
|
|
<p>(0.63 to 1.6)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30 per 1000</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0 fewer per 1000</p>
|
|
<p>(from 11 fewer to 18 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab9_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Stroke - 6 months</td><td headers="hd_h_niceng185er7.tab9_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.67</p>
|
|
<p>(0.27 to 1.63)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_1 hd_h_niceng185er7.tab9_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 per 1000</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3 fewer per 1000</p>
|
|
<p>(from 7 fewer to 6 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Any stent thrombosis - 6 months</td><td headers="hd_h_niceng185er7.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.92</p>
|
|
<p>(0.41 to 2.07)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 per 1000</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1 fewer per 1000</p>
|
|
<p>(from 6 fewer to 11 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - TIMI major bleeding - 6 months</td><td headers="hd_h_niceng185er7.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2268</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.85</p>
|
|
<p>(0.5 to 1.43)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 per 1000</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>4 fewer per 1000</p>
|
|
<p>(from 13 fewer to 11 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - TIMI minor bleeding - 6 months</td><td headers="hd_h_niceng185er7.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2268</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.78</p>
|
|
<p>(0.57 to 1.08)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71 per 1000</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>16 fewer per 1000</p>
|
|
<p>(from 31 fewer to 6 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - Intracranial haemorrhage - 6 months</td><td headers="hd_h_niceng185er7.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2268</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.98</p>
|
|
<p>(0.25 to 3.91)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 per 1000</td><td headers="hd_h_niceng185er7.tab9_1_1_1_5 hd_h_niceng185er7.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0 fewer per 1000</p>
|
|
<p>(from 3 fewer to 12 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.tab9_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7tab10"><div id="niceng185er7.tab10" class="table"><h3><span class="label">Table 10</span><span class="title">Clinical evidence summary: Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab10/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab10_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.tab10_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab10_1_1_1_1" style="text-align:left;vertical-align:bottom;">
|
|
<p>Outcomes</p>
|
|
<p>Follow up</p>
|
|
</th><th id="hd_h_niceng185er7.tab10_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab10_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies)</th><th id="hd_h_niceng185er7.tab10_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab10_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_niceng185er7.tab10_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab10_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng185er7.tab10_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng185er7.tab10_1_1_1_5" id="hd_h_niceng185er7.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with warfarin + clopidogrel</th><th headers="hd_h_niceng185er7.tab10_1_1_1_5" id="hd_h_niceng185er7.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Apixaban + clopidogrel + aspirin (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality - 6 months</td><td headers="hd_h_niceng185er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.95</p>
|
|
<p>(0.61 to 1.47)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 per 1000</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2 fewer per 1000</p>
|
|
<p>(from 14 fewer to 16 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction- 6 months</td><td headers="hd_h_niceng185er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.74</p>
|
|
<p>(0.48 to 1.14)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40 per 1000</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>10 fewer per 1000</p>
|
|
<p>(from 21 fewer to 6 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stroke- 6 months</td><td headers="hd_h_niceng185er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.57</p>
|
|
<p>(0.24 to 1.36)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 per 1000</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>5 fewer per 1000</p>
|
|
<p>(from 9 fewer to 4 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Any stent thrombosis- 6 months</td><td headers="hd_h_niceng185er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.58</p>
|
|
<p>(0.28 to 1.21)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 per 1000</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>7 fewer per 1000</p>
|
|
<p>(from 12 fewer to 4 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - TIMI major bleeding- 6 months</td><td headers="hd_h_niceng185er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2271</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.37</p>
|
|
<p>(0.75 to 2.49)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 per 1000</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>6 more per 1000</p>
|
|
<p>(from 4 fewer to 24 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - TIMI major and minor bleeding 6 months</td><td headers="hd_h_niceng185er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2271</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.23</p>
|
|
<p>(0.86 to 1.77)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45 per 1000</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>10 more per 1000</p>
|
|
<p>(from 6 fewer to 35 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - Intracranial haemorrhage 6 months</td><td headers="hd_h_niceng185er7.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2271</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.98</p>
|
|
<p>(0.25 to 3.92)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 per 1000</td><td headers="hd_h_niceng185er7.tab10_1_1_1_5 hd_h_niceng185er7.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0 fewer per 1000</p>
|
|
<p>(from 3 fewer to 12 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.tab10_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7tab11"><div id="niceng185er7.tab11" class="table"><h3><span class="label">Table 11</span><span class="title">Clinical evidence summary: Warfarin + clopidogrel + aspirin versus apixaban + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab11/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab11_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.tab11_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab11_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng185er7.tab11_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab11_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_niceng185er7.tab11_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab11_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_niceng185er7.tab11_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab11_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng185er7.tab11_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng185er7.tab11_1_1_1_5" id="hd_h_niceng185er7.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with apixaban + clopidogrel</th><th headers="hd_h_niceng185er7.tab11_1_1_1_5" id="hd_h_niceng185er7.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Warfarin + clopidogrel + aspirin (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality- 6 months</td><td headers="hd_h_niceng185er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.02</p>
|
|
<p>(0.66 to 1.58)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34 per 1000</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1 more per 1000</p>
|
|
<p>(from 12 fewer to 20 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction - 6 months</td><td headers="hd_h_niceng185er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.35</p>
|
|
<p>(0.87 to 2.09)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30 per 1000</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>11 more per 1000</p>
|
|
<p>(from 4 fewer to 33 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stroke- 6 months</td><td headers="hd_h_niceng185er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.75</p>
|
|
<p>(0.74 to 4.15)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 per 1000</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>5 more per 1000</p>
|
|
<p>(from 2 fewer to 22 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Any stent thrombosis -6 months</td><td headers="hd_h_niceng185er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.73</p>
|
|
<p>(0.82 to 3.61)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 per 1000</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>7 more per 1000</p>
|
|
<p>(from 2 fewer to 26 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - TIMI major bleeding - 6 months</td><td headers="hd_h_niceng185er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2269</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.41</p>
|
|
<p>(0.69 to 2.85)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 per 1000</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>5 more per 1000</p>
|
|
<p>(from 3 fewer to 20 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - TIMI major and minor bleeding -6 months</td><td headers="hd_h_niceng185er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2269</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.62</p>
|
|
<p>(1.05 to 2.5)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28 per 1000</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>17 more per 1000</p>
|
|
<p>(from 1 more to 42 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - Intracranial haemorrhage- 6 months</td><td headers="hd_h_niceng185er7.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2269</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 8.12</p>
|
|
<p>(1.02 to 64.82)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 per 1000</td><td headers="hd_h_niceng185er7.tab11_1_1_1_5 hd_h_niceng185er7.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>7 more per 1000</p>
|
|
<p>(from 0 more to 64 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.tab11_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7tab12"><div id="niceng185er7.tab12" class="table"><h3><span class="label">Table 12</span><span class="title">Clinical evidence summary: Apixaban + clopidogrel versus warfarin + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab12/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab12_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.tab12_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab12_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng185er7.tab12_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab12_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_niceng185er7.tab12_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab12_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_niceng185er7.tab12_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab12_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng185er7.tab12_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng185er7.tab12_1_1_1_5" id="hd_h_niceng185er7.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with warfarin + clopidogrel</th><th headers="hd_h_niceng185er7.tab12_1_1_1_5" id="hd_h_niceng185er7.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Apixaban + clopidogrel (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality - 6 months</td><td headers="hd_h_niceng185er7.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.98</p>
|
|
<p>(0.63 to 1.51)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 per 1000</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1 fewer per 1000</p>
|
|
<p>(from 13 fewer to 18 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction- 6 months</td><td headers="hd_h_niceng185er7.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.83</p>
|
|
<p>(0.54 to 1.26)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40 per 1000</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>7 fewer per 1000</p>
|
|
<p>(from 18 fewer to 10 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stroke- 6 months</td><td headers="hd_h_niceng185er7.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.36</p>
|
|
<p>(0.13 to 0.99)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 per 1000</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>8 fewer per 1000</p>
|
|
<p>(from 0 fewer to 10 fewer)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Any stent thrombosis- 6 months</td><td headers="hd_h_niceng185er7.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2307</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.11</p>
|
|
<p>(0.6 to 2.05)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 per 1000</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2 more per 1000</p>
|
|
<p>(from 7 fewer to 18 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - TIMI major bleeding - 6 months</td><td headers="hd_h_niceng185er7.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2269</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.71</p>
|
|
<p>(0.35 to 1.45)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 per 1000</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>5 fewer per 1000</p>
|
|
<p>(from 10 fewer to 7 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - TIMI major and minor bleeding - 6 months</td><td headers="hd_h_niceng185er7.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2269</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.62</p>
|
|
<p>(0.4 to 0.95)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45 per 1000</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>17 fewer per 1000</p>
|
|
<p>(from 2 fewer to 27 fewer)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - Intracranial haemorrhage- 6 months</td><td headers="hd_h_niceng185er7.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2269</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.12</p>
|
|
<p>(0.02 to 0.98)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 per 1000</td><td headers="hd_h_niceng185er7.tab12_1_1_1_5 hd_h_niceng185er7.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>6 fewer per 1000</p>
|
|
<p>(from 0 fewer to 7 fewer)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.tab12_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7tab13"><div id="niceng185er7.tab13" class="table"><h3><span class="label">Table 13</span><span class="title">Clinical evidence summary: edoxaban + clopidogrel versus VKA + clopidogrel + aspirin</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab13/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab13_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.tab13_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab13_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng185er7.tab13_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab13_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_niceng185er7.tab13_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab13_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_niceng185er7.tab13_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.tab13_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng185er7.tab13_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng185er7.tab13_1_1_1_5" id="hd_h_niceng185er7.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with VKA + clopidogrel + aspirin</th><th headers="hd_h_niceng185er7.tab13_1_1_1_5" id="hd_h_niceng185er7.tab13_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with Edoxaban + clopidogrel (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality -12 months</td><td headers="hd_h_niceng185er7.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1506</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.25</p>
|
|
<p>(0.82 to 1.9)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49 per 1000</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>12 more per 1000</p>
|
|
<p>(from 9 fewer to 44 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stroke- 12 months</td><td headers="hd_h_niceng185er7.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1506</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.84</p>
|
|
<p>(0.36 to 1.93)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 per 1000</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>3 fewer per 1000</p>
|
|
<p>(from 10 fewer to 15 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction- 12 months</td><td headers="hd_h_niceng185er7.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1506</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.27</p>
|
|
<p>(0.74 to 2.17)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31 per 1000</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>8 more per 1000</p>
|
|
<p>(from 8 fewer to 36 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stent thrombosis - 12 months</td><td headers="hd_h_niceng185er7.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1506</p>
|
|
<p>(1 study)</p>
|
|
<p>12 months</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 1.31</p>
|
|
<p>(0.58 to 2.96)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13 per 1000</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>4 more per 1000</p>
|
|
<p>(from 5 fewer to 25 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - Major or clinically relevant non-major bleeding (ISTH)- 12 months</td><td headers="hd_h_niceng185er7.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1506</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.85</p>
|
|
<p>(0.68 to 1.05)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">201 per 1000</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>30 fewer per 1000</p>
|
|
<p>(from 64 fewer to 10 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - Major bleeding (ISTH)- 12 months</td><td headers="hd_h_niceng185er7.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1506</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.94</p>
|
|
<p>(0.64 to 1.4)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64 per 1000</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>4 fewer per 1000</p>
|
|
<p>(from 23 fewer to 26 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complications related to bleeding - Intracranial haemorrhage 12 months</td><td headers="hd_h_niceng185er7.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1506</p>
|
|
<p>(1 study)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup></p>
|
|
<p>due to imprecision</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.45</p>
|
|
<p>(0.14 to 1.44)</p>
|
|
</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 per 1000</td><td headers="hd_h_niceng185er7.tab13_1_1_1_5 hd_h_niceng185er7.tab13_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>7 fewer per 1000</p>
|
|
<p>(from 10 fewer to 5 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.tab13_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7tab14"><div id="niceng185er7.tab14" class="table"><h3><span class="label">Table 14</span><span class="title">UK costs of anticoagulants and antiplatelets</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.tab14/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.tab14_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Drug</th><th id="hd_h_niceng185er7.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Preparation</th><th id="hd_h_niceng185er7.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Daily dose<sup>(a)</sup></th><th id="hd_h_niceng185er7.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cost per day</th><th id="hd_h_niceng185er7.tab14_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cost per year</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_h_niceng185er7.tab14_1_1_1_2 hd_h_niceng185er7.tab14_1_1_1_3 hd_h_niceng185er7.tab14_1_1_1_4 hd_h_niceng185er7.tab14_1_1_1_5" id="hd_b_niceng185er7.tab14_1_1_1_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>Anticoagulants</i>
|
|
</th></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Apixaban</td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tablet</td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.5mg twice daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.90</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£693.50</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5mg twice daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.90</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£693.50</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dabigatran</td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Capsule</td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">110mg twice daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.70</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£620.50</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">150mg twice daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.70</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£620.50</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Edoxaban</td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tablet</td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30mg once daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.75</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£638.75</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60mg once daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.75</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£638.75</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rivaroxaban</td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tablet</td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.5mg twice daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.80</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£657.00</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10mg once daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.80</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£657.00</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15mg once daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.80</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£657.00</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20mg once daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.80</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£657.00</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Warfarin</td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tablet</td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3mg once daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.01</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4.82</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5mg once daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.02</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£5.48</td></tr><tr><th headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_h_niceng185er7.tab14_1_1_1_2 hd_h_niceng185er7.tab14_1_1_1_3 hd_h_niceng185er7.tab14_1_1_1_4 hd_h_niceng185er7.tab14_1_1_1_5" id="hd_b_niceng185er7.tab14_1_1_14_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Antiplatelets</i>
|
|
<sup>
|
|
(b)
|
|
</sup>
|
|
</th></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Aspirin</td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tablet</td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75mg once daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.02</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£7.95</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clopidogrel</td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tablet</td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75mg once daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.05</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£16.95</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prasugrel</td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tablet</td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5mg once daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.39</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£507.22</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10mg once daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.39</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£507.22</td></tr><tr><td headers="hd_h_niceng185er7.tab14_1_1_1_1 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ticagrelor</td><td headers="hd_h_niceng185er7.tab14_1_1_1_2 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tablet</td><td headers="hd_h_niceng185er7.tab14_1_1_1_3 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90mg twice daily</td><td headers="hd_h_niceng185er7.tab14_1_1_1_4 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.95</td><td headers="hd_h_niceng185er7.tab14_1_1_1_5 hd_b_niceng185er7.tab14_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£711.75</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Source: NHS Drug Tariff prices obtained from the BNF; accessed September 2018<a class="bibr" href="#niceng185er7.ref48" rid="niceng185er7.ref48"><sup>48</sup></a></p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng185er7.tab14_1"><p class="no_margin">Dose obtained from the BNF</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng185er7.tab14_2"><p class="no_margin">Cost of antiplatelets do not include loading dose</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7appatab1"><div id="niceng185er7.appa.tab1" class="table"><h3><span class="label">Table 16</span><span class="title">Health economic review protocol</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appa.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appa.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Review question</th><th id="hd_h_niceng185er7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All questions – health economic evidence</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Objectives</b>
|
|
</td><td headers="hd_h_niceng185er7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">To identify health economic studies relevant to any of the review questions.</td></tr><tr><td headers="hd_h_niceng185er7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Search criteria</b>
|
|
</td><td headers="hd_h_niceng185er7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Populations, interventions and comparators must be as specified in the clinical review protocol above.</div></li><li class="half_rhythm"><div>Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).</div></li><li class="half_rhythm"><div>Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)</div></li><li class="half_rhythm"><div>Unpublished reports will not be considered unless submitted as part of a call for evidence.</div></li><li class="half_rhythm"><div>Studies must be in English.</div></li></ul></td></tr><tr><td headers="hd_h_niceng185er7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Search strategy</b>
|
|
</td><td headers="hd_h_niceng185er7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A health economic study search will be undertaken using population-specific terms and a health economic study filter – see <a href="#niceng185er7.appb">appendix B</a> below.</td></tr><tr><td headers="hd_h_niceng185er7.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Review strategy</b>
|
|
</td><td headers="hd_h_niceng185er7.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p><p>Studies published after 2003 that were included in the previous guidelines will be reassessed for inclusion and may be included or selectively excluded based on their relevance to the questions covered in this update and whether more applicable evidence is also identified.</p><p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).<a class="bibr" href="#niceng185er7.ref70" rid="niceng185er7.ref70"><sup>70</sup></a></p><p><b>Inclusion and exclusion criteria</b>
|
|
<ul><li class="half_rhythm"><div>If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.</div></li><li class="half_rhythm"><div>If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.</div></li><li class="half_rhythm"><div>If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included.</div></li></ul></p>
|
|
<p><b>Where there is discretion</b></p><p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.</p><p>The health economist will be guided by the following hierarchies.</p><p><i>Setting:</i>
|
|
<ul><li class="half_rhythm"><div>UK NHS (most applicable).</div></li><li class="half_rhythm"><div>OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).</div></li><li class="half_rhythm"><div>OECD countries with predominantly private health insurance systems (for example, Switzerland).</div></li><li class="half_rhythm"><div>Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.</div></li></ul></p>
|
|
<p><i>Health economic study type:</i>
|
|
<ul><li class="half_rhythm"><div>Cost–utility analysis (most applicable).</div></li><li class="half_rhythm"><div>Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).</div></li><li class="half_rhythm"><div>Comparative cost analysis.</div></li><li class="half_rhythm"><div>Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.</div></li></ul></p>
|
|
<p><i>Year of analysis:</i>
|
|
<ul><li class="half_rhythm"><div>The more recent the study, the more applicable it will be.</div></li><li class="half_rhythm"><div>Studies published in 2003 or later (including any such studies included in the previous guideline(s)) but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as ‘Not applicable’.</div></li><li class="half_rhythm"><div>Studies published before 2003 (including any such studies included in the previous guidelines) will be excluded before being assessed for applicability and methodological limitations.</div></li></ul></p>
|
|
<p><i>Quality and relevance of effectiveness data used in the health economic analysis:</i>
|
|
<ul><li class="half_rhythm"><div>The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.</div></li><li class="half_rhythm"><div>The following will be rated as ‘Very serious limitations’ and excluded: economic analyses undertaken as part of clinical studies that are excluded from the clinical review; economic models where relative treatment effects are based entirely on studies that are excluded from the clinical review.</div></li></ul></p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er7appbtab1"><div id="niceng185er7.appb.tab1" class="table"><h3><span class="label">Table 17</span><span class="title">Database date parameters and filters used</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appb.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appb.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er7.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Database</th><th id="hd_h_niceng185er7.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dates searched</th><th id="hd_h_niceng185er7.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Search filter used</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medline (OVID)</td><td headers="hd_h_niceng185er7.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">01 January 2008 – 22 July 2019</td><td headers="hd_h_niceng185er7.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Randomised controlled trials</p>
|
|
<p>Systematic review studies</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Embase (OVID)</td><td headers="hd_h_niceng185er7.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">01 January 2008 – 22 July 2019</td><td headers="hd_h_niceng185er7.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Randomised controlled trials</p>
|
|
<p>Systematic review studies</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The Cochrane Library (Wiley)</td><td headers="hd_h_niceng185er7.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Cochrane Reviews 2008 to 2019 Issue 7 of 12</p>
|
|
<p>CENTRAL 2008 to 2019 Issue 7 of 12</p>
|
|
</td><td headers="hd_h_niceng185er7.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er7appbtab2"><div id="niceng185er7.appb.tab2" class="table"><h3><span class="title">Medline (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appb.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appb.tab2_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Acute Coronary Syndrome/ or Angina Pectoris/ or Angina, Unstable/ or Coronary Thrombosis/ or exp Myocardial Infarction/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Heart Arrest/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(acute coronary adj2 syndrome*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((myocardial or heart) adj infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(heart adj (attack* or event*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((heart or cardiac) adj arrest*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(coronary adj2 thrombos*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(stemi or st-segment or st segment or st-elevation or st elevation).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non-ST-segment elevation”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(non-STEMI or NSTEMI or nonSTEMI).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“Q wave myocardial infarction”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non Q wave MI”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(NSTE-ACS or STE-ACS).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(subendocardial adj3 infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((unstable or variant) adj2 angina*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(unstable adj2 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1-16</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">news/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp historical article/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anecdotes as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/18-25</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 not 27</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animals/ not humans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animals, Laboratory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experimentation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Models, Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodentia/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/28-34</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 not 35</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 36 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">controlled clinical trial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomi#ed.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo.ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomly.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clinical Trials as topic.sh.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">trial.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/38-44</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-Analysis/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Meta-Analysis as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search strategy or search criteria or systematic search or study selection or data extraction).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search* adj4 literature).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cochrane.jw.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/46-55</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Coronary Intervention/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous coronary intervention*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(PPCI or PCI).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Coronary Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PTCA.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angioplasty, Balloon, Coronary/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Angioplasty/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon adj3 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((primary or coronary or transluminal or balloon) adj3 angioplasty).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary artery dilat*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp *Stents/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">drug eluting stent*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(eluting adj3 stent*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((paclitaxel or sirolimus or everolimus or biolimus or ridaforolimus or zotarolimus or novolimus) adj3 stent*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/57-70</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(37 or 71) and (45 or 56)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Factor Xa Inhibitors/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(factor Xa inhibitors or apixaban or eliquis or rivaroxaban or xarelto or edoxaban or lixiana or dabigatran or pradaxa or warfarin or coumadin).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">rivaroxaban/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DABIGATRAN/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">warfarin/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oral anticoagul*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/73-78</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72 and 79</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er7appbtab3"><div id="niceng185er7.appb.tab3" class="table"><h3><span class="title">Embase (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appb.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appb.tab3_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">acute coronary syndrome/ or angina pectoris/ or unstable angina pectoris/ or coronary artery thrombosis/ or exp heart infarction/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">heart arrest/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(acute coronary adj2 syndrome*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((myocardial or heart) adj infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(heart adj (attack* or event*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((heart or cardiac) adj arrest*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(coronary adj2 thrombos*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(stemi or st-segment or st segment or st-elevation or st elevation).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non-ST-segment elevation”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(non-STEMI or NSTEMI or nonSTEMI).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“Q wave myocardial infarction”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non Q wave MI”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(NSTE-ACS or STE-ACS).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(subendocardial adj3 infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((unstable or variant) adj2 angina*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(unstable adj2 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1-16</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter.pt. or letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">note.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Case report/ or Case study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/18-22</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 not 24</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal/ not human/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nonhuman/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experiment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Experimental animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Animal model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/25-32</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 not 33</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 34 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">factorial*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(crossover* or cross over*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((doubl* or singl*) adj blind*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(assign* or allocat* or volunteer* or placebo*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">crossover procedure/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">single blind procedure/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">double blind procedure/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/36-44</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">systematic review/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">meta-analysis/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((systematic or evidence) adj3 (review* or overview*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search strategy or search criteria or systematic search or study selection or data extraction).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search* adj4 literature).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((pool* or combined) adj2 (data or trials or studies or results)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cochrane.jw.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/46-56</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">transluminal coronary angioplasty/ or percutaneous coronary intervention/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous coronary intervention*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(PPCI or PCI).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Coronary Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PTCA.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">transluminal coronary angioplasty/ or percutaneous transluminal angioplasty/ or angioplasty/ or percutaneous transluminal angioplasty balloon/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon adj3 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((primary or coronary or transluminal or balloon) adj3 angioplasty).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary artery dilat*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/58-66</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*stent/ or exp *cardiovascular stent/ or exp *drug eluting stent/ or exp *metal stent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">drug eluting stent*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(eluting adj3 stent*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((paclitaxel or sirolimus or everolimus or biolimus or ridaforolimus or zotarolimus or novolimus) adj3 stent*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/68-71</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 or 67 or 72</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73 and (45 or 57)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">blood clotting factor 10a inhibitor/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(factor Xa inhibitors or apixaban or eliquis or rivaroxaban or xarelto or edoxaban or lixiana or dabigatran or pradaxa or warfarin or coumadin).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">apixaban/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">rivaroxaban/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">edoxaban/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dabigatran/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">warfarin/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oral anticoagul*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/75-82</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">84.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74 and 83</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er7appbtab4"><div id="niceng185er7.appb.tab4" class="table"><h3><span class="title">Cochrane Library (Wiley) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appb.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appb.tab4_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Acute Coronary Syndrome] this term only</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Angina Pectoris] this term only</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Angina, Unstable] this term only</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Coronary Thrombosis] this term only</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Myocardial Infarction] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or #1-#5)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Heart Arrest] this term only</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(acute coronary near/2 syndrome*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((myocardial or heart) next infarct*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(heart next (attack* or event*)):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((heart or cardiac) next arrest*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(coronary near/2 thrombos*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(stemi or st-segment or st segment or st-elevation or st elevation):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">non-ST-segment elevation:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(non-STEMI or NSTEMI or nonSTEMI):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Q wave myocardial infarction:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">non Q wave MI:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(NSTE-ACS or STE-ACS):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(subendocardial near/3 infarct*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((unstable or variant) near/2 angina*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(unstable near/2 coronary):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or #6-#21)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Percutaneous Coronary Intervention] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous coronary intervention*:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(PPCI or PCI):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Angioplasty, Balloon, Coronary] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Coronary Angioplasty:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PTCA:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Angioplasty] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon near/3 coronary):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((primary or coronary or transluminal or balloon) near/3 angioplasty):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary artery dilat*:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or #23-#32)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Stents] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(drug next eluting next stent*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(eluting near/3 stent*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((paclitaxel or sirolimus or everolimus or biolimus or ridaforolimus or zotarolimus or novolimus) near/3 stent*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or #34-#37)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#22 or #33 or #38</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Factor Xa Inhibitors] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(factor Xa inhibitors or apixaban or eliquis or rivaroxaban or xarelto or edoxaban or lixiana or dabigatran or pradaxa or warfarin or coumadin):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Rivaroxaban] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Dabigatran] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Warfarin] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oral anticoagul*:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or #40-#45)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#39 and #46</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er7appbtab5"><div id="niceng185er7.appb.tab5" class="table"><h3><span class="label">Table 18</span><span class="title">Database date parameters and filters used</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appb.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appb.tab5_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er7.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Database</th><th id="hd_h_niceng185er7.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dates searched</th><th id="hd_h_niceng185er7.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Search filter used</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medline</td><td headers="hd_h_niceng185er7.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">01 January 2014 – 18 June 2019</td><td headers="hd_h_niceng185er7.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Health economics studies</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Embase</td><td headers="hd_h_niceng185er7.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">01 January 2014 – 18 June 2019</td><td headers="hd_h_niceng185er7.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Health economics studies</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er7.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Centre for Research and Dissemination (CRD)</td><td headers="hd_h_niceng185er7.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>HTA - 2003 – 31 March 2018</p>
|
|
<p>NHSEED - 2003 to 31 March 2015</p>
|
|
</td><td headers="hd_h_niceng185er7.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er7appbtab6"><div id="niceng185er7.appb.tab6" class="table"><h3><span class="title">Medline (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appb.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appb.tab6_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Acute Coronary Syndrome/ or Angina Pectoris/ or Angina, Unstable/ or Coronary Thrombosis/ or exp Myocardial Infarction/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Heart Arrest/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(acute coronary adj2 syndrome*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((myocardial or heart) adj infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(heart adj (attack* or event*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((heart or cardiac) adj arrest*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(coronary adj2 thrombos*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(stemi or st-segment or st segment or st-elevation or st elevation).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non-ST-segment elevation”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(non-STEMI or NSTEMI or nonSTEMI).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“Q wave myocardial infarction”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non Q wave MI”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSTE-ACS.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(subendocardial adj3 infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((unstable or variant) adj2 angina*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(unstable adj2 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1-16</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">news/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp historical article/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anecdotes as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/18-25</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 not 27</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animals/ not humans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animals, Laboratory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experimentation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Models, Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodentia/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/28-34</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 not 35</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 36 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Value of life/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp “Costs and Cost Analysis”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Economics, Hospital/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Economics, Medical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics, Nursing/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics, Pharmaceutical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp “Fees and Charges”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Budgets/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cost*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(economic* or pharmaco?economic*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(price* or pricing*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(financ* or fee or fees).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(value adj2 (money or monetary)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/38-53</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37 and 54</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*Angiography/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiocardiography/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary Angiography/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiograph*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Arteriograph*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiocardiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary Angiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiogram*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cardioangiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiocardiogram.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angio Cardiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary Arteriogra*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronarograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*Myocardial Revascularization/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angioplasty, Balloon, Coronary/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Myocardial adj revasculari?ation).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PCI.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous coronary intervention.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Coronary Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PTCA.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Angioplasty/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Blunt microdissection.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((laser or patch) adj angioplasty).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Transluminal Coronary Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon adj3 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon adj3 angioplasty).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp STENTS/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">84.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">stent*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">85.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Or/56-84</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">aspirin/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">87.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(aspirin or acetylsalicylic acid).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">88.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(clopidogrel or plavix).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">89.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(ticagrelor or brilique).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(prasugrel or efient or effient or prasita).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">91.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prasugrel Hydrochloride/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">92.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">platelet aggregation inhibitors/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">93.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Glycoproteins IIb-IIIa or GPIIb-IIIa Receptors or Integrin alpha-IIb beta-3 or Integrin alphaIIbbeta3 or GPIIB IIIA).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">94.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Platelet Glycoprotein GPIIb-IIIa Complex/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">95.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Receptors, Fibrinogen/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">96.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Abciximab or Reopro or Eptifibatide or Integrelin or Integrilin or Intrifiban or Tirofiban or Aggrastat).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">97.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp adrenergic beta-antagonists/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">98.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(propranolol or angilol or inderal-la or half-inderal or inderal or bedranol or prograne or slo-pro or acebutolol or sectral or atenolol or tenormin or bisoprolol or cardicor or emcor or carvedilol or eucardic or celiprolol or celectol or co-tenidone or tenoret or tenoretic or esmolol or brevibloc or labetalol or trandate or metoprolol or betaloc or lopresor or nadolol or corgard or nebivolol or nebilet or hypoloc or oxprenolol or trasicor or slow-trasicor or pindolol or visken or sotalol or beta-cardone or sotacor or timolol or betim).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">99.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">propranolol/ or acebutolol/ or atenolol/ or bisoprolol/ or celiprolol/ or labetalol/ or metoprolol/ or nadolol/ or nebivolol/ or oxprenolol/ or pindolol/ or sotalol/ or timolol/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">100.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(beta adj3 block*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">101.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(b adj3 block*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">102.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(beta adj2 antagonist*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">103.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Antithrombins/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">104.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Antithrombin*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">105.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thrombin adj3 inhibitor*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">106.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hirudins/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">107.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hirudin*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">108.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hirulog.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">109.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bivalirudin.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">110.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Or/86-109</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">111.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55 and (85 or 110)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er7appbtab7"><div id="niceng185er7.appb.tab7" class="table"><h3><span class="title">Embase (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appb.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appb.tab7_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">acute coronary syndrome/ or angina pectoris/ or unstable angina pectoris/ or coronary artery thrombosis/ or exp heart infarction/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">heart arrest/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(acute coronary adj2 syndrome*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((myocardial or heart) adj infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(heart adj (attack* or event*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((heart or cardiac) adj arrest*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(coronary adj2 thrombos*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(stemi or st-segment or st segment or st-elevation or st elevation).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non-ST-segment elevation”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(non-STEMI or NSTEMI or nonSTEMI).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“Q wave myocardial infarction”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non Q wave MI”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSTE-ACS.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(subendocardial adj3 infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((unstable or variant) adj2 angina*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(unstable adj2 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1-16</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter.pt. or letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">note.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Case report/ or Case study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/18-22</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 not 24</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal/ not human/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nonhuman/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experiment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Experimental animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Animal model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/25-32</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 not 33</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 34 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">health economics/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp economic evaluation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp health care cost/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp fee/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">funding/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cost*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(economic* or pharmaco?economic*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(price* or pricing*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(financ* or fee or fees).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(value adj2 (money or monetary)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/36-48</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 and 49</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">angiography/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">angiocardiography/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">coronary angiography/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiograph*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Arteriograph*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiocardiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary Angiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiogram*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cardioangiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiocardiogram.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angio Cardiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary Arteriogra*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronarograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*heart muscle revascularization/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">transluminal coronary angioplasty/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Myocardial adj revasculari?ation).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PCI.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous coronary intervention.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Coronary Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PTCA.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*angioplasty/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Blunt microdissection.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((laser or patch) adj angioplasty).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Transluminal Coronary Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon adj3 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon adj3 angioplasty).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp STENTS/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">stent*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Or/51-79</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">acetylsalicylic acid/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(aspirin or acetylsalicylic acid).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(clopidogrel or plavix).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">84.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(ticagrelor or brilique).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">85.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(prasugrel or efient or effient or prasita).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">prasugrel/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">87.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">antithrombocytic agent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">88.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Glycoproteins IIb-IIIa or GPIIb-IIIa Receptors or Integrin alpha-IIb beta-3 or Integrin alphaIIbbeta3 or GPIIB IIIA).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">89.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp fibrinogen receptor/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Abciximab or Reopro or Eptifibatide or Integrelin or Integrilin or Intrifiban or Tirofiban or Aggrastat).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">91.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">abciximab/ or eptifibatide/ or tirofiban/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">92.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp beta adrenergic receptor blocking agent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">93.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(propranolol or angilol or inderal-la or half-inderal or inderal or bedranol or prograne or slo-pro or acebutolol or sectral or atenolol or tenormin or bisoprolol or cardicor or emcor or carvedilol or eucardic or celiprolol or celectol or co-tenidone or tenoret or tenoretic or esmolol or brevibloc or labetalol or trandate or metoprolol or betaloc or lopresor or nadolol or corgard or nebivolol or nebilet or hypoloc or oxprenolol or trasicor or slow-trasicor or pindolol or visken or sotalol or beta-cardone or sotacor or timolol or betim).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">94.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">propranolol/ or acebutolol/ or atenolol/ or bisoprolol/ or bisoprolol fumarate/ or carvedilol/ or celiprolol/ or esmolol/ or labetalol/ or metoprolol/ or nadolol/ or nebivolol/ or oxprenolol/ or pindolol/ or sotalol/ or timolol/ or timolol maleate/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">95.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(beta adj3 block*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">96.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(b adj3 block*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">97.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(beta adj2 antagonist*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">98.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">antithrombin/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">99.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Antithrombin*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">100.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thrombin adj3 inhibitor*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">101.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hirudin derivative/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">102.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hirudin*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">103.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hirulog.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">104.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bivalirudin.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">105.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Or/81-104</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">106.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50 and (80 or 105)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er7appbtab8"><div id="niceng185er7.appb.tab8" class="table"><h3><span class="title">NHS EED and HTA (CRD) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appb.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appb.tab8_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Acute Coronary Syndrome</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR angina pectoris)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Angina, Unstable)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Coronary Thrombosis)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Myocardial Infarction EXPLODE ALL TREES</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1 OR #2 OR #3 OR #4 OR #5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Heart Arrest)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((acute coronary adj2 syndrome*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((myocardial or heart) adj infarct*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((heart adj (attack* or event*)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((heart or cardiac) adj arrest*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((coronary adj2 thrombos*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((stemi or st-segment or st segment or st-elevation or st elevation))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(“non-ST-segment elevation”)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((non-STEMI or NSTEMI or nonSTEMI))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(“Q wave myocardial infarction”)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(“non Q wave MI”)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(NSTE-ACS)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(STE-ACS)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((subendocardial adj3 infarct*)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((((unstable or variant) adj2 angina*)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((unstable adj2 coronary)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Angiography)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Angiocardiography)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((MeSH DESCRIPTOR Coronary Angiography))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Angiograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Arteriograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Angiocardiograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Coronary Angiograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Angiogram*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Cardioangiograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Angiocardiogram))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Angio Cardiograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Coronary Arteriogra*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Coronarograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Myocardial Revascularization)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Angioplasty, Balloon, Coronary)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((Myocardial adj revasculari?ation)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((PCI))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Percutaneous coronary intervention))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Percutaneous Transluminal Coronary Angioplasty))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((PTCA))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Angioplasty EXPLODE ALL TREES)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Blunt microdissection))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((((laser or patch) adj angioplasty)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Percutaneous Transluminal Angioplasty))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Transluminal Coronary Angioplasty))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((Balloon adj3 coronary)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Balloon adj3 angioplasty))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Stents EXPLODE ALL TREES)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((stent*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(#24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Aspirin)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((aspirin or acetylsalicylic acid))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((clopidogrel or plavix))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((ticagrelor or brilique))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((prasugrel or efient or effient or prasita))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Prasugrel Hydrochloride</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Platelet Aggregation Inhibitors</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Glycoproteins IIb-IIIa or GPIIb-IIIa Receptors or Integrin alpha-IIb beta-3 or Integrin alphaIIbbeta3 or GPIIB IIIA))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Platelet Glycoprotein GPIIb-IIIa Complex EXPLODE ALL TREES</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Receptors, Fibrinogen EXPLODE ALL TREES</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Abciximab or Reopro or Eptifibatide or Integrelin or Integrilin or Intrifiban or Tirofiban or Aggrastat))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Adrenergic beta-Antagonists EXPLODE ALL TREES</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((propranolol or angilol or inderal-la or half-inderal or inderal or bedranol or prograne or slo-pro or acebutolol or sectral or atenolol or tenormin or bisoprolol or cardicor or emcor or carvedilol or eucardic or celiprolol or celectol or co-tenidone or tenoret or tenoretic or esmolol or brevibloc or labetalol or trandate or metoprolol or betaloc or lopresor or nadolol or corgard or nebivolol or nebilet or hypoloc or oxprenolol or trasicor or slow-trasicor or pindolol or visken or sotalol or beta-cardone or sotacor or timolol or betim))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR propranolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR acebutolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR atenolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR bisoprolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR celiprolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR labetalol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR metoprolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR nadolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#75.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR nebivolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#76.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR oxprenolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#77.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR pindolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#78.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR sotalol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#79.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR timolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#80.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((beta adj3 block*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#81.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((b adj3 block*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#82.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((beta adj2 antagonist*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#83.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Antithrombins</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#84.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Antithrombin*)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#85.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((thrombin adj3 inhibitor*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#86.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Hirudins</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#87.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Hirudin*)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#88.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Hirulog)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#89.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Bivalirudin)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#90.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 OR #83 OR #84 OR #85 OR #86 OR #87 OR #88 OR #89</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#91.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(#23 AND (#53 OR #90))</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng185er7appcfig1"><div id="niceng185er7.appc.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20Flow%20chart%20of%20clinical%20study%20selection%20for%20the%20review%20of%20combination%20therapy.&p=BOOKS&id=565359_niceng185er7appcf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appcf1.jpg" alt="Figure 1. Flow chart of clinical study selection for the review of combination therapy." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title">Flow chart of clinical study selection for the review of combination therapy</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig1"><div id="niceng185er7.appe.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%202.%20All-cause%20mortality%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef1.jpg" alt="Figure 2. All-cause mortality (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 2</span><span class="title">All-cause mortality (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig2"><div id="niceng185er7.appe.fig2" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%203.%20Myocardial%20infarction%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef2.jpg" alt="Figure 3. Myocardial infarction (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 3</span><span class="title">Myocardial infarction (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig3"><div id="niceng185er7.appe.fig3" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%204.%20Stroke%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef3.jpg" alt="Figure 4. Stroke (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 4</span><span class="title">Stroke (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig4"><div id="niceng185er7.appe.fig4" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%205.%20Any%20stent%20thrombosis%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef4.jpg" alt="Figure 5. Any stent thrombosis (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 5</span><span class="title">Any stent thrombosis (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig5"><div id="niceng185er7.appe.fig5" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%206.%20Complications%20relating%20to%20bleeding%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef5.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef5.jpg" alt="Figure 6. Complications relating to bleeding (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 6</span><span class="title">Complications relating to bleeding (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig6"><div id="niceng185er7.appe.fig6" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%207.%20All-cause%20mortality%20(14%20months).&p=BOOKS&id=565359_niceng185er7appef6.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef6.jpg" alt="Figure 7. All-cause mortality (14 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 7</span><span class="title">All-cause mortality (14 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig7"><div id="niceng185er7.appe.fig7" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%208.%20Myocardial%20infarction%20(14%20months).&p=BOOKS&id=565359_niceng185er7appef7.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef7.jpg" alt="Figure 8. Myocardial infarction (14 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 8</span><span class="title">Myocardial infarction (14 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig8"><div id="niceng185er7.appe.fig8" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%209.%20Stroke%20(14%20months).&p=BOOKS&id=565359_niceng185er7appef8.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef8.jpg" alt="Figure 9. Stroke (14 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 9</span><span class="title">Stroke (14 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig9"><div id="niceng185er7.appe.fig9" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2010.%20Definite%20stent%20thrombosis%20(14%20months).&p=BOOKS&id=565359_niceng185er7appef9.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef9.jpg" alt="Figure 10. Definite stent thrombosis (14 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 10</span><span class="title">Definite stent thrombosis (14 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig10"><div id="niceng185er7.appe.fig10" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2011.%20Complications%20relating%20to%20bleeding%20(14%20months).&p=BOOKS&id=565359_niceng185er7appef10.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef10.jpg" alt="Figure 11. Complications relating to bleeding (14 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 11</span><span class="title">Complications relating to bleeding (14 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig11"><div id="niceng185er7.appe.fig11" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2012.%20All%20cause%20mortality%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef11.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef11.jpg" alt="Figure 12. All cause mortality (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 12</span><span class="title">All cause mortality (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig12"><div id="niceng185er7.appe.fig12" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2013.%20Myocardial%20infarction%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef12.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef12.jpg" alt="Figure 13. Myocardial infarction (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 13</span><span class="title">Myocardial infarction (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig13"><div id="niceng185er7.appe.fig13" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2014.%20Stroke%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef13.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef13.jpg" alt="Figure 14. Stroke (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 14</span><span class="title">Stroke (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig14"><div id="niceng185er7.appe.fig14" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2015.%20Stent%20thrombosis%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef14.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef14.jpg" alt="Figure 15. Stent thrombosis (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 15</span><span class="title">Stent thrombosis (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig15"><div id="niceng185er7.appe.fig15" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2016.%20Complications%20relating%20to%20bleeding%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef15.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef15.jpg" alt="Figure 16. Complications relating to bleeding (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 16</span><span class="title">Complications relating to bleeding (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig16"><div id="niceng185er7.appe.fig16" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2017.%20All-cause%20mortality%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef16.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef16.jpg" alt="Figure 17. All-cause mortality (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 17</span><span class="title">All-cause mortality (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig17"><div id="niceng185er7.appe.fig17" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2018.%20Myocardial%20infarction%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef17.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef17.jpg" alt="Figure 18. Myocardial infarction (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 18</span><span class="title">Myocardial infarction (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig18"><div id="niceng185er7.appe.fig18" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2019.%20Stroke%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef18.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef18.jpg" alt="Figure 19. Stroke (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 19</span><span class="title">Stroke (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig19"><div id="niceng185er7.appe.fig19" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2020.%20Stent%20thrombosis%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef19.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef19.jpg" alt="Figure 20. Stent thrombosis (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 20</span><span class="title">Stent thrombosis (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig20"><div id="niceng185er7.appe.fig20" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2021.%20Complications%20relating%20to%20bleeding%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef20.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef20.jpg" alt="Figure 21. Complications relating to bleeding (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 21</span><span class="title">Complications relating to bleeding (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig21"><div id="niceng185er7.appe.fig21" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2022.%20All-cause%20mortality%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef21.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef21.jpg" alt="Figure 22. All-cause mortality (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 22</span><span class="title">All-cause mortality (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig22"><div id="niceng185er7.appe.fig22" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2023.%20Myocardial%20infarction%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef22.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef22.jpg" alt="Figure 23. Myocardial infarction (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 23</span><span class="title">Myocardial infarction (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig23"><div id="niceng185er7.appe.fig23" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2024.%20Stroke%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef23.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef23.jpg" alt="Figure 24. Stroke (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 24</span><span class="title">Stroke (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig24"><div id="niceng185er7.appe.fig24" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2025.%20Stent%20thrombosis%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef24.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef24.jpg" alt="Figure 25. Stent thrombosis (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 25</span><span class="title">Stent thrombosis (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig25"><div id="niceng185er7.appe.fig25" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2026.%20Complications%20relating%20to%20bleeding%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef25.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef25.jpg" alt="Figure 26. Complications relating to bleeding (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 26</span><span class="title">Complications relating to bleeding (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig26"><div id="niceng185er7.appe.fig26" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2027.%20All-cause%20mortality%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef26.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef26.jpg" alt="Figure 27. All-cause mortality (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 27</span><span class="title">All-cause mortality (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig27"><div id="niceng185er7.appe.fig27" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2028.%20Myocardial%20infarction%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef27.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef27.jpg" alt="Figure 28. Myocardial infarction (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 28</span><span class="title">Myocardial infarction (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig28"><div id="niceng185er7.appe.fig28" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2029.%20Stroke%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef28.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef28.jpg" alt="Figure 29. Stroke (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 29</span><span class="title">Stroke (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig29"><div id="niceng185er7.appe.fig29" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2030.%20Any%20stent%20thrombosis%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef29.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef29.jpg" alt="Figure 30. Any stent thrombosis (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 30</span><span class="title">Any stent thrombosis (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig30"><div id="niceng185er7.appe.fig30" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2031.%20Complications%20related%20to%20bleeding%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef30.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef30.jpg" alt="Figure 31. Complications related to bleeding (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 31</span><span class="title">Complications related to bleeding (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig31"><div id="niceng185er7.appe.fig31" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2032.%20All-cause%20mortality%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef31.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef31.jpg" alt="Figure 32. All-cause mortality (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 32</span><span class="title">All-cause mortality (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig32"><div id="niceng185er7.appe.fig32" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2033.%20Myocardial%20infarction%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef32.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef32.jpg" alt="Figure 33. Myocardial infarction (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 33</span><span class="title">Myocardial infarction (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig33"><div id="niceng185er7.appe.fig33" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2034.%20Stroke%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef33.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef33.jpg" alt="Figure 34. Stroke (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 34</span><span class="title">Stroke (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig34"><div id="niceng185er7.appe.fig34" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2035.%20Any%20stent%20thrombosis%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef34.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef34.jpg" alt="Figure 35. Any stent thrombosis (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 35</span><span class="title">Any stent thrombosis (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig35"><div id="niceng185er7.appe.fig35" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2036.%20Complications%20related%20to%20bleeding%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef35.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef35.jpg" alt="Figure 36. Complications related to bleeding (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 36</span><span class="title">Complications related to bleeding (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig36"><div id="niceng185er7.appe.fig36" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2037.%20All-cause%20mortality%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef36.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef36.jpg" alt="Figure 37. All-cause mortality (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 37</span><span class="title">All-cause mortality (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig37"><div id="niceng185er7.appe.fig37" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2038.%20Myocardial%20infarction%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef37.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef37.jpg" alt="Figure 38. Myocardial infarction (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 38</span><span class="title">Myocardial infarction (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig38"><div id="niceng185er7.appe.fig38" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2039.%20Stroke%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef38.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef38.jpg" alt="Figure 39. Stroke (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 39</span><span class="title">Stroke (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig39"><div id="niceng185er7.appe.fig39" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2040.%20Any%20stent%20thrombosis%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef39.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef39.jpg" alt="Figure 40. Any stent thrombosis (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 40</span><span class="title">Any stent thrombosis (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig40"><div id="niceng185er7.appe.fig40" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2041.%20Complications%20related%20to%20bleeding%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef40.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef40.jpg" alt="Figure 41. Complications related to bleeding (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 41</span><span class="title">Complications related to bleeding (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig41"><div id="niceng185er7.appe.fig41" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2042.%20All-cause%20mortality%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef41.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef41.jpg" alt="Figure 42. All-cause mortality (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 42</span><span class="title">All-cause mortality (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig42"><div id="niceng185er7.appe.fig42" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2043.%20Myocardial%20infarction%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef42.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef42.jpg" alt="Figure 43. Myocardial infarction (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 43</span><span class="title">Myocardial infarction (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig43"><div id="niceng185er7.appe.fig43" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2044.%20Stroke%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef43.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef43.jpg" alt="Figure 44. Stroke (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 44</span><span class="title">Stroke (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig44"><div id="niceng185er7.appe.fig44" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2045.%20Any%20stent%20thrombosis%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef44.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef44.jpg" alt="Figure 45. Any stent thrombosis (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 45</span><span class="title">Any stent thrombosis (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig45"><div id="niceng185er7.appe.fig45" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2046.%20Complications%20relating%20to%20bleeding%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef45.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef45.jpg" alt="Figure 46. Complications relating to bleeding (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 46</span><span class="title">Complications relating to bleeding (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig46"><div id="niceng185er7.appe.fig46" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2047.%20All-cause%20mortality%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef46.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef46.jpg" alt="Figure 47. All-cause mortality (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 47</span><span class="title">All-cause mortality (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig47"><div id="niceng185er7.appe.fig47" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2048.%20Myocardial%20infarction%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef47.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef47.jpg" alt="Figure 48. Myocardial infarction (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 48</span><span class="title">Myocardial infarction (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig48"><div id="niceng185er7.appe.fig48" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2049.%20Stroke%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef48.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef48.jpg" alt="Figure 49. Stroke (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 49</span><span class="title">Stroke (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig49"><div id="niceng185er7.appe.fig49" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2050.%20Any%20stent%20thrombosis%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef49.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef49.jpg" alt="Figure 50. Any stent thrombosis (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 50</span><span class="title">Any stent thrombosis (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig50"><div id="niceng185er7.appe.fig50" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2051.%20Complications%20related%20to%20bleeding%20(6%20months).&p=BOOKS&id=565359_niceng185er7appef50.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef50.jpg" alt="Figure 51. Complications related to bleeding (6 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 51</span><span class="title">Complications related to bleeding (6 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig51"><div id="niceng185er7.appe.fig51" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2052.%20Complications%20relating%20to%20bleeding%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef51.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef51.jpg" alt="Figure 52. Complications relating to bleeding (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 52</span><span class="title">Complications relating to bleeding (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig52"><div id="niceng185er7.appe.fig52" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2053.%20All-cause%20mortality%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef52.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef52.jpg" alt="Figure 53. All-cause mortality (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 53</span><span class="title">All-cause mortality (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig53"><div id="niceng185er7.appe.fig53" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2054.%20Stroke%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef53.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef53.jpg" alt="Figure 54. Stroke (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 54</span><span class="title">Stroke (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig54"><div id="niceng185er7.appe.fig54" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2055.%20Myocardial%20infarction%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef54.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef54.jpg" alt="Figure 55. Myocardial infarction (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 55</span><span class="title">Myocardial infarction (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig55"><div id="niceng185er7.appe.fig55" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2056.%20Stent%20thrombosis%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef55.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef55.jpg" alt="Figure 56. Stent thrombosis (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 56</span><span class="title">Stent thrombosis (12 months)</span></h3></div></article><article data-type="fig" id="figobniceng185er7appefig56"><div id="niceng185er7.appe.fig56" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2057.%20Complications%20relating%20to%20bleeding%20(12%20months).&p=BOOKS&id=565359_niceng185er7appef56.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appef56.jpg" alt="Figure 57. Complications relating to bleeding (12 months)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 57</span><span class="title">Complications relating to bleeding (12 months)</span></h3></div></article><article data-type="table-wrap" id="figobniceng185er7appftab1"><div id="niceng185er7.appf.tab1" class="table"><h3><span class="label">Table 19</span><span class="title">Clinical evidence profile: Warfarin + clopidogrel + aspirin versus warfarin + clopidogrel (AUGUSTUS data only)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appf.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appf.tab1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appf.tab1_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_niceng185er7.appf.tab1_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_niceng185er7.appf.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_niceng185er7.appf.tab1_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab1_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_niceng185er7.appf.tab1_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab1_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1" id="hd_h_niceng185er7.appf.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1" id="hd_h_niceng185er7.appf.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1" id="hd_h_niceng185er7.appf.tab1_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1" id="hd_h_niceng185er7.appf.tab1_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1" id="hd_h_niceng185er7.appf.tab1_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1" id="hd_h_niceng185er7.appf.tab1_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1" id="hd_h_niceng185er7.appf.tab1_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_2" id="hd_h_niceng185er7.appf.tab1_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Warfarin + clopidogrel + aspirin versus warfarin + clopidogrel</th><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_2" id="hd_h_niceng185er7.appf.tab1_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Control</th><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_3" id="hd_h_niceng185er7.appf.tab1_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_3" id="hd_h_niceng185er7.appf.tab1_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_h_niceng185er7.appf.tab1_1_1_1_5" id="hd_b_niceng185er7.appf.tab1_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_b_niceng185er7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_b_niceng185er7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_b_niceng185er7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_b_niceng185er7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_b_niceng185er7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_b_niceng185er7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_b_niceng185er7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_b_niceng185er7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>34/1154</p>
|
|
<p>(2.9%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_b_niceng185er7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.5%</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_b_niceng185er7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.85 (0.54 to 1.33)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_b_niceng185er7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5 fewer per 1000 (from 16 fewer to 12 more)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_b_niceng185er7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_5 hd_b_niceng185er7.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_h_niceng185er7.appf.tab1_1_1_1_5" id="hd_b_niceng185er7.appf.tab1_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Myocardial infarction (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_b_niceng185er7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_b_niceng185er7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_b_niceng185er7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_b_niceng185er7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_b_niceng185er7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_b_niceng185er7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_b_niceng185er7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_b_niceng185er7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>34/1154</p>
|
|
<p>(2.9%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_b_niceng185er7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4%</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_b_niceng185er7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.74 (0.48 to 1.14)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_b_niceng185er7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10 fewer per 1000 (from 21 fewer to 6 more)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_b_niceng185er7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_5 hd_b_niceng185er7.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_h_niceng185er7.appf.tab1_1_1_1_5" id="hd_b_niceng185er7.appf.tab1_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stroke (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_b_niceng185er7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_b_niceng185er7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_b_niceng185er7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_b_niceng185er7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_b_niceng185er7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_b_niceng185er7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_b_niceng185er7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_b_niceng185er7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>12/1154</p>
|
|
<p>(1%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_b_niceng185er7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.2%</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_b_niceng185er7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.86 (0.4 to 1.85)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_b_niceng185er7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2 fewer per 1000 (from 7 fewer to 10 more)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_b_niceng185er7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_5 hd_b_niceng185er7.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_h_niceng185er7.appf.tab1_1_1_1_5" id="hd_b_niceng185er7.appf.tab1_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Any stent thrombosis (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_b_niceng185er7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_b_niceng185er7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_b_niceng185er7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_b_niceng185er7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_b_niceng185er7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_b_niceng185er7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_b_niceng185er7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_b_niceng185er7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>12/1154</p>
|
|
<p>(1%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_b_niceng185er7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.7%</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_b_niceng185er7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.63 (0.31 to 1.3)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_b_niceng185er7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6 fewer per 1000 (from 12 fewer to 5 more)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_b_niceng185er7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_5 hd_b_niceng185er7.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_h_niceng185er7.appf.tab1_1_1_1_5" id="hd_b_niceng185er7.appf.tab1_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - TIMI major (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_b_niceng185er7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_b_niceng185er7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_b_niceng185er7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_b_niceng185er7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_b_niceng185er7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_b_niceng185er7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_b_niceng185er7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_b_niceng185er7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>29/1123</p>
|
|
<p>(2.6%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_b_niceng185er7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.6%</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_b_niceng185er7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.62 (0.9 to 2.89)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_b_niceng185er7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10 more per 1000 (from 2 fewer to 30 more)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_b_niceng185er7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_5 hd_b_niceng185er7.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_h_niceng185er7.appf.tab1_1_1_1_5" id="hd_b_niceng185er7.appf.tab1_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - TIMI major and minor (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_b_niceng185er7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_b_niceng185er7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_b_niceng185er7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_b_niceng185er7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_b_niceng185er7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_b_niceng185er7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_b_niceng185er7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_b_niceng185er7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>80/1123</p>
|
|
<p>(7.1%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_b_niceng185er7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.5%</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_b_niceng185er7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.57 (1.12 to 2.21)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_b_niceng185er7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">26 more per 1000 (from 5 more to 54 more)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_b_niceng185er7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_5 hd_b_niceng185er7.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_h_niceng185er7.appf.tab1_1_1_1_5" id="hd_b_niceng185er7.appf.tab1_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - Intracranial haemorhhage (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_1 hd_b_niceng185er7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_2 hd_b_niceng185er7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_3 hd_b_niceng185er7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_4 hd_b_niceng185er7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_5 hd_b_niceng185er7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_6 hd_b_niceng185er7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_1 hd_h_niceng185er7.appf.tab1_1_1_2_7 hd_b_niceng185er7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_8 hd_b_niceng185er7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>4/1123</p>
|
|
<p>(0.36%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_2 hd_h_niceng185er7.appf.tab1_1_1_2_9 hd_b_niceng185er7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.7%</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_10 hd_b_niceng185er7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.5 (0.15 to 1.66)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_3 hd_h_niceng185er7.appf.tab1_1_1_2_11 hd_b_niceng185er7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3 fewer per 1000 (from 6 fewer to 5 more)</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_4 hd_b_niceng185er7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab1_1_1_1_5 hd_b_niceng185er7.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.appf.tab1_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7appftab2"><div id="niceng185er7.appf.tab2" class="table"><h3><span class="label">Table 20</span><span class="title">Clinical evidence profile: Warfarin + clopidogrel + aspirin versus dabigatran + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appf.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appf.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appf.tab2_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_niceng185er7.appf.tab2_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_niceng185er7.appf.tab2_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_niceng185er7.appf.tab2_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab2_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_niceng185er7.appf.tab2_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab2_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1" id="hd_h_niceng185er7.appf.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1" id="hd_h_niceng185er7.appf.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1" id="hd_h_niceng185er7.appf.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1" id="hd_h_niceng185er7.appf.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1" id="hd_h_niceng185er7.appf.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1" id="hd_h_niceng185er7.appf.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1" id="hd_h_niceng185er7.appf.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_2" id="hd_h_niceng185er7.appf.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Warfarin + clopidogrel + aspirin</th><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_2" id="hd_h_niceng185er7.appf.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Dabigatran + clopidogrel</th><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_3" id="hd_h_niceng185er7.appf.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_3" id="hd_h_niceng185er7.appf.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_h_niceng185er7.appf.tab2_1_1_1_5" id="hd_b_niceng185er7.appf.tab2_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 14 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_b_niceng185er7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_b_niceng185er7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_b_niceng185er7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_b_niceng185er7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_b_niceng185er7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_b_niceng185er7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_b_niceng185er7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_b_niceng185er7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>48/981</p>
|
|
<p>(4.9%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_b_niceng185er7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5.6%</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_b_niceng185er7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.87 (0.6 to 1.27)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_b_niceng185er7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7 fewer per 1000 (from 22 fewer to 15 more)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_b_niceng185er7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_5 hd_b_niceng185er7.appf.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_h_niceng185er7.appf.tab2_1_1_1_5" id="hd_b_niceng185er7.appf.tab2_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Myocardial infarction (follow-up 14 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_b_niceng185er7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_b_niceng185er7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_b_niceng185er7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_b_niceng185er7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_b_niceng185er7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_b_niceng185er7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_b_niceng185er7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_b_niceng185er7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>29/981</p>
|
|
<p>(3%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_b_niceng185er7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.5%</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_b_niceng185er7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.66 (0.42 to 1.04)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_b_niceng185er7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">15 fewer per 1000 (from 26 fewer to 2 more)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_b_niceng185er7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_5 hd_b_niceng185er7.appf.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_h_niceng185er7.appf.tab2_1_1_1_5" id="hd_b_niceng185er7.appf.tab2_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stroke (follow-up 14 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_b_niceng185er7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_b_niceng185er7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_b_niceng185er7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_b_niceng185er7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_b_niceng185er7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_b_niceng185er7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_b_niceng185er7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_b_niceng185er7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>13/981</p>
|
|
<p>(1.3%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_b_niceng185er7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.7%</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_b_niceng185er7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.76 (0.37 to 1.57)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_b_niceng185er7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 fewer per 1000 (from 11 fewer to 10 more)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_b_niceng185er7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_5 hd_b_niceng185er7.appf.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_h_niceng185er7.appf.tab2_1_1_1_5" id="hd_b_niceng185er7.appf.tab2_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Definite stent thrombosis (follow-up 14 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_b_niceng185er7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_b_niceng185er7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_b_niceng185er7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_b_niceng185er7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_b_niceng185er7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_b_niceng185er7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_b_niceng185er7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_b_niceng185er7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>8/981</p>
|
|
<p>(0.82%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_b_niceng185er7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.5%</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_b_niceng185er7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.53 (0.23 to 1.25)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_b_niceng185er7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7 fewer per 1000 (from 12 fewer to 4 more)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_b_niceng185er7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_5 hd_b_niceng185er7.appf.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_h_niceng185er7.appf.tab2_1_1_1_5" id="hd_b_niceng185er7.appf.tab2_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - Intracranial haemorrhage (follow-up 14 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_b_niceng185er7.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_b_niceng185er7.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_b_niceng185er7.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_b_niceng185er7.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_b_niceng185er7.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_b_niceng185er7.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_b_niceng185er7.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_b_niceng185er7.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10/981</p>
|
|
<p>(1%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_b_niceng185er7.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.3%</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_b_niceng185er7.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 3.33 (0.92 to 12.08)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_b_niceng185er7.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7 more per 1000 (from 0 fewer to 33 more)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_b_niceng185er7.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_5 hd_b_niceng185er7.appf.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_h_niceng185er7.appf.tab2_1_1_1_5" id="hd_b_niceng185er7.appf.tab2_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - TIMI major bleeding (follow-up 14 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_b_niceng185er7.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_b_niceng185er7.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_b_niceng185er7.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_b_niceng185er7.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_b_niceng185er7.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_b_niceng185er7.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_b_niceng185er7.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_b_niceng185er7.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>37/981</p>
|
|
<p>(3.8%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_b_niceng185er7.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.4%</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_b_niceng185er7.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 2.64 (1.44 to 4.86)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_b_niceng185er7.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">23 more per 1000 (from 6 more to 54 more)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_b_niceng185er7.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_5 hd_b_niceng185er7.appf.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_h_niceng185er7.appf.tab2_1_1_1_5" id="hd_b_niceng185er7.appf.tab2_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - TIMI major and minor bleeding (follow-up 14 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_1 hd_b_niceng185er7.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_2 hd_b_niceng185er7.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_3 hd_b_niceng185er7.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_4 hd_b_niceng185er7.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_5 hd_b_niceng185er7.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_6 hd_b_niceng185er7.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_1 hd_h_niceng185er7.appf.tab2_1_1_2_7 hd_b_niceng185er7.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_8 hd_b_niceng185er7.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>69/981</p>
|
|
<p>(7%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_2 hd_h_niceng185er7.appf.tab2_1_1_2_9 hd_b_niceng185er7.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3%</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_10 hd_b_niceng185er7.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 2.38 (1.56 to 3.64)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_3 hd_h_niceng185er7.appf.tab2_1_1_2_11 hd_b_niceng185er7.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">41 more per 1000 (from 17 more to 79 more)</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_4 hd_b_niceng185er7.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab2_1_1_1_5 hd_b_niceng185er7.appf.tab2_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.appf.tab2_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng185er7.appf.tab2_2"><p class="no_margin">Downgraded once for serious imprecision, and twice for very serious imprecision</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7appftab3"><div id="niceng185er7.appf.tab3" class="table"><h3><span class="label">Table 21</span><span class="title">Clinical evidence profile: Rivaroxaban + clopidogrel + aspirin versus rivaroxaban + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appf.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appf.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appf.tab3_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_niceng185er7.appf.tab3_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_niceng185er7.appf.tab3_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_niceng185er7.appf.tab3_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab3_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_niceng185er7.appf.tab3_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab3_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1" id="hd_h_niceng185er7.appf.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1" id="hd_h_niceng185er7.appf.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1" id="hd_h_niceng185er7.appf.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1" id="hd_h_niceng185er7.appf.tab3_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1" id="hd_h_niceng185er7.appf.tab3_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1" id="hd_h_niceng185er7.appf.tab3_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1" id="hd_h_niceng185er7.appf.tab3_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_2" id="hd_h_niceng185er7.appf.tab3_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Rivaroxaban + clopidogrel + aspirin versus rivaroxaban + clopidogrel</th><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_2" id="hd_h_niceng185er7.appf.tab3_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Control</th><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_3" id="hd_h_niceng185er7.appf.tab3_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_3" id="hd_h_niceng185er7.appf.tab3_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_h_niceng185er7.appf.tab3_1_1_1_5" id="hd_b_niceng185er7.appf.tab3_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_b_niceng185er7.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_b_niceng185er7.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_b_niceng185er7.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_b_niceng185er7.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_b_niceng185er7.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_b_niceng185er7.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_b_niceng185er7.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_b_niceng185er7.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>17/704</p>
|
|
<p>(2.4%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_b_niceng185er7.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.3%</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_b_niceng185er7.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.05 (0.53 to 2.06)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_b_niceng185er7.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 more per 1000 (from 11 fewer to 24 more)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_b_niceng185er7.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_5 hd_b_niceng185er7.appf.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_h_niceng185er7.appf.tab3_1_1_1_5" id="hd_b_niceng185er7.appf.tab3_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Myocardial infarction (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_b_niceng185er7.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_b_niceng185er7.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_b_niceng185er7.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_b_niceng185er7.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_b_niceng185er7.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_b_niceng185er7.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_b_niceng185er7.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_b_niceng185er7.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>17/704</p>
|
|
<p>(2.4%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_b_niceng185er7.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.7%</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_b_niceng185er7.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.88 (0.46 to 1.68)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_b_niceng185er7.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3 fewer per 1000 (from 15 fewer to 18 more)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_b_niceng185er7.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_5 hd_b_niceng185er7.appf.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_h_niceng185er7.appf.tab3_1_1_1_5" id="hd_b_niceng185er7.appf.tab3_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stroke (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_b_niceng185er7.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_b_niceng185er7.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_b_niceng185er7.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_b_niceng185er7.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_b_niceng185er7.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_b_niceng185er7.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_b_niceng185er7.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_b_niceng185er7.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10/704</p>
|
|
<p>(1.4%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_b_niceng185er7.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.2%</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_b_niceng185er7.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.23 (0.49 to 3.1)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_b_niceng185er7.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3 more per 1000 (from 6 fewer to 25 more)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_b_niceng185er7.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_5 hd_b_niceng185er7.appf.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_h_niceng185er7.appf.tab3_1_1_1_5" id="hd_b_niceng185er7.appf.tab3_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stent thrombosis (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_b_niceng185er7.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_b_niceng185er7.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_b_niceng185er7.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_b_niceng185er7.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_b_niceng185er7.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_b_niceng185er7.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_b_niceng185er7.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_b_niceng185er7.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>6/704</p>
|
|
<p>(0.85%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_b_niceng185er7.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.7%</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_b_niceng185er7.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.18 (0.36 to 3.86)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_b_niceng185er7.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 more per 1000 (from 4 fewer to 20 more)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_b_niceng185er7.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_5 hd_b_niceng185er7.appf.tab3_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_h_niceng185er7.appf.tab3_1_1_1_5" id="hd_b_niceng185er7.appf.tab3_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - Bleeding requiring medical attention (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_b_niceng185er7.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_b_niceng185er7.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_b_niceng185er7.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_b_niceng185er7.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_b_niceng185er7.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_b_niceng185er7.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_b_niceng185er7.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_b_niceng185er7.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>102/706</p>
|
|
<p>(14.4%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_b_niceng185er7.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">13.4%</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_b_niceng185er7.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.08 (0.83 to 1.4)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_b_niceng185er7.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11 more per 1000 (from 23 fewer to 54 more)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_b_niceng185er7.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_5 hd_b_niceng185er7.appf.tab3_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_h_niceng185er7.appf.tab3_1_1_1_5" id="hd_b_niceng185er7.appf.tab3_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - Major bleeding (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_b_niceng185er7.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_b_niceng185er7.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_b_niceng185er7.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_b_niceng185er7.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_b_niceng185er7.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_b_niceng185er7.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_b_niceng185er7.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_b_niceng185er7.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>12/706</p>
|
|
<p>(1.7%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_b_niceng185er7.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2%</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_b_niceng185er7.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.85 (0.39 to 1.81)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_b_niceng185er7.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3 fewer per 1000 (from 12 fewer to 16 more)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_b_niceng185er7.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_5 hd_b_niceng185er7.appf.tab3_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_h_niceng185er7.appf.tab3_1_1_1_5" id="hd_b_niceng185er7.appf.tab3_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - Minor bleeding (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_1 hd_b_niceng185er7.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_2 hd_b_niceng185er7.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_3 hd_b_niceng185er7.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_4 hd_b_niceng185er7.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_5 hd_b_niceng185er7.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_6 hd_b_niceng185er7.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_1 hd_h_niceng185er7.appf.tab3_1_1_2_7 hd_b_niceng185er7.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_8 hd_b_niceng185er7.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>7/706</p>
|
|
<p>(0.99%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_2 hd_h_niceng185er7.appf.tab3_1_1_2_9 hd_b_niceng185er7.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1%</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_10 hd_b_niceng185er7.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.99 (0.35 to 2.8)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_3 hd_h_niceng185er7.appf.tab3_1_1_2_11 hd_b_niceng185er7.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0 fewer per 1000 (from 7 fewer to 18 more)</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_4 hd_b_niceng185er7.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab3_1_1_1_5 hd_b_niceng185er7.appf.tab3_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.appf.tab3_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng185er7.appf.tab3_2"><p class="no_margin">Downgraded once for serious imprecision, and twice for very serious imprecision</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7appftab4"><div id="niceng185er7.appf.tab4" class="table"><h3><span class="label">Table 22</span><span class="title">Clinical evidence profile: Rivaroxaban + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appf.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appf.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appf.tab4_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_niceng185er7.appf.tab4_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_niceng185er7.appf.tab4_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_niceng185er7.appf.tab4_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab4_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_niceng185er7.appf.tab4_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab4_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1" id="hd_h_niceng185er7.appf.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1" id="hd_h_niceng185er7.appf.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1" id="hd_h_niceng185er7.appf.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1" id="hd_h_niceng185er7.appf.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1" id="hd_h_niceng185er7.appf.tab4_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1" id="hd_h_niceng185er7.appf.tab4_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1" id="hd_h_niceng185er7.appf.tab4_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_2" id="hd_h_niceng185er7.appf.tab4_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Rivaroxaban + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin</th><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_2" id="hd_h_niceng185er7.appf.tab4_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Control</th><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_3" id="hd_h_niceng185er7.appf.tab4_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_3" id="hd_h_niceng185er7.appf.tab4_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_h_niceng185er7.appf.tab4_1_1_1_5" id="hd_b_niceng185er7.appf.tab4_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_b_niceng185er7.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_b_niceng185er7.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_b_niceng185er7.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_b_niceng185er7.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_b_niceng185er7.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_b_niceng185er7.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_b_niceng185er7.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_b_niceng185er7.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>17/704</p>
|
|
<p>(2.4%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_b_niceng185er7.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.9%</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_b_niceng185er7.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.29 (0.63 to 2.64)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_b_niceng185er7.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5 more per 1000 (from 7 fewer to 31 more)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_b_niceng185er7.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_5 hd_b_niceng185er7.appf.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_h_niceng185er7.appf.tab4_1_1_1_5" id="hd_b_niceng185er7.appf.tab4_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Myocardial infarction (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_b_niceng185er7.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_b_niceng185er7.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_b_niceng185er7.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_b_niceng185er7.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_b_niceng185er7.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_b_niceng185er7.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_b_niceng185er7.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_b_niceng185er7.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>17/704</p>
|
|
<p>(2.4%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_b_niceng185er7.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3%</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_b_niceng185er7.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.8 (0.43 to 1.5)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_b_niceng185er7.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6 fewer per 1000 (from 17 fewer to 15 more)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_b_niceng185er7.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_5 hd_b_niceng185er7.appf.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_h_niceng185er7.appf.tab4_1_1_1_5" id="hd_b_niceng185er7.appf.tab4_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stroke (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_b_niceng185er7.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_b_niceng185er7.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_b_niceng185er7.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_b_niceng185er7.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_b_niceng185er7.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_b_niceng185er7.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_b_niceng185er7.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_b_niceng185er7.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10/704</p>
|
|
<p>(1.4%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_b_niceng185er7.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1%</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_b_niceng185er7.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.41 (0.54 to 3.68)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_b_niceng185er7.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 more per 1000 (from 5 fewer to 27 more)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_b_niceng185er7.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_5 hd_b_niceng185er7.appf.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_h_niceng185er7.appf.tab4_1_1_1_5" id="hd_b_niceng185er7.appf.tab4_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stent thrombosis (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_b_niceng185er7.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_b_niceng185er7.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_b_niceng185er7.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_b_niceng185er7.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_b_niceng185er7.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_b_niceng185er7.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_b_niceng185er7.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_b_niceng185er7.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>6/704</p>
|
|
<p>(0.85%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_b_niceng185er7.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.6%</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_b_niceng185er7.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.48 (0.42 to 5.22)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_b_niceng185er7.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3 more per 1000 (from 3 fewer to 25 more)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_b_niceng185er7.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_5 hd_b_niceng185er7.appf.tab4_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_h_niceng185er7.appf.tab4_1_1_1_5" id="hd_b_niceng185er7.appf.tab4_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - Bleeding requiring medical attention (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_b_niceng185er7.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_b_niceng185er7.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_b_niceng185er7.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_b_niceng185er7.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_b_niceng185er7.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_b_niceng185er7.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_b_niceng185er7.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_b_niceng185er7.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>102/706</p>
|
|
<p>(14.4%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_b_niceng185er7.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">19.9%</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_b_niceng185er7.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.72 (0.57 to 0.91)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_b_niceng185er7.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">56 fewer per 1000 (from 18 fewer to 86 fewer)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_b_niceng185er7.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_5 hd_b_niceng185er7.appf.tab4_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_h_niceng185er7.appf.tab4_1_1_1_5" id="hd_b_niceng185er7.appf.tab4_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - Major bleeding (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_b_niceng185er7.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_b_niceng185er7.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_b_niceng185er7.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_b_niceng185er7.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_b_niceng185er7.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_b_niceng185er7.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_b_niceng185er7.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_b_niceng185er7.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>12/706</p>
|
|
<p>(1.7%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_b_niceng185er7.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.9%</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_b_niceng185er7.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.59 (0.29 to 1.2)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_b_niceng185er7.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">12 fewer per 1000 (from 21 fewer to 6 more)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_b_niceng185er7.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_5 hd_b_niceng185er7.appf.tab4_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_h_niceng185er7.appf.tab4_1_1_1_5" id="hd_b_niceng185er7.appf.tab4_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - Minor bleeding (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_1 hd_b_niceng185er7.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_2 hd_b_niceng185er7.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_3 hd_b_niceng185er7.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_4 hd_b_niceng185er7.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_5 hd_b_niceng185er7.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_6 hd_b_niceng185er7.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_1 hd_h_niceng185er7.appf.tab4_1_1_2_7 hd_b_niceng185er7.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_8 hd_b_niceng185er7.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>7/706</p>
|
|
<p>(0.99%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_2 hd_h_niceng185er7.appf.tab4_1_1_2_9 hd_b_niceng185er7.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.9%</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_10 hd_b_niceng185er7.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.53 (0.21 to 1.32)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_3 hd_h_niceng185er7.appf.tab4_1_1_2_11 hd_b_niceng185er7.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9 fewer per 1000 (from 15 fewer to 6 more)</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_4 hd_b_niceng185er7.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab4_1_1_1_5 hd_b_niceng185er7.appf.tab4_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.appf.tab4_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng185er7.appf.tab4_2"><p class="no_margin">Downgraded once for serious imprecision, and twice for very serious imprecision</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7appftab5"><div id="niceng185er7.appf.tab5" class="table"><h3><span class="label">Table 23</span><span class="title">Clinical evidence profile: Warfarin + clopidogrel + aspirin versus Rivaroxaban + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appf.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appf.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appf.tab5_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_niceng185er7.appf.tab5_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_niceng185er7.appf.tab5_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_niceng185er7.appf.tab5_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab5_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_niceng185er7.appf.tab5_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab5_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1" id="hd_h_niceng185er7.appf.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1" id="hd_h_niceng185er7.appf.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1" id="hd_h_niceng185er7.appf.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1" id="hd_h_niceng185er7.appf.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1" id="hd_h_niceng185er7.appf.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1" id="hd_h_niceng185er7.appf.tab5_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1" id="hd_h_niceng185er7.appf.tab5_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_2" id="hd_h_niceng185er7.appf.tab5_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Warfarin + clopidogrel + aspirin versus Rivaroxaban + clopidogrel</th><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_2" id="hd_h_niceng185er7.appf.tab5_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Control</th><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_3" id="hd_h_niceng185er7.appf.tab5_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_3" id="hd_h_niceng185er7.appf.tab5_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_h_niceng185er7.appf.tab5_1_1_1_5" id="hd_b_niceng185er7.appf.tab5_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_b_niceng185er7.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_b_niceng185er7.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_b_niceng185er7.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_b_niceng185er7.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_b_niceng185er7.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_b_niceng185er7.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_b_niceng185er7.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_b_niceng185er7.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>13/695</p>
|
|
<p>(1.9%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_b_niceng185er7.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.3%</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_b_niceng185er7.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.81 (0.39 to 1.67)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_b_niceng185er7.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 fewer per 1000 (from 14 fewer to 15 more)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_b_niceng185er7.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_5 hd_b_niceng185er7.appf.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_h_niceng185er7.appf.tab5_1_1_1_5" id="hd_b_niceng185er7.appf.tab5_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Myocardial infarction (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_b_niceng185er7.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_b_niceng185er7.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_b_niceng185er7.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_b_niceng185er7.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_b_niceng185er7.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_b_niceng185er7.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_b_niceng185er7.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_b_niceng185er7.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>21/695</p>
|
|
<p>(3%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_b_niceng185er7.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.7%</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_b_niceng185er7.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.1 (0.6 to 2.03)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_b_niceng185er7.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3 more per 1000 (from 11 fewer to 28 more)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_b_niceng185er7.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_5 hd_b_niceng185er7.appf.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_h_niceng185er7.appf.tab5_1_1_1_5" id="hd_b_niceng185er7.appf.tab5_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stroke (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_b_niceng185er7.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_b_niceng185er7.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_b_niceng185er7.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_b_niceng185er7.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_b_niceng185er7.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_b_niceng185er7.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_b_niceng185er7.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_b_niceng185er7.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>7/695</p>
|
|
<p>(1%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_b_niceng185er7.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.2%</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_b_niceng185er7.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.87 (0.32 to 2.4)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_b_niceng185er7.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2 fewer per 1000 (from 8 fewer to 17 more)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_b_niceng185er7.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_5 hd_b_niceng185er7.appf.tab5_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_h_niceng185er7.appf.tab5_1_1_1_5" id="hd_b_niceng185er7.appf.tab5_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stent thrombosis (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_b_niceng185er7.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_b_niceng185er7.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_b_niceng185er7.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_b_niceng185er7.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_b_niceng185er7.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_b_niceng185er7.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_b_niceng185er7.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_b_niceng185er7.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>4/695</p>
|
|
<p>(0.58%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_b_niceng185er7.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.7%</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_b_niceng185er7.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.8 (0.22 to 2.96)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_b_niceng185er7.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 fewer per 1000 (from 5 fewer to 14 more)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_b_niceng185er7.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_5 hd_b_niceng185er7.appf.tab5_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_h_niceng185er7.appf.tab5_1_1_1_5" id="hd_b_niceng185er7.appf.tab5_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - Bleeding requiring medical attention (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_b_niceng185er7.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_b_niceng185er7.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_b_niceng185er7.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_b_niceng185er7.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_b_niceng185er7.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_b_niceng185er7.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_b_niceng185er7.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_b_niceng185er7.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>139/697</p>
|
|
<p>(19.9%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_b_niceng185er7.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">13.4%</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_b_niceng185er7.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.49 (1.17 to 1.9)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_b_niceng185er7.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">66 more per 1000 (from 23 more to 121 more)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_b_niceng185er7.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_5 hd_b_niceng185er7.appf.tab5_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_h_niceng185er7.appf.tab5_1_1_1_5" id="hd_b_niceng185er7.appf.tab5_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - Major bleeding (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_b_niceng185er7.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_b_niceng185er7.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_b_niceng185er7.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_b_niceng185er7.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_b_niceng185er7.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_b_niceng185er7.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_b_niceng185er7.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_b_niceng185er7.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>20/697</p>
|
|
<p>(2.9%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_b_niceng185er7.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2%</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_b_niceng185er7.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.43 (0.73 to 2.8)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_b_niceng185er7.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9 more per 1000 (from 5 fewer to 36 more)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_b_niceng185er7.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_5 hd_b_niceng185er7.appf.tab5_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_h_niceng185er7.appf.tab5_1_1_1_5" id="hd_b_niceng185er7.appf.tab5_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - Minor bleeding (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_1 hd_b_niceng185er7.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_2 hd_b_niceng185er7.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_3 hd_b_niceng185er7.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_4 hd_b_niceng185er7.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_5 hd_b_niceng185er7.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_6 hd_b_niceng185er7.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_1 hd_h_niceng185er7.appf.tab5_1_1_2_7 hd_b_niceng185er7.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_8 hd_b_niceng185er7.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>13/697</p>
|
|
<p>(1.9%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_2 hd_h_niceng185er7.appf.tab5_1_1_2_9 hd_b_niceng185er7.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1%</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_10 hd_b_niceng185er7.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.85 (0.74 to 4.62)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_3 hd_h_niceng185er7.appf.tab5_1_1_2_11 hd_b_niceng185er7.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9 more per 1000 (from 3 fewer to 36 more)</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_4 hd_b_niceng185er7.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕ΟΟΟ</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab5_1_1_1_5 hd_b_niceng185er7.appf.tab5_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.appf.tab5_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng185er7.appf.tab5_2"><p class="no_margin">Downgraded once for serious imprecision and twice for very serious imprecision</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7appftab6"><div id="niceng185er7.appf.tab6" class="table"><h3><span class="label">Table 24</span><span class="title">Clinical evidence profile: AUGUSTUS – apixaban + clopidogrel + aspirin versus apixaban + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appf.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appf.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appf.tab6_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_niceng185er7.appf.tab6_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_niceng185er7.appf.tab6_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_niceng185er7.appf.tab6_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab6_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_niceng185er7.appf.tab6_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab6_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1" id="hd_h_niceng185er7.appf.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1" id="hd_h_niceng185er7.appf.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1" id="hd_h_niceng185er7.appf.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1" id="hd_h_niceng185er7.appf.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1" id="hd_h_niceng185er7.appf.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1" id="hd_h_niceng185er7.appf.tab6_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1" id="hd_h_niceng185er7.appf.tab6_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_2" id="hd_h_niceng185er7.appf.tab6_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Apixaban + clopidogrel + aspirin versus apixaban + clopidogrel</th><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_2" id="hd_h_niceng185er7.appf.tab6_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Control</th><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_3" id="hd_h_niceng185er7.appf.tab6_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_3" id="hd_h_niceng185er7.appf.tab6_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_h_niceng185er7.appf.tab6_1_1_1_5" id="hd_b_niceng185er7.appf.tab6_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_b_niceng185er7.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_b_niceng185er7.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_b_niceng185er7.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_b_niceng185er7.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_b_niceng185er7.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_b_niceng185er7.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_b_niceng185er7.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_b_niceng185er7.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>38/1153</p>
|
|
<p>(3.3%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_b_niceng185er7.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.4%</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_b_niceng185er7.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.97 (0.63 to 1.51)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_b_niceng185er7.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 fewer per 1000 (from 13 fewer to 17 more)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_b_niceng185er7.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_5 hd_b_niceng185er7.appf.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_h_niceng185er7.appf.tab6_1_1_1_5" id="hd_b_niceng185er7.appf.tab6_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Myocardial infarction (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_b_niceng185er7.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_b_niceng185er7.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_b_niceng185er7.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_b_niceng185er7.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_b_niceng185er7.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_b_niceng185er7.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_b_niceng185er7.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_b_niceng185er7.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>34/1153</p>
|
|
<p>(2.9%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_b_niceng185er7.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.3%</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_b_niceng185er7.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.89 (0.57 to 1.41)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_b_niceng185er7.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 fewer per 1000 (from 14 fewer to 14 more)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_b_niceng185er7.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_5 hd_b_niceng185er7.appf.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_h_niceng185er7.appf.tab6_1_1_1_5" id="hd_b_niceng185er7.appf.tab6_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stroke (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_b_niceng185er7.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_b_niceng185er7.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_b_niceng185er7.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_b_niceng185er7.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_b_niceng185er7.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_b_niceng185er7.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_b_niceng185er7.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_b_niceng185er7.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>8/1153</p>
|
|
<p>(0.69%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_b_niceng185er7.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.4%</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_b_niceng185er7.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.6 (0.52 to 4.88)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_b_niceng185er7.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2 more per 1000 (from 2 fewer to 16 more)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_b_niceng185er7.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_5 hd_b_niceng185er7.appf.tab6_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_h_niceng185er7.appf.tab6_1_1_1_5" id="hd_b_niceng185er7.appf.tab6_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stent thrombosis (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_b_niceng185er7.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_b_niceng185er7.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_b_niceng185er7.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_b_niceng185er7.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_b_niceng185er7.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_b_niceng185er7.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_b_niceng185er7.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_b_niceng185er7.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>11/1153</p>
|
|
<p>(0.95%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_b_niceng185er7.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.8%</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_b_niceng185er7.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.52 (0.25 to 1.08)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_b_niceng185er7.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9 fewer per 1000 (from 13 fewer to 1 more)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_b_niceng185er7.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_5 hd_b_niceng185er7.appf.tab6_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_h_niceng185er7.appf.tab6_1_1_1_5" id="hd_b_niceng185er7.appf.tab6_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - TIMI major bleeding (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_b_niceng185er7.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_b_niceng185er7.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_b_niceng185er7.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_b_niceng185er7.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_b_niceng185er7.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_b_niceng185er7.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_b_niceng185er7.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_b_niceng185er7.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>25/1145</p>
|
|
<p>(2.2%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_b_niceng185er7.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.1%</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_b_niceng185er7.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.92 (0.99 to 3.73)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_b_niceng185er7.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10 more per 1000 (from 0 fewer to 30 more)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_b_niceng185er7.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_5 hd_b_niceng185er7.appf.tab6_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_h_niceng185er7.appf.tab6_1_1_1_5" id="hd_b_niceng185er7.appf.tab6_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - TIMI major and minor bleeding (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_b_niceng185er7.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_b_niceng185er7.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_b_niceng185er7.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_b_niceng185er7.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_b_niceng185er7.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_b_niceng185er7.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_b_niceng185er7.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_b_niceng185er7.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>64/1145</p>
|
|
<p>(5.6%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_b_niceng185er7.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.8%</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_b_niceng185er7.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 2 (1.32 to 3.03)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_b_niceng185er7.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">28 more per 1000 (from 9 more to 57 more)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_b_niceng185er7.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕⊕</p>
|
|
<p>HIGH</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_5 hd_b_niceng185er7.appf.tab6_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_h_niceng185er7.appf.tab6_1_1_1_5" id="hd_b_niceng185er7.appf.tab6_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications relating to bleeding - Intracranial haemorrhage (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_1 hd_b_niceng185er7.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_2 hd_b_niceng185er7.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_3 hd_b_niceng185er7.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_4 hd_b_niceng185er7.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_5 hd_b_niceng185er7.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_6 hd_b_niceng185er7.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_1 hd_h_niceng185er7.appf.tab6_1_1_2_7 hd_b_niceng185er7.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_8 hd_b_niceng185er7.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>4/1145</p>
|
|
<p>(0.35%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_2 hd_h_niceng185er7.appf.tab6_1_1_2_9 hd_b_niceng185er7.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.1%</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_10 hd_b_niceng185er7.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 3.99 (0.45 to 35.67)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_3 hd_h_niceng185er7.appf.tab6_1_1_2_11 hd_b_niceng185er7.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3 more per 1000 (from 1 fewer to 35 more)</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_4 hd_b_niceng185er7.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab6_1_1_1_5 hd_b_niceng185er7.appf.tab6_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.appf.tab6_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7appftab7"><div id="niceng185er7.appf.tab7" class="table"><h3><span class="label">Table 25</span><span class="title">Clinical evidence profile: AUGUSTUS – Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appf.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appf.tab7_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appf.tab7_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_niceng185er7.appf.tab7_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_niceng185er7.appf.tab7_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_niceng185er7.appf.tab7_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab7_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_niceng185er7.appf.tab7_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab7_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1" id="hd_h_niceng185er7.appf.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1" id="hd_h_niceng185er7.appf.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1" id="hd_h_niceng185er7.appf.tab7_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1" id="hd_h_niceng185er7.appf.tab7_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1" id="hd_h_niceng185er7.appf.tab7_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1" id="hd_h_niceng185er7.appf.tab7_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1" id="hd_h_niceng185er7.appf.tab7_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_2" id="hd_h_niceng185er7.appf.tab7_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel + aspirin</th><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_2" id="hd_h_niceng185er7.appf.tab7_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Control</th><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_3" id="hd_h_niceng185er7.appf.tab7_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_3" id="hd_h_niceng185er7.appf.tab7_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_h_niceng185er7.appf.tab7_1_1_1_5" id="hd_b_niceng185er7.appf.tab7_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_b_niceng185er7.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_b_niceng185er7.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_b_niceng185er7.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_b_niceng185er7.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_b_niceng185er7.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_b_niceng185er7.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_b_niceng185er7.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_b_niceng185er7.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>38/1153</p>
|
|
<p>(3.3%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_b_niceng185er7.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3%</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_b_niceng185er7.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.12 (0.71 to 1.76)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_b_niceng185er7.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 more per 1000 (from 9 fewer to 23 more)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_b_niceng185er7.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_5 hd_b_niceng185er7.appf.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_h_niceng185er7.appf.tab7_1_1_1_5" id="hd_b_niceng185er7.appf.tab7_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Myocardial infarction (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_b_niceng185er7.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_b_niceng185er7.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_b_niceng185er7.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_b_niceng185er7.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_b_niceng185er7.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_b_niceng185er7.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_b_niceng185er7.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_b_niceng185er7.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>34/1153</p>
|
|
<p>(2.9%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_b_niceng185er7.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3%</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_b_niceng185er7.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1 (0.63 to 1.6)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_b_niceng185er7.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0 fewer per 1000 (from 11 fewer to 18 more)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_b_niceng185er7.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_5 hd_b_niceng185er7.appf.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_h_niceng185er7.appf.tab7_1_1_1_5" id="hd_b_niceng185er7.appf.tab7_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stroke (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_b_niceng185er7.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_b_niceng185er7.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_b_niceng185er7.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_b_niceng185er7.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_b_niceng185er7.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_b_niceng185er7.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_b_niceng185er7.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_b_niceng185er7.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>8/1153</p>
|
|
<p>(0.69%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_b_niceng185er7.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1%</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_b_niceng185er7.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.67 (0.27 to 1.63)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_b_niceng185er7.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3 fewer per 1000 (from 7 fewer to 6 more)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_b_niceng185er7.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_5 hd_b_niceng185er7.appf.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_h_niceng185er7.appf.tab7_1_1_1_5" id="hd_b_niceng185er7.appf.tab7_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Any stent thrombosis (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_b_niceng185er7.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_b_niceng185er7.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_b_niceng185er7.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_b_niceng185er7.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_b_niceng185er7.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_b_niceng185er7.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_b_niceng185er7.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_b_niceng185er7.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>11/1153</p>
|
|
<p>(0.95%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_b_niceng185er7.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1%</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_b_niceng185er7.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.92 (0.41 to 2.07)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_b_niceng185er7.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 fewer per 1000 (from 6 fewer to 11 more)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_b_niceng185er7.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_5 hd_b_niceng185er7.appf.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_h_niceng185er7.appf.tab7_1_1_1_5" id="hd_b_niceng185er7.appf.tab7_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - TIMI major bleeding (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_b_niceng185er7.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_b_niceng185er7.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_b_niceng185er7.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_b_niceng185er7.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_b_niceng185er7.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_b_niceng185er7.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_b_niceng185er7.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_b_niceng185er7.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>25/1145</p>
|
|
<p>(2.2%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_b_niceng185er7.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.6%</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_b_niceng185er7.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.85 (0.5 to 1.43)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_b_niceng185er7.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 fewer per 1000 (from 13 fewer to 11 more)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_b_niceng185er7.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_5 hd_b_niceng185er7.appf.tab7_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_h_niceng185er7.appf.tab7_1_1_1_5" id="hd_b_niceng185er7.appf.tab7_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - TIMI minor bleeding (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_b_niceng185er7.appf.tab7_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_b_niceng185er7.appf.tab7_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_b_niceng185er7.appf.tab7_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_b_niceng185er7.appf.tab7_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_b_niceng185er7.appf.tab7_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_b_niceng185er7.appf.tab7_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_b_niceng185er7.appf.tab7_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_b_niceng185er7.appf.tab7_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>64/1145</p>
|
|
<p>(5.6%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_b_niceng185er7.appf.tab7_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7.1%</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_b_niceng185er7.appf.tab7_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.78 (0.57 to 1.08)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_b_niceng185er7.appf.tab7_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">16 fewer per 1000 (from 31 fewer to 6 more)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_b_niceng185er7.appf.tab7_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_5 hd_b_niceng185er7.appf.tab7_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_h_niceng185er7.appf.tab7_1_1_1_5" id="hd_b_niceng185er7.appf.tab7_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - Intracranial haemorrhage (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_1 hd_b_niceng185er7.appf.tab7_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_2 hd_b_niceng185er7.appf.tab7_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_3 hd_b_niceng185er7.appf.tab7_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_4 hd_b_niceng185er7.appf.tab7_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_5 hd_b_niceng185er7.appf.tab7_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_6 hd_b_niceng185er7.appf.tab7_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_1 hd_h_niceng185er7.appf.tab7_1_1_2_7 hd_b_niceng185er7.appf.tab7_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_8 hd_b_niceng185er7.appf.tab7_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>4/1145</p>
|
|
<p>(0.35%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_2 hd_h_niceng185er7.appf.tab7_1_1_2_9 hd_b_niceng185er7.appf.tab7_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.4%</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_10 hd_b_niceng185er7.appf.tab7_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.98 (0.25 to 3.91)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_3 hd_h_niceng185er7.appf.tab7_1_1_2_11 hd_b_niceng185er7.appf.tab7_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0 fewer per 1000 (from 3 fewer to 12 more)</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_4 hd_b_niceng185er7.appf.tab7_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab7_1_1_1_5 hd_b_niceng185er7.appf.tab7_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.appf.tab7_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7appftab8"><div id="niceng185er7.appf.tab8" class="table"><h3><span class="label">Table 26</span><span class="title">Clinical evidence profile: AUGUSTUS – Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appf.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appf.tab8_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appf.tab8_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_niceng185er7.appf.tab8_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_niceng185er7.appf.tab8_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_niceng185er7.appf.tab8_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab8_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_niceng185er7.appf.tab8_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab8_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1" id="hd_h_niceng185er7.appf.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1" id="hd_h_niceng185er7.appf.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1" id="hd_h_niceng185er7.appf.tab8_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1" id="hd_h_niceng185er7.appf.tab8_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1" id="hd_h_niceng185er7.appf.tab8_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1" id="hd_h_niceng185er7.appf.tab8_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1" id="hd_h_niceng185er7.appf.tab8_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_2" id="hd_h_niceng185er7.appf.tab8_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Apixaban + clopidogrel + aspirin versus warfarin + clopidogrel</th><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_2" id="hd_h_niceng185er7.appf.tab8_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Control</th><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_3" id="hd_h_niceng185er7.appf.tab8_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_3" id="hd_h_niceng185er7.appf.tab8_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_h_niceng185er7.appf.tab8_1_1_1_5" id="hd_b_niceng185er7.appf.tab8_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_b_niceng185er7.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_b_niceng185er7.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_b_niceng185er7.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_b_niceng185er7.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_b_niceng185er7.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_b_niceng185er7.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_b_niceng185er7.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_b_niceng185er7.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>38/1153</p>
|
|
<p>(3.3%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_b_niceng185er7.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.5%</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_b_niceng185er7.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.95 (0.61 to 1.47)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_b_niceng185er7.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2 fewer per 1000 (from 14 fewer to 16 more)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_b_niceng185er7.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_5 hd_b_niceng185er7.appf.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_h_niceng185er7.appf.tab8_1_1_1_5" id="hd_b_niceng185er7.appf.tab8_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Myocardial infarction (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_b_niceng185er7.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_b_niceng185er7.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_b_niceng185er7.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_b_niceng185er7.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_b_niceng185er7.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_b_niceng185er7.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_b_niceng185er7.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_b_niceng185er7.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>34/1153</p>
|
|
<p>(2.9%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_b_niceng185er7.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4%</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_b_niceng185er7.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.74 (0.48 to 1.14)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_b_niceng185er7.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10 fewer per 1000 (from 21 fewer to 6 more)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_b_niceng185er7.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_5 hd_b_niceng185er7.appf.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_h_niceng185er7.appf.tab8_1_1_1_5" id="hd_b_niceng185er7.appf.tab8_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stroke (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_b_niceng185er7.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_b_niceng185er7.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_b_niceng185er7.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_b_niceng185er7.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_b_niceng185er7.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_b_niceng185er7.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_b_niceng185er7.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_b_niceng185er7.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>8/1153</p>
|
|
<p>(0.69%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_b_niceng185er7.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.2%</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_b_niceng185er7.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.57 (0.24 to 1.36)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_b_niceng185er7.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5 fewer per 1000 (from 9 fewer to 4 more)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_b_niceng185er7.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_5 hd_b_niceng185er7.appf.tab8_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_h_niceng185er7.appf.tab8_1_1_1_5" id="hd_b_niceng185er7.appf.tab8_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Any stent thrombosis (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_b_niceng185er7.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_b_niceng185er7.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_b_niceng185er7.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_b_niceng185er7.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_b_niceng185er7.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_b_niceng185er7.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_b_niceng185er7.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_b_niceng185er7.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>11/1153</p>
|
|
<p>(0.95%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_b_niceng185er7.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.7%</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_b_niceng185er7.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.58 (0.28 to 1.21)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_b_niceng185er7.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7 fewer per 1000 (from 12 fewer to 4 more)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_b_niceng185er7.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_5 hd_b_niceng185er7.appf.tab8_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_h_niceng185er7.appf.tab8_1_1_1_5" id="hd_b_niceng185er7.appf.tab8_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - TIMI major bleeding (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_b_niceng185er7.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_b_niceng185er7.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_b_niceng185er7.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_b_niceng185er7.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_b_niceng185er7.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_b_niceng185er7.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_b_niceng185er7.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_b_niceng185er7.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>25/1145</p>
|
|
<p>(2.2%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_b_niceng185er7.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.6%</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_b_niceng185er7.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.37 (0.75 to 2.49)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_b_niceng185er7.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6 more per 1000 (from 4 fewer to 24 more)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_b_niceng185er7.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_5 hd_b_niceng185er7.appf.tab8_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_h_niceng185er7.appf.tab8_1_1_1_5" id="hd_b_niceng185er7.appf.tab8_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - TIMI major and minor bleeding (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_b_niceng185er7.appf.tab8_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_b_niceng185er7.appf.tab8_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_b_niceng185er7.appf.tab8_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_b_niceng185er7.appf.tab8_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_b_niceng185er7.appf.tab8_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_b_niceng185er7.appf.tab8_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_b_niceng185er7.appf.tab8_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_b_niceng185er7.appf.tab8_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>64/1145</p>
|
|
<p>(5.6%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_b_niceng185er7.appf.tab8_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.5%</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_b_niceng185er7.appf.tab8_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.23 (0.86 to 1.77)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_b_niceng185er7.appf.tab8_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10 more per 1000 (from 6 fewer to 35 more)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_b_niceng185er7.appf.tab8_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_5 hd_b_niceng185er7.appf.tab8_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_h_niceng185er7.appf.tab8_1_1_1_5" id="hd_b_niceng185er7.appf.tab8_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - Intracranial haemorrhage (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_1 hd_b_niceng185er7.appf.tab8_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_2 hd_b_niceng185er7.appf.tab8_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_3 hd_b_niceng185er7.appf.tab8_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_4 hd_b_niceng185er7.appf.tab8_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_5 hd_b_niceng185er7.appf.tab8_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_6 hd_b_niceng185er7.appf.tab8_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_1 hd_h_niceng185er7.appf.tab8_1_1_2_7 hd_b_niceng185er7.appf.tab8_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_8 hd_b_niceng185er7.appf.tab8_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>4/1145</p>
|
|
<p>(0.35%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_2 hd_h_niceng185er7.appf.tab8_1_1_2_9 hd_b_niceng185er7.appf.tab8_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.4%</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_10 hd_b_niceng185er7.appf.tab8_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.98 (0.25 to 3.92)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_3 hd_h_niceng185er7.appf.tab8_1_1_2_11 hd_b_niceng185er7.appf.tab8_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0 fewer per 1000 (from 3 fewer to 12 more)</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_4 hd_b_niceng185er7.appf.tab8_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab8_1_1_1_5 hd_b_niceng185er7.appf.tab8_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.appf.tab8_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7appftab9"><div id="niceng185er7.appf.tab9" class="table"><h3><span class="label">Table 27</span><span class="title">Clinical evidence profile: AUGUSTUS – Warfarin + clopidogrel + aspirin versus apixaban + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appf.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appf.tab9_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appf.tab9_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_niceng185er7.appf.tab9_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_niceng185er7.appf.tab9_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_niceng185er7.appf.tab9_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab9_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_niceng185er7.appf.tab9_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab9_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1" id="hd_h_niceng185er7.appf.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1" id="hd_h_niceng185er7.appf.tab9_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1" id="hd_h_niceng185er7.appf.tab9_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1" id="hd_h_niceng185er7.appf.tab9_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1" id="hd_h_niceng185er7.appf.tab9_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1" id="hd_h_niceng185er7.appf.tab9_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1" id="hd_h_niceng185er7.appf.tab9_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_2" id="hd_h_niceng185er7.appf.tab9_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Warfarin + clopidogrel + aspirin versus apixaban + clopidogrel</th><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_2" id="hd_h_niceng185er7.appf.tab9_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Control</th><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_3" id="hd_h_niceng185er7.appf.tab9_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_3" id="hd_h_niceng185er7.appf.tab9_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_h_niceng185er7.appf.tab9_1_1_1_5" id="hd_b_niceng185er7.appf.tab9_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_b_niceng185er7.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_b_niceng185er7.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_b_niceng185er7.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_b_niceng185er7.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_b_niceng185er7.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_b_niceng185er7.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_b_niceng185er7.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_b_niceng185er7.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>40/1154</p>
|
|
<p>(3.5%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_b_niceng185er7.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.4%</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_b_niceng185er7.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.02 (0.66 to 1.58)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_b_niceng185er7.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 more per 1000 (from 12 fewer to 20 more)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_b_niceng185er7.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_5 hd_b_niceng185er7.appf.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_h_niceng185er7.appf.tab9_1_1_1_5" id="hd_b_niceng185er7.appf.tab9_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Myocardial infarction (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_b_niceng185er7.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_b_niceng185er7.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_b_niceng185er7.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_b_niceng185er7.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_b_niceng185er7.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_b_niceng185er7.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_b_niceng185er7.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_b_niceng185er7.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>46/1154</p>
|
|
<p>(4%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_b_niceng185er7.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3%</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_b_niceng185er7.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.35 (0.87 to 2.09)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_b_niceng185er7.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11 more per 1000 (from 4 fewer to 33 more)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_b_niceng185er7.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_5 hd_b_niceng185er7.appf.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_h_niceng185er7.appf.tab9_1_1_1_5" id="hd_b_niceng185er7.appf.tab9_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stroke (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_b_niceng185er7.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_b_niceng185er7.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_b_niceng185er7.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_b_niceng185er7.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_b_niceng185er7.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_b_niceng185er7.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_b_niceng185er7.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_b_niceng185er7.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>14/1154</p>
|
|
<p>(1.2%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_b_niceng185er7.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.7%</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_b_niceng185er7.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.75 (0.74 to 4.15)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_b_niceng185er7.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5 more per 1000 (from 2 fewer to 22 more)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_b_niceng185er7.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_5 hd_b_niceng185er7.appf.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_h_niceng185er7.appf.tab9_1_1_1_5" id="hd_b_niceng185er7.appf.tab9_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Any stent thrombosis (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_b_niceng185er7.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_b_niceng185er7.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_b_niceng185er7.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_b_niceng185er7.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_b_niceng185er7.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_b_niceng185er7.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_b_niceng185er7.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_b_niceng185er7.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>19/1154</p>
|
|
<p>(1.6%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_b_niceng185er7.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1%</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_b_niceng185er7.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.73 (0.82 to 3.61)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_b_niceng185er7.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7 more per 1000 (from 2 fewer to 26 more)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_b_niceng185er7.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_5 hd_b_niceng185er7.appf.tab9_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_h_niceng185er7.appf.tab9_1_1_1_5" id="hd_b_niceng185er7.appf.tab9_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - TIMI major bleeding (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_b_niceng185er7.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_b_niceng185er7.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_b_niceng185er7.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_b_niceng185er7.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_b_niceng185er7.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_b_niceng185er7.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_b_niceng185er7.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_b_niceng185er7.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>18/1126</p>
|
|
<p>(1.6%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_b_niceng185er7.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.1%</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_b_niceng185er7.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.41 (0.69 to 2.85)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_b_niceng185er7.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5 more per 1000 (from 3 fewer to 20 more)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_b_niceng185er7.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_5 hd_b_niceng185er7.appf.tab9_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_h_niceng185er7.appf.tab9_1_1_1_5" id="hd_b_niceng185er7.appf.tab9_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - TIMI major and minor bleeding (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_b_niceng185er7.appf.tab9_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_b_niceng185er7.appf.tab9_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_b_niceng185er7.appf.tab9_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_b_niceng185er7.appf.tab9_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_b_niceng185er7.appf.tab9_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_b_niceng185er7.appf.tab9_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_b_niceng185er7.appf.tab9_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_b_niceng185er7.appf.tab9_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>51/1126</p>
|
|
<p>(4.5%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_b_niceng185er7.appf.tab9_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2.8%</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_b_niceng185er7.appf.tab9_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.62 (1.05 to 2.5)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_b_niceng185er7.appf.tab9_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">17 more per 1000 (from 1 more to 42 more)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_b_niceng185er7.appf.tab9_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_5 hd_b_niceng185er7.appf.tab9_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_h_niceng185er7.appf.tab9_1_1_1_5" id="hd_b_niceng185er7.appf.tab9_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - Intracranial haemorrhage (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_1 hd_b_niceng185er7.appf.tab9_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_2 hd_b_niceng185er7.appf.tab9_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_3 hd_b_niceng185er7.appf.tab9_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_4 hd_b_niceng185er7.appf.tab9_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_5 hd_b_niceng185er7.appf.tab9_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_6 hd_b_niceng185er7.appf.tab9_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_1 hd_h_niceng185er7.appf.tab9_1_1_2_7 hd_b_niceng185er7.appf.tab9_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_8 hd_b_niceng185er7.appf.tab9_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>8/1126</p>
|
|
<p>(0.71%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_2 hd_h_niceng185er7.appf.tab9_1_1_2_9 hd_b_niceng185er7.appf.tab9_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.1%</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_10 hd_b_niceng185er7.appf.tab9_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 8.12 (1.02 to 64.82)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_3 hd_h_niceng185er7.appf.tab9_1_1_2_11 hd_b_niceng185er7.appf.tab9_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7 more per 1000 (from 0 more to 64 more)</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_4 hd_b_niceng185er7.appf.tab9_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab9_1_1_1_5 hd_b_niceng185er7.appf.tab9_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.appf.tab9_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7appftab10"><div id="niceng185er7.appf.tab10" class="table"><h3><span class="label">Table 28</span><span class="title">Clinical evidence profile: AUGUSTUS – Apixaban + clopidogrel versus warfarin + clopidogrel</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appf.tab10/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appf.tab10_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appf.tab10_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_niceng185er7.appf.tab10_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_niceng185er7.appf.tab10_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_niceng185er7.appf.tab10_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab10_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_niceng185er7.appf.tab10_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab10_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1" id="hd_h_niceng185er7.appf.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1" id="hd_h_niceng185er7.appf.tab10_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1" id="hd_h_niceng185er7.appf.tab10_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1" id="hd_h_niceng185er7.appf.tab10_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1" id="hd_h_niceng185er7.appf.tab10_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1" id="hd_h_niceng185er7.appf.tab10_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1" id="hd_h_niceng185er7.appf.tab10_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_2" id="hd_h_niceng185er7.appf.tab10_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Apixaban + clopidogrel versus warfarin + clopidogrel</th><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_2" id="hd_h_niceng185er7.appf.tab10_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Control</th><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_3" id="hd_h_niceng185er7.appf.tab10_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_3" id="hd_h_niceng185er7.appf.tab10_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_h_niceng185er7.appf.tab10_1_1_1_5" id="hd_b_niceng185er7.appf.tab10_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_b_niceng185er7.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_b_niceng185er7.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_b_niceng185er7.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_b_niceng185er7.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_b_niceng185er7.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_b_niceng185er7.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_b_niceng185er7.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_b_niceng185er7.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>39/1153</p>
|
|
<p>(3.4%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_b_niceng185er7.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.5%</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_b_niceng185er7.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.98 (0.63 to 1.51)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_b_niceng185er7.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 fewer per 1000 (from 13 fewer to 18 more)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_b_niceng185er7.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_5 hd_b_niceng185er7.appf.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_h_niceng185er7.appf.tab10_1_1_1_5" id="hd_b_niceng185er7.appf.tab10_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Myocardial infarction (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_b_niceng185er7.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_b_niceng185er7.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_b_niceng185er7.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_b_niceng185er7.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_b_niceng185er7.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_b_niceng185er7.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_b_niceng185er7.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_b_niceng185er7.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>38/1153</p>
|
|
<p>(3.3%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_b_niceng185er7.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4%</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_b_niceng185er7.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.83 (0.54 to 1.26)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_b_niceng185er7.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7 fewer per 1000 (from 18 fewer to 10 more)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_b_niceng185er7.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_5 hd_b_niceng185er7.appf.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_h_niceng185er7.appf.tab10_1_1_1_5" id="hd_b_niceng185er7.appf.tab10_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stroke (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_b_niceng185er7.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_b_niceng185er7.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_b_niceng185er7.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_b_niceng185er7.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_b_niceng185er7.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_b_niceng185er7.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_b_niceng185er7.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_b_niceng185er7.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>5/1153</p>
|
|
<p>(0.43%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_b_niceng185er7.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.2%</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_b_niceng185er7.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.36 (0.13 to 0.99)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_b_niceng185er7.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8 fewer per 1000 (from 0 fewer to 10 fewer)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_b_niceng185er7.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_5 hd_b_niceng185er7.appf.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_h_niceng185er7.appf.tab10_1_1_1_5" id="hd_b_niceng185er7.appf.tab10_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Any stent thrombosis (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_b_niceng185er7.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_b_niceng185er7.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_b_niceng185er7.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_b_niceng185er7.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_b_niceng185er7.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_b_niceng185er7.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_b_niceng185er7.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_b_niceng185er7.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>21/1153</p>
|
|
<p>(1.8%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_b_niceng185er7.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.7%</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_b_niceng185er7.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.11 (0.6 to 2.05)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_b_niceng185er7.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2 more per 1000 (from 7 fewer to 18 more)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_b_niceng185er7.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_5 hd_b_niceng185er7.appf.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_h_niceng185er7.appf.tab10_1_1_1_5" id="hd_b_niceng185er7.appf.tab10_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - TIMI major bleeding</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_b_niceng185er7.appf.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_b_niceng185er7.appf.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_b_niceng185er7.appf.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_b_niceng185er7.appf.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_b_niceng185er7.appf.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_b_niceng185er7.appf.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_b_niceng185er7.appf.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_b_niceng185er7.appf.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>13/1143</p>
|
|
<p>(1.1%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_b_niceng185er7.appf.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.6%</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_b_niceng185er7.appf.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.71 (0.35 to 1.45)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_b_niceng185er7.appf.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5 fewer per 1000 (from 10 fewer to 7 more)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_b_niceng185er7.appf.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_5 hd_b_niceng185er7.appf.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_h_niceng185er7.appf.tab10_1_1_1_5" id="hd_b_niceng185er7.appf.tab10_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - TIMI major and minor bleeding (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_b_niceng185er7.appf.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_b_niceng185er7.appf.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_b_niceng185er7.appf.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_b_niceng185er7.appf.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_b_niceng185er7.appf.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_b_niceng185er7.appf.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_b_niceng185er7.appf.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_b_niceng185er7.appf.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>32/1143</p>
|
|
<p>(2.8%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_b_niceng185er7.appf.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.5%</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_b_niceng185er7.appf.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.62 (0.4 to 0.95)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_b_niceng185er7.appf.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">17 fewer per 1000 (from 2 fewer to 27 fewer)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_b_niceng185er7.appf.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_5 hd_b_niceng185er7.appf.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_h_niceng185er7.appf.tab10_1_1_1_5" id="hd_b_niceng185er7.appf.tab10_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - Intracranial haemorrhage (follow-up 6 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_1 hd_b_niceng185er7.appf.tab10_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_2 hd_b_niceng185er7.appf.tab10_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_3 hd_b_niceng185er7.appf.tab10_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_4 hd_b_niceng185er7.appf.tab10_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_5 hd_b_niceng185er7.appf.tab10_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_6 hd_b_niceng185er7.appf.tab10_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_1 hd_h_niceng185er7.appf.tab10_1_1_2_7 hd_b_niceng185er7.appf.tab10_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_8 hd_b_niceng185er7.appf.tab10_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1/1143</p>
|
|
<p>(0.09%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_2 hd_h_niceng185er7.appf.tab10_1_1_2_9 hd_b_niceng185er7.appf.tab10_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.7%</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_10 hd_b_niceng185er7.appf.tab10_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.12 (0.02 to 0.98)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_3 hd_h_niceng185er7.appf.tab10_1_1_2_11 hd_b_niceng185er7.appf.tab10_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6 fewer per 1000 (from 0 fewer to 7 fewer)</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_4 hd_b_niceng185er7.appf.tab10_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab10_1_1_1_5 hd_b_niceng185er7.appf.tab10_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.appf.tab10_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7appftab11"><div id="niceng185er7.appf.tab11" class="table"><h3><span class="label">Table 29</span><span class="title">Clinical evidence profile: VKA + clopidogrel + aspirin versus edoxaban + clopidogrel (ENTRUST-AF PCI)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appf.tab11/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appf.tab11_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appf.tab11_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_niceng185er7.appf.tab11_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_niceng185er7.appf.tab11_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_niceng185er7.appf.tab11_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab11_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_niceng185er7.appf.tab11_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab11_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_niceng185er7.appf.tab11_1_1_1_1" id="hd_h_niceng185er7.appf.tab11_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_niceng185er7.appf.tab11_1_1_1_1" id="hd_h_niceng185er7.appf.tab11_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_niceng185er7.appf.tab11_1_1_1_1" id="hd_h_niceng185er7.appf.tab11_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_niceng185er7.appf.tab11_1_1_1_1" id="hd_h_niceng185er7.appf.tab11_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_niceng185er7.appf.tab11_1_1_1_1" id="hd_h_niceng185er7.appf.tab11_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_niceng185er7.appf.tab11_1_1_1_1" id="hd_h_niceng185er7.appf.tab11_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_niceng185er7.appf.tab11_1_1_1_1" id="hd_h_niceng185er7.appf.tab11_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_niceng185er7.appf.tab11_1_1_1_2" id="hd_h_niceng185er7.appf.tab11_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">VKA + clopidogrel + aspirin</th><th headers="hd_h_niceng185er7.appf.tab11_1_1_1_2" id="hd_h_niceng185er7.appf.tab11_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Edoxaban + clopidogrel</th><th headers="hd_h_niceng185er7.appf.tab11_1_1_1_3" id="hd_h_niceng185er7.appf.tab11_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_niceng185er7.appf.tab11_1_1_1_3" id="hd_h_niceng185er7.appf.tab11_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_1 hd_h_niceng185er7.appf.tab11_1_1_2_2 hd_h_niceng185er7.appf.tab11_1_1_2_3 hd_h_niceng185er7.appf.tab11_1_1_2_4 hd_h_niceng185er7.appf.tab11_1_1_2_5 hd_h_niceng185er7.appf.tab11_1_1_2_6 hd_h_niceng185er7.appf.tab11_1_1_2_7 hd_h_niceng185er7.appf.tab11_1_1_1_2 hd_h_niceng185er7.appf.tab11_1_1_2_8 hd_h_niceng185er7.appf.tab11_1_1_2_9 hd_h_niceng185er7.appf.tab11_1_1_1_3 hd_h_niceng185er7.appf.tab11_1_1_2_10 hd_h_niceng185er7.appf.tab11_1_1_2_11 hd_h_niceng185er7.appf.tab11_1_1_1_4 hd_h_niceng185er7.appf.tab11_1_1_1_5" id="hd_b_niceng185er7.appf.tab11_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding – Major or clinically relevant non-major bleeding (ISTH) (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_1 hd_b_niceng185er7.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_2 hd_b_niceng185er7.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_3 hd_b_niceng185er7.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_4 hd_b_niceng185er7.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_5 hd_b_niceng185er7.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_6 hd_b_niceng185er7.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_7 hd_b_niceng185er7.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_2 hd_h_niceng185er7.appf.tab11_1_1_2_8 hd_b_niceng185er7.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>152/755</p>
|
|
<p>(20.1%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_2 hd_h_niceng185er7.appf.tab11_1_1_2_9 hd_b_niceng185er7.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">17%</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_3 hd_h_niceng185er7.appf.tab11_1_1_2_10 hd_b_niceng185er7.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.18 (0.96 to 1.46)</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_3 hd_h_niceng185er7.appf.tab11_1_1_2_11 hd_b_niceng185er7.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">31 more per 1000 (from 7 fewer to 78 more)</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_4 hd_b_niceng185er7.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_5 hd_b_niceng185er7.appf.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_1 hd_h_niceng185er7.appf.tab11_1_1_2_2 hd_h_niceng185er7.appf.tab11_1_1_2_3 hd_h_niceng185er7.appf.tab11_1_1_2_4 hd_h_niceng185er7.appf.tab11_1_1_2_5 hd_h_niceng185er7.appf.tab11_1_1_2_6 hd_h_niceng185er7.appf.tab11_1_1_2_7 hd_h_niceng185er7.appf.tab11_1_1_1_2 hd_h_niceng185er7.appf.tab11_1_1_2_8 hd_h_niceng185er7.appf.tab11_1_1_2_9 hd_h_niceng185er7.appf.tab11_1_1_1_3 hd_h_niceng185er7.appf.tab11_1_1_2_10 hd_h_niceng185er7.appf.tab11_1_1_2_11 hd_h_niceng185er7.appf.tab11_1_1_1_4 hd_h_niceng185er7.appf.tab11_1_1_1_5" id="hd_b_niceng185er7.appf.tab11_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - Major bleeding (ISTH)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_1 hd_b_niceng185er7.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_2 hd_b_niceng185er7.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_3 hd_b_niceng185er7.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_4 hd_b_niceng185er7.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_5 hd_b_niceng185er7.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_6 hd_b_niceng185er7.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_1 hd_h_niceng185er7.appf.tab11_1_1_2_7 hd_b_niceng185er7.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_2 hd_h_niceng185er7.appf.tab11_1_1_2_8 hd_b_niceng185er7.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>48/755</p>
|
|
<p>(6.4%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_2 hd_h_niceng185er7.appf.tab11_1_1_2_9 hd_b_niceng185er7.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6%</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_3 hd_h_niceng185er7.appf.tab11_1_1_2_10 hd_b_niceng185er7.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.06 (0.72 to 1.57)</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_3 hd_h_niceng185er7.appf.tab11_1_1_2_11 hd_b_niceng185er7.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 more per 1000 (from 17 fewer to 34 more)</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_4 hd_b_niceng185er7.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab11_1_1_1_5 hd_b_niceng185er7.appf.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.appf.tab11_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er7appftab12"><div id="niceng185er7.appf.tab12" class="table"><h3><span class="label">Table 30</span><span class="title">Clinical evidence summary: edoxaban + clopidogrel versus VKA + clopidogrel + aspirin (ENTRUST-AF PCI)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appf.tab12/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appf.tab12_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appf.tab12_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_niceng185er7.appf.tab12_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_niceng185er7.appf.tab12_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_niceng185er7.appf.tab12_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab12_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_niceng185er7.appf.tab12_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng185er7.appf.tab12_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1" id="hd_h_niceng185er7.appf.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1" id="hd_h_niceng185er7.appf.tab12_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1" id="hd_h_niceng185er7.appf.tab12_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1" id="hd_h_niceng185er7.appf.tab12_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1" id="hd_h_niceng185er7.appf.tab12_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1" id="hd_h_niceng185er7.appf.tab12_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1" id="hd_h_niceng185er7.appf.tab12_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_2" id="hd_h_niceng185er7.appf.tab12_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Edoxaban + clopidogrel versus VKA + clopidogrel + aspirin</th><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_2" id="hd_h_niceng185er7.appf.tab12_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Control</th><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_3" id="hd_h_niceng185er7.appf.tab12_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_3" id="hd_h_niceng185er7.appf.tab12_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_h_niceng185er7.appf.tab12_1_1_1_5" id="hd_b_niceng185er7.appf.tab12_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">All-cause mortality (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_b_niceng185er7.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_b_niceng185er7.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_b_niceng185er7.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_b_niceng185er7.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_b_niceng185er7.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_b_niceng185er7.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_b_niceng185er7.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_b_niceng185er7.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>46/751</p>
|
|
<p>(6.1%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_b_niceng185er7.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.9%</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_b_niceng185er7.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.25 (0.82 to 1.9)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_b_niceng185er7.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">12 more per 1000 (from 9 fewer to 44 more)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_b_niceng185er7.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_5 hd_b_niceng185er7.appf.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_h_niceng185er7.appf.tab12_1_1_1_5" id="hd_b_niceng185er7.appf.tab12_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stroke (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_b_niceng185er7.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_b_niceng185er7.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_b_niceng185er7.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_b_niceng185er7.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_b_niceng185er7.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_b_niceng185er7.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_b_niceng185er7.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_b_niceng185er7.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>10/751</p>
|
|
<p>(1.3%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_b_niceng185er7.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.6%</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_b_niceng185er7.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.84 (0.36 to 1.93)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_b_niceng185er7.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3 fewer per 1000 (from 10 fewer to 15 more)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_b_niceng185er7.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_5 hd_b_niceng185er7.appf.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_h_niceng185er7.appf.tab12_1_1_1_5" id="hd_b_niceng185er7.appf.tab12_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Myocardial infarction (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_b_niceng185er7.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_b_niceng185er7.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_b_niceng185er7.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_b_niceng185er7.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_b_niceng185er7.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_b_niceng185er7.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_b_niceng185er7.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_b_niceng185er7.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>29/751</p>
|
|
<p>(3.9%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_b_niceng185er7.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3.1%</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_b_niceng185er7.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.27 (0.74 to 2.17)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_b_niceng185er7.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8 more per 1000 (from 8 fewer to 36 more)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_b_niceng185er7.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_5 hd_b_niceng185er7.appf.tab12_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_h_niceng185er7.appf.tab12_1_1_1_5" id="hd_b_niceng185er7.appf.tab12_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Stent thrombosis (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_b_niceng185er7.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_b_niceng185er7.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_b_niceng185er7.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_b_niceng185er7.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_b_niceng185er7.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_b_niceng185er7.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_b_niceng185er7.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_b_niceng185er7.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>13/751</p>
|
|
<p>(1.7%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_b_niceng185er7.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.3%</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_b_niceng185er7.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 1.31 (0.58 to 2.96)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_b_niceng185er7.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 more per 1000 (from 5 fewer to 25 more)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_b_niceng185er7.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_5 hd_b_niceng185er7.appf.tab12_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_h_niceng185er7.appf.tab12_1_1_1_5" id="hd_b_niceng185er7.appf.tab12_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - Major or clinically relevant non-major bleeding (ISTH) (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_b_niceng185er7.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_b_niceng185er7.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_b_niceng185er7.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_b_niceng185er7.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_b_niceng185er7.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_b_niceng185er7.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_b_niceng185er7.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_b_niceng185er7.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>128/751</p>
|
|
<p>(17%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_b_niceng185er7.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">20.1%</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_b_niceng185er7.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.85 (0.68 to 1.05)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_b_niceng185er7.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">30 fewer per 1000 (from 64 fewer to 10 more)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_b_niceng185er7.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕⊕Ο</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_5 hd_b_niceng185er7.appf.tab12_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_h_niceng185er7.appf.tab12_1_1_1_5" id="hd_b_niceng185er7.appf.tab12_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - Major bleeding (ISTH) (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_b_niceng185er7.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_b_niceng185er7.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_b_niceng185er7.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_b_niceng185er7.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_b_niceng185er7.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_b_niceng185er7.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_b_niceng185er7.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_b_niceng185er7.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>45/751</p>
|
|
<p>(6%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_b_niceng185er7.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6.4%</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_b_niceng185er7.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.94 (0.64 to 1.4)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_b_niceng185er7.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 fewer per 1000 (from 23 fewer to 26 more)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_b_niceng185er7.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_5 hd_b_niceng185er7.appf.tab12_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_h_niceng185er7.appf.tab12_1_1_1_5" id="hd_b_niceng185er7.appf.tab12_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:middle;">Complications related to bleeding - Intracranial haemorrhage (follow-up 12 months)</th></tr><tr><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_1 hd_b_niceng185er7.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_2 hd_b_niceng185er7.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_3 hd_b_niceng185er7.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious risk of bias</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_4 hd_b_niceng185er7.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_5 hd_b_niceng185er7.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_6 hd_b_niceng185er7.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>1</sup></td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_1 hd_h_niceng185er7.appf.tab12_1_1_2_7 hd_b_niceng185er7.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_8 hd_b_niceng185er7.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>4/751</p>
|
|
<p>(0.53%)</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_2 hd_h_niceng185er7.appf.tab12_1_1_2_9 hd_b_niceng185er7.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.2%</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_10 hd_b_niceng185er7.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.45 (0.14 to 1.44)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_3 hd_h_niceng185er7.appf.tab12_1_1_2_11 hd_b_niceng185er7.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7 fewer per 1000 (from 10 fewer to 5 more)</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_4 hd_b_niceng185er7.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⊕⊕ΟΟ</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er7.appf.tab12_1_1_1_5 hd_b_niceng185er7.appf.tab12_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er7.appf.tab12_1"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng185er7appgfig1"><div id="niceng185er7.appg.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2058.%20Network%20diagram%20for%20the%20three%20outcomes%20(all-cause%20mortality%2C%20myocardial%20infarction%20and%20major%20bleeding).&p=BOOKS&id=565359_niceng185er7appgf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appgf1.jpg" alt="Figure 58. Network diagram for the three outcomes (all-cause mortality, myocardial infarction and major bleeding)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 58</span><span class="title">Network diagram for the three outcomes (all-cause mortality, myocardial infarction and major bleeding)</span></h3></div></article><article data-type="table-wrap" id="figobniceng185er7appgtab1"><div id="niceng185er7.appg.tab1" class="table"><h3><span class="label">Table 31</span><span class="title">Study data for all-cause mortality network meta-analysis – guideline review evidence-base</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appg.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appg.tab1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appg.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;"></th><th id="hd_h_niceng185er7.appg.tab1_1_1_1_2" colspan="4" rowspan="1" style="text-align:left;vertical-align:bottom;">Interventions</th><th id="hd_h_niceng185er7.appg.tab1_1_1_1_3" colspan="4" rowspan="1" style="text-align:left;vertical-align:bottom;">Number of events/number of participants (per intervention)</th></tr><tr><th headers="hd_h_niceng185er7.appg.tab1_1_1_1_1" id="hd_h_niceng185er7.appg.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study ID</th><th headers="hd_h_niceng185er7.appg.tab1_1_1_1_2" id="hd_h_niceng185er7.appg.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">1</th><th headers="hd_h_niceng185er7.appg.tab1_1_1_1_2" id="hd_h_niceng185er7.appg.tab1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2</th><th headers="hd_h_niceng185er7.appg.tab1_1_1_1_2" id="hd_h_niceng185er7.appg.tab1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3</th><th headers="hd_h_niceng185er7.appg.tab1_1_1_1_2" id="hd_h_niceng185er7.appg.tab1_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">4</th><th headers="hd_h_niceng185er7.appg.tab1_1_1_1_3" id="hd_h_niceng185er7.appg.tab1_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">1</th><th headers="hd_h_niceng185er7.appg.tab1_1_1_1_3" id="hd_h_niceng185er7.appg.tab1_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2</th><th headers="hd_h_niceng185er7.appg.tab1_1_1_1_3" id="hd_h_niceng185er7.appg.tab1_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3</th><th headers="hd_h_niceng185er7.appg.tab1_1_1_1_3" id="hd_h_niceng185er7.appg.tab1_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">4</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appg.tab1_1_1_1_1 hd_h_niceng185er7.appg.tab1_1_1_2_1" id="hd_b_niceng185er7.appg.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">REDUAL</th><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_2 hd_b_niceng185er7.appg.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + DAPT</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_3 hd_b_niceng185er7.appg.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_4 hd_b_niceng185er7.appg.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_5 hd_b_niceng185er7.appg.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_6 hd_b_niceng185er7.appg.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48/981</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_7 hd_b_niceng185er7.appg.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55/981</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_8 hd_b_niceng185er7.appg.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_9 hd_b_niceng185er7.appg.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng185er7.appg.tab1_1_1_1_1 hd_h_niceng185er7.appg.tab1_1_1_2_1" id="hd_b_niceng185er7.appg.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PIONEER</th><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_2 hd_b_niceng185er7.appg.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_3 hd_b_niceng185er7.appg.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + DAPT</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_4 hd_b_niceng185er7.appg.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + DAPT</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_5 hd_b_niceng185er7.appg.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_6 hd_b_niceng185er7.appg.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16/694</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_7 hd_b_niceng185er7.appg.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17/704</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_8 hd_b_niceng185er7.appg.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13/695</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_9 hd_b_niceng185er7.appg.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng185er7.appg.tab1_1_1_1_1 hd_h_niceng185er7.appg.tab1_1_1_2_1" id="hd_b_niceng185er7.appg.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AUGUSTUS</th><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_2 hd_b_niceng185er7.appg.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + DAPT</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_3 hd_b_niceng185er7.appg.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + DAPT</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_4 hd_b_niceng185er7.appg.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_5 hd_b_niceng185er7.appg.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_6 hd_b_niceng185er7.appg.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34/1154</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_7 hd_b_niceng185er7.appg.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38/1153</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_8 hd_b_niceng185er7.appg.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39/1153</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_9 hd_b_niceng185er7.appg.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40/1154</td></tr><tr><th headers="hd_h_niceng185er7.appg.tab1_1_1_1_1 hd_h_niceng185er7.appg.tab1_1_1_2_1" id="hd_b_niceng185er7.appg.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ENTRUST</th><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_2 hd_b_niceng185er7.appg.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_3 hd_b_niceng185er7.appg.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + DAPT</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_4 hd_b_niceng185er7.appg.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_2 hd_h_niceng185er7.appg.tab1_1_1_2_5 hd_b_niceng185er7.appg.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_6 hd_b_niceng185er7.appg.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46/751</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_7 hd_b_niceng185er7.appg.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37/755</td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_8 hd_b_niceng185er7.appg.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab1_1_1_1_3 hd_h_niceng185er7.appg.tab1_1_1_2_9 hd_b_niceng185er7.appg.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">VKA – vitamin K antagonist; DAPT – dual antiplatelet therapy; NOAC – novel oral antagonist</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng185er7appgfig2"><div id="niceng185er7.appg.fig2" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2059.%20Sensitivity%20analysis%20results%20(odds%20ratios)%20%02013%20NMA%20conducted%20for%20this%20evidence%20review%20compared%20with%20Lopes%202019%20results%20%02013%20all-cause%20mortality.&p=BOOKS&id=565359_niceng185er7appgf2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appgf2.jpg" alt="Figure 59. Sensitivity analysis results (odds ratios) – NMA conducted for this evidence review compared with Lopes 2019 results – all-cause mortality." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 59</span><span class="title">Sensitivity analysis results (odds ratios) – NMA conducted for this evidence review compared with Lopes 2019 results – all-cause mortality</span></h3><div class="caption"><p>Blue circle = Lopes 2019; Orange circle = National Guideline Centre</p></div></div></article><article data-type="table-wrap" id="figobniceng185er7appgtab2"><div id="niceng185er7.appg.tab2" class="table"><h3><span class="label">Table 32</span><span class="title">Study data for myocardial infarction network meta-analysis – guideline review evidence-base</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appg.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appg.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appg.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;"></th><th id="hd_h_niceng185er7.appg.tab2_1_1_1_2" colspan="4" rowspan="1" style="text-align:left;vertical-align:bottom;">Intervention</th><th id="hd_h_niceng185er7.appg.tab2_1_1_1_3" colspan="4" rowspan="1" style="text-align:left;vertical-align:bottom;">Number of events/number of participants (per intervention)</th></tr><tr><th headers="hd_h_niceng185er7.appg.tab2_1_1_1_1" id="hd_h_niceng185er7.appg.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study ID</th><th headers="hd_h_niceng185er7.appg.tab2_1_1_1_2" id="hd_h_niceng185er7.appg.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">1</th><th headers="hd_h_niceng185er7.appg.tab2_1_1_1_2" id="hd_h_niceng185er7.appg.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2</th><th headers="hd_h_niceng185er7.appg.tab2_1_1_1_2" id="hd_h_niceng185er7.appg.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3</th><th headers="hd_h_niceng185er7.appg.tab2_1_1_1_2" id="hd_h_niceng185er7.appg.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">4</th><th headers="hd_h_niceng185er7.appg.tab2_1_1_1_3" id="hd_h_niceng185er7.appg.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">1</th><th headers="hd_h_niceng185er7.appg.tab2_1_1_1_3" id="hd_h_niceng185er7.appg.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2</th><th headers="hd_h_niceng185er7.appg.tab2_1_1_1_3" id="hd_h_niceng185er7.appg.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3</th><th headers="hd_h_niceng185er7.appg.tab2_1_1_1_3" id="hd_h_niceng185er7.appg.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">4</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appg.tab2_1_1_1_1 hd_h_niceng185er7.appg.tab2_1_1_2_1" id="hd_b_niceng185er7.appg.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">REDUAL</th><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_2 hd_b_niceng185er7.appg.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + DAPT</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_3 hd_b_niceng185er7.appg.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_4 hd_b_niceng185er7.appg.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_5 hd_b_niceng185er7.appg.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_6 hd_b_niceng185er7.appg.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29/981</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_7 hd_b_niceng185er7.appg.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44/981</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_8 hd_b_niceng185er7.appg.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_9 hd_b_niceng185er7.appg.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng185er7.appg.tab2_1_1_1_1 hd_h_niceng185er7.appg.tab2_1_1_2_1" id="hd_b_niceng185er7.appg.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PIONEER</th><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_2 hd_b_niceng185er7.appg.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_3 hd_b_niceng185er7.appg.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + DAPT</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_4 hd_b_niceng185er7.appg.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + DAPT</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_5 hd_b_niceng185er7.appg.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_6 hd_b_niceng185er7.appg.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19/694</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_7 hd_b_niceng185er7.appg.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17/704</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_8 hd_b_niceng185er7.appg.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21/695</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_9 hd_b_niceng185er7.appg.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng185er7.appg.tab2_1_1_1_1 hd_h_niceng185er7.appg.tab2_1_1_2_1" id="hd_b_niceng185er7.appg.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AUGUSTUS</th><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_2 hd_b_niceng185er7.appg.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + DAPT</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_3 hd_b_niceng185er7.appg.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + DAPT</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_4 hd_b_niceng185er7.appg.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_5 hd_b_niceng185er7.appg.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_6 hd_b_niceng185er7.appg.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34/1154</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_7 hd_b_niceng185er7.appg.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34/1153</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_8 hd_b_niceng185er7.appg.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38/1153</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_9 hd_b_niceng185er7.appg.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46/1154</td></tr><tr><th headers="hd_h_niceng185er7.appg.tab2_1_1_1_1 hd_h_niceng185er7.appg.tab2_1_1_2_1" id="hd_b_niceng185er7.appg.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ENTRUST</th><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_2 hd_b_niceng185er7.appg.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_3 hd_b_niceng185er7.appg.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + DAPT</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_4 hd_b_niceng185er7.appg.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_2 hd_h_niceng185er7.appg.tab2_1_1_2_5 hd_b_niceng185er7.appg.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_6 hd_b_niceng185er7.appg.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29/751</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_7 hd_b_niceng185er7.appg.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23/755</td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_8 hd_b_niceng185er7.appg.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab2_1_1_1_3 hd_h_niceng185er7.appg.tab2_1_1_2_9 hd_b_niceng185er7.appg.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">VKA – vitamin K antagonist; DAPT – dual antiplatelet therapy; NOAC – novel oral antagonist</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng185er7appgfig3"><div id="niceng185er7.appg.fig3" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2060.%20Sensitivity%20analysis%20results%20(odds%20ratios)%20%02013%20NMA%20conducted%20for%20this%20evidence%20review%20compared%20with%20Lopes%202019%20results%20%02013%20myocardial%20infarction.&p=BOOKS&id=565359_niceng185er7appgf3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appgf3.jpg" alt="Figure 60. Sensitivity analysis results (odds ratios) – NMA conducted for this evidence review compared with Lopes 2019 results – myocardial infarction." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 60</span><span class="title">Sensitivity analysis results (odds ratios) – NMA conducted for this evidence review compared with Lopes 2019 results – myocardial infarction</span></h3><div class="caption"><p>Blue circle = Lopes 2019; Orange circle = National Guideline Centre</p></div></div></article><article data-type="table-wrap" id="figobniceng185er7appgtab3"><div id="niceng185er7.appg.tab3" class="table"><h3><span class="label">Table 33</span><span class="title">Study data for major bleeding network meta-analysis – guideline review evidence-base</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appg.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appg.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er7.appg.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;"></th><th id="hd_h_niceng185er7.appg.tab3_1_1_1_2" colspan="4" rowspan="1" style="text-align:left;vertical-align:bottom;">Interventions</th><th id="hd_h_niceng185er7.appg.tab3_1_1_1_3" colspan="4" rowspan="1" style="text-align:left;vertical-align:bottom;">Number of events/number of participants (per intervention)</th></tr><tr><th headers="hd_h_niceng185er7.appg.tab3_1_1_1_1" id="hd_h_niceng185er7.appg.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study ID</th><th headers="hd_h_niceng185er7.appg.tab3_1_1_1_2" id="hd_h_niceng185er7.appg.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">1</th><th headers="hd_h_niceng185er7.appg.tab3_1_1_1_2" id="hd_h_niceng185er7.appg.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2</th><th headers="hd_h_niceng185er7.appg.tab3_1_1_1_2" id="hd_h_niceng185er7.appg.tab3_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3</th><th headers="hd_h_niceng185er7.appg.tab3_1_1_1_2" id="hd_h_niceng185er7.appg.tab3_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">4</th><th headers="hd_h_niceng185er7.appg.tab3_1_1_1_3" id="hd_h_niceng185er7.appg.tab3_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">1</th><th headers="hd_h_niceng185er7.appg.tab3_1_1_1_3" id="hd_h_niceng185er7.appg.tab3_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2</th><th headers="hd_h_niceng185er7.appg.tab3_1_1_1_3" id="hd_h_niceng185er7.appg.tab3_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3</th><th headers="hd_h_niceng185er7.appg.tab3_1_1_1_3" id="hd_h_niceng185er7.appg.tab3_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">4</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er7.appg.tab3_1_1_1_1 hd_h_niceng185er7.appg.tab3_1_1_2_1" id="hd_b_niceng185er7.appg.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">REDUAL</th><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_2 hd_b_niceng185er7.appg.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + DAPT</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_3 hd_b_niceng185er7.appg.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_4 hd_b_niceng185er7.appg.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_5 hd_b_niceng185er7.appg.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_6 hd_b_niceng185er7.appg.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37/981</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_7 hd_b_niceng185er7.appg.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14/981</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_8 hd_b_niceng185er7.appg.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_9 hd_b_niceng185er7.appg.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng185er7.appg.tab3_1_1_1_1 hd_h_niceng185er7.appg.tab3_1_1_2_1" id="hd_b_niceng185er7.appg.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PIONEER</th><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_2 hd_b_niceng185er7.appg.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_3 hd_b_niceng185er7.appg.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + DAPT</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_4 hd_b_niceng185er7.appg.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + DAPT</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_5 hd_b_niceng185er7.appg.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_6 hd_b_niceng185er7.appg.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14/696</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_7 hd_b_niceng185er7.appg.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12/706</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_8 hd_b_niceng185er7.appg.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20/697</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_9 hd_b_niceng185er7.appg.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng185er7.appg.tab3_1_1_1_1 hd_h_niceng185er7.appg.tab3_1_1_2_1" id="hd_b_niceng185er7.appg.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AUGUSTUS</th><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_2 hd_b_niceng185er7.appg.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + DAPT</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_3 hd_b_niceng185er7.appg.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + DAPT</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_4 hd_b_niceng185er7.appg.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_5 hd_b_niceng185er7.appg.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_6 hd_b_niceng185er7.appg.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29/1123</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_7 hd_b_niceng185er7.appg.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25/1145</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_8 hd_b_niceng185er7.appg.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13/1143</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_9 hd_b_niceng185er7.appg.tab3_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18/1126</td></tr><tr><th headers="hd_h_niceng185er7.appg.tab3_1_1_1_1 hd_h_niceng185er7.appg.tab3_1_1_2_1" id="hd_b_niceng185er7.appg.tab3_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ENTRUST</th><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_2 hd_b_niceng185er7.appg.tab3_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOAC + PY12 inhibitor</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_3 hd_b_niceng185er7.appg.tab3_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VKA + DAPT</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_4 hd_b_niceng185er7.appg.tab3_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_2 hd_h_niceng185er7.appg.tab3_1_1_2_5 hd_b_niceng185er7.appg.tab3_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_6 hd_b_niceng185er7.appg.tab3_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45/751</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_7 hd_b_niceng185er7.appg.tab3_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48/755</td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_8 hd_b_niceng185er7.appg.tab3_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er7.appg.tab3_1_1_1_3 hd_h_niceng185er7.appg.tab3_1_1_2_9 hd_b_niceng185er7.appg.tab3_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">VKA – vitamin K antagonist; DAPT – dual antiplatelet therapy; NOAC – novel oral antagonist</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng185er7appgfig4"><div id="niceng185er7.appg.fig4" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2061.%20Sensitivity%20analysis%20results%20(odds%20ratios)%20%02013%20NMA%20conducted%20for%20this%20evidence%20review%20compared%20with%20Lopes%202019%20results%20%02013%20major%20bleeding.&p=BOOKS&id=565359_niceng185er7appgf4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7appgf4.jpg" alt="Figure 61. Sensitivity analysis results (odds ratios) – NMA conducted for this evidence review compared with Lopes 2019 results – major bleeding." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 61</span><span class="title">Sensitivity analysis results (odds ratios) – NMA conducted for this evidence review compared with Lopes 2019 results – major bleeding</span></h3><div class="caption"><p>Blue circle = Lopes 2019; Orange circle = National Guideline Centre</p></div></div></article><article data-type="fig" id="figobniceng185er7apphfig1"><div id="niceng185er7.apph.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2062.%20Flow%20chart%20of%20health%20economic%20study%20selection%20for%20the%20guideline.&p=BOOKS&id=565359_niceng185er7apphf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565359/bin/niceng185er7apphf1.jpg" alt="Figure 62. Flow chart of health economic study selection for the guideline." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 62</span><span class="title">Flow chart of health economic study selection for the guideline</span></h3><div class="caption"><p>* Non-relevant population, intervention, comparison, design or setting; non-English language</p><p>Review A = dual-antiplatelet therapy; Review B = early invasive investigation for UA/NSTEMI; Review C = antithrombins in UA/NSTEMI; Review D = bivalirudin in STEMI; Review E = multi-vessel PCI; Review = F drug-eluting stents; Review G = combination of antiplatelets and anticoagulants; Review H = beta-blocker therapy.</p></div></div></article><article data-type="table-wrap" id="figobniceng185er7appjtab1"><div id="niceng185er7.appj.tab1" class="table"><h3><span class="label">Table 34</span><span class="title">Studies excluded from the clinical review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appj.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appj.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Exclusion reason</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ako 2019<a class="bibr" href="#niceng185er7.ref1" rid="niceng185er7.ref1"><sup>1</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sub-population of REDUAL</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alexander 2008<a class="bibr" href="#niceng185er7.ref2" rid="niceng185er7.ref2"><sup>2</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alexander 2009<a class="bibr" href="#niceng185er7.ref3" rid="niceng185er7.ref3"><sup>3</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alexander 2011<a class="bibr" href="#niceng185er7.ref4" rid="niceng185er7.ref4"><sup>4</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alexander 2014<a class="bibr" href="#niceng185er7.ref5" rid="niceng185er7.ref5"><sup>5</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Amarenco 2014<a class="bibr" href="#niceng185er7.ref6" rid="niceng185er7.ref6"><sup>6</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anand 2018<a class="bibr" href="#niceng185er7.ref7" rid="niceng185er7.ref7"><sup>7</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anastasius 2017<a class="bibr" href="#niceng185er7.ref8" rid="niceng185er7.ref8"><sup>8</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anonymous 2012<a class="bibr" href="#niceng185er7.ref9" rid="niceng185er7.ref9"><sup>9</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Banerjee 2019<a class="bibr" href="#niceng185er7.ref10" rid="niceng185er7.ref10"><sup>10</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population. Incorrect study design</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bastiany 2018<a class="bibr" href="#niceng185er7.ref11" rid="niceng185er7.ref11"><sup>11</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bennaghmouch 2018<a class="bibr" href="#niceng185er7.ref12" rid="niceng185er7.ref12"><sup>12</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analysis - checked for references</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bhagirath 2018<a class="bibr" href="#niceng185er7.ref13" rid="niceng185er7.ref13"><sup>13</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bosch 2017<a class="bibr" href="#niceng185er7.ref14" rid="niceng185er7.ref14"><sup>14</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Brodin 2009<a class="bibr" href="#niceng185er7.ref15" rid="niceng185er7.ref15"><sup>15</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Brunetti 2018<a class="bibr" href="#niceng185er7.ref16" rid="niceng185er7.ref16"><sup>16</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analysis - checked for references</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bunmark 2018<a class="bibr" href="#niceng185er7.ref17" rid="niceng185er7.ref17"><sup>17</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analysis - checked for references</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cairns 2008<a class="bibr" href="#niceng185er7.ref18" rid="niceng185er7.ref18"><sup>18</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cavallari 2018<a class="bibr" href="#niceng185er7.ref21" rid="niceng185er7.ref21"><sup>21</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analysis - checked for references</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Chi 2018<a class="bibr" href="#niceng185er7.ref22" rid="niceng185er7.ref22"><sup>22</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bivariate analysis of PIONEER and REDUAL, no usable outcomes</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Connolly 2018<a class="bibr" href="#niceng185er7.ref24" rid="niceng185er7.ref24"><sup>24</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dewilde 2009<a class="bibr" href="#niceng185er7.ref25" rid="niceng185er7.ref25"><sup>25</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dewilde 2013<a class="bibr" href="#niceng185er7.ref27" rid="niceng185er7.ref27"><sup>27</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dewilde 2015<a class="bibr" href="#niceng185er7.ref26" rid="niceng185er7.ref26"><sup>26</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eikelboom 2017<a class="bibr" href="#niceng185er7.ref28" rid="niceng185er7.ref28"><sup>28</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review - checked for reference</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Fortuni 2018<a class="bibr" href="#niceng185er7.ref29" rid="niceng185er7.ref29"><sup>29</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review - checked for references</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Franchi 2016<a class="bibr" href="#niceng185er7.ref30" rid="niceng185er7.ref30"><sup>30</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gao 2013<a class="bibr" href="#niceng185er7.ref32" rid="niceng185er7.ref32"><sup>32</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Results not yet published</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gao 2015<a class="bibr" href="#niceng185er7.ref31" rid="niceng185er7.ref31"><sup>31</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Results not yet published</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gibson 2011<a class="bibr" href="#niceng185er7.ref34" rid="niceng185er7.ref34"><sup>34</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gibson 2018<a class="bibr" href="#niceng185er7.ref33" rid="niceng185er7.ref33"><sup>33</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gibson 2019<a class="bibr" href="#niceng185er7.ref38" rid="niceng185er7.ref38"><sup>38</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Goette 2016<a class="bibr" href="#niceng185er7.ref39" rid="niceng185er7.ref39"><sup>39</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Golwala 2018<a class="bibr" href="#niceng185er7.ref40" rid="niceng185er7.ref40"><sup>40</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analysis - checked for references</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Greenberg 2019<a class="bibr" href="#niceng185er7.ref41" rid="niceng185er7.ref41"><sup>41</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Halg 2009<a class="bibr" href="#niceng185er7.ref42" rid="niceng185er7.ref42"><sup>42</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hess 2015<a class="bibr" href="#niceng185er7.ref44" rid="niceng185er7.ref44"><sup>44</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hoshi 2017<a class="bibr" href="#niceng185er7.ref45" rid="niceng185er7.ref45"><sup>45</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Jackson 2015<a class="bibr" href="#niceng185er7.ref46" rid="niceng185er7.ref46"><sup>46</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Jackson 2016<a class="bibr" href="#niceng185er7.ref47" rid="niceng185er7.ref47"><sup>47</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Khan 2018<a class="bibr" href="#niceng185er7.ref52" rid="niceng185er7.ref52"><sup>52</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analysis - checked for references</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Khan 2018<a class="bibr" href="#niceng185er7.ref51" rid="niceng185er7.ref51"><sup>51</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-anlaysis - check for references</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Korjian 2019<a class="bibr" href="#niceng185er7.ref53" rid="niceng185er7.ref53"><sup>53</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lamy 2019<a class="bibr" href="#niceng185er7.ref54" rid="niceng185er7.ref54"><sup>54</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Li 2018<a class="bibr" href="#niceng185er7.ref55" rid="niceng185er7.ref55"><sup>55</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analysis - checked for references</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Liang 2012<a class="bibr" href="#niceng185er7.ref56" rid="niceng185er7.ref56"><sup>56</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not in English</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lip 2017<a class="bibr" href="#niceng185er7.ref58" rid="niceng185er7.ref58"><sup>58</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lip 2017<a class="bibr" href="#niceng185er7.ref57" rid="niceng185er7.ref57"><sup>57</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lip 2019<a class="bibr" href="#niceng185er7.ref59" rid="niceng185er7.ref59"><sup>59</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ancillary study of the REDUAL trial that does not address the clinical question</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lopes 2019<a class="bibr" href="#niceng185er7.ref61" rid="niceng185er7.ref61"><sup>61</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Network meta-analysis – incorrect population. This network meta-analysis did not have a threshold for the proportion of ACS in the study populations. The committee agreed a threshold of >60% ACS. One of the studies included in Lopes 2019 has been excluded from this evidence review as proportion of ACS is <60%.</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lou 2018<a class="bibr" href="#niceng185er7.ref63" rid="niceng185er7.ref63"><sup>63</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analysis - checked for references</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lu 2015<a class="bibr" href="#niceng185er7.ref64" rid="niceng185er7.ref64"><sup>64</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Results not yet published</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Maegdefessel 2008<a class="bibr" href="#niceng185er7.ref65" rid="niceng185er7.ref65"><sup>65</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Massie 2009<a class="bibr" href="#niceng185er7.ref66" rid="niceng185er7.ref66"><sup>66</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Matsumura-Nakano 2019<a class="bibr" href="#niceng185er7.ref67" rid="niceng185er7.ref67"><sup>67</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mega 2009<a class="bibr" href="#niceng185er7.ref68" rid="niceng185er7.ref68"><sup>68</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mo 2018<a class="bibr" href="#niceng185er7.ref69" rid="niceng185er7.ref69"><sup>69</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analysis - references checked</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nijenhuis 2016<a class="bibr" href="#niceng185er7.ref71" rid="niceng185er7.ref71"><sup>71</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Results not yet publishes</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ogawa 2013<a class="bibr" href="#niceng185er7.ref72" rid="niceng185er7.ref72"><sup>72</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ohman 2017<a class="bibr" href="#niceng185er7.ref73" rid="niceng185er7.ref73"><sup>73</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oldgren 2011<a class="bibr" href="#niceng185er7.ref74" rid="niceng185er7.ref74"><sup>74</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Özdemir 2017<a class="bibr" href="#niceng185er7.ref76" rid="niceng185er7.ref76"><sup>76</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not in English</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Palla 2019<a class="bibr" href="#niceng185er7.ref77" rid="niceng185er7.ref77"><sup>77</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analysis - references checked</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pandor 2016<a class="bibr" href="#niceng185er7.ref78" rid="niceng185er7.ref78"><sup>78</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patti 2018<a class="bibr" href="#niceng185er7.ref79" rid="niceng185er7.ref79"><sup>79</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Povsic 2016<a class="bibr" href="#niceng185er7.ref80" rid="niceng185er7.ref80"><sup>80</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sambola 2013<a class="bibr" href="#niceng185er7.ref81" rid="niceng185er7.ref81"><sup>81</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Results not yet published</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Schwalm 2010<a class="bibr" href="#niceng185er7.ref82" rid="niceng185er7.ref82"><sup>82</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not review population</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Shin 2018<a class="bibr" href="#niceng185er7.ref83" rid="niceng185er7.ref83"><sup>83</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analysis - references checked</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Steg 2011<a class="bibr" href="#niceng185er7.ref84" rid="niceng185er7.ref84"><sup>84</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tan 2008<a class="bibr" href="#niceng185er7.ref85" rid="niceng185er7.ref85"><sup>85</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not in English</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vafaey 2018<a class="bibr" href="#niceng185er7.ref86" rid="niceng185er7.ref86"><sup>86</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No outcomes</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vranckx 2018<a class="bibr" href="#niceng185er7.ref87" rid="niceng185er7.ref87"><sup>87</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Design and rationale only, full paper not yet publishes</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Windecker 2017<a class="bibr" href="#niceng185er7.ref89" rid="niceng185er7.ref89"><sup>89</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study terminated, no results</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Yasuda 2018<a class="bibr" href="#niceng185er7.ref90" rid="niceng185er7.ref90"><sup>90</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Results not yet published</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Yuan 2018<a class="bibr" href="#niceng185er7.ref91" rid="niceng185er7.ref91"><sup>91</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analysis - references checked</td></tr><tr><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Zhang 2019<a class="bibr" href="#niceng185er7.ref92" rid="niceng185er7.ref92"><sup>92</sup></a></td><td headers="hd_h_niceng185er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analysis - references checked</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er7appjtab2"><div id="niceng185er7.appj.tab2" class="table"><h3><span class="label">Table 35</span><span class="title">Studies excluded from the health economic review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565359/table/niceng185er7.appj.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er7.appj.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er7.appj.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference</th><th id="hd_h_niceng185er7.appj.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reason for exclusion</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er7.appj.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None.</td><td headers="hd_h_niceng185er7.appj.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|